64th ASH Annual Meeting and Exposition: Author Index W

Waack, K.

423 - Revision of Complete Remission Criteria in Pediatric AML
2709 - Second Malignancy after Childhood AML Treatment – a Retrospective Analysis of the AML-BFM Stud
2710 - Management and Outcome of Hyperleukocytosis As Early Complication in Childhood AML – an AML-BFM Experience
2722 - RAS Pathway Alterations in Pediatric AML Patients
2813 - Molecular Relapse in Pediatric AML: Clinical Relapse May be Predicted By Increasingin MRD Level - Experiences from Real-World Data in Patients with Inv(16), t(8;21), t(9;11), t(10;11) or NPM1

Waanders, E.

1377 - A Novel Germline PAX5 Single Exon Deletion in a Paediatric Patient with B-Cell Leukaemia

Waarts, M. R.

330 - Jak2^V617F Reversible Activation Shows an Essential Requirement for Jak2^V617F in Myeloproliferative Neoplasms (MPNs)

Wachowiak, J.

370 - Relapse Is the Most Common Treatment Failure Post HSCT in Children with ALL below 4 Years of Age Given a Chemo-Based Conditioning Regimen. Results from the Prospective Multinational Forum-Trial
372 - Superior Graft-Versus-Leukemia Effect in Matched Unrelated Donor Versus HLA-Identical Sibling Pediatric Recipients Transplanted for Acute Lymphoblastic Leukemia within the Forum Study

Wachsmann, T. L.

1961 - Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain
4625 - T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma

Waclawiczek, A.

836 - Macs - a Leukemic Stem Cell- Based Predictor of Clinical Response to Venetoclax and Other BH3 Mimetics for Acute Myeloid Leukemia

Wada, D.

3134 - High Prevalence of Beta-Human Papilloma Virus in Patients with Concurrent Chronic Lymphocytic Leukemia and Non-Melanoma Skin Cancer

Wada, D.

617 - Mogamulizumab-Associated Rash (MAR) Correlates with Longer Progression Free Survival in Cutaneous T Cell Lymphoma (CTCL)

Wada, R.

3590 - High Incidence and Mortality of Invasive Fungal Disease in Children and Young Adults with Hematologic Malignancies in Hawaii and Pacific Islands

Wade, D.

3911 - PDZD2 Is Essential for Steady-State Hematopoiesis and Its 37-Kda Secreted Product, sPDZD2, Functions As a Soluble Tumor Suppressor in AML

Wade, M.

240 - Preliminary Data from the Phase I/II Study of TP-3654, a Selective Oral PIM1 Kinase Inhibitor, in Patients with Myelofibrosis Previously Treated with or Ineligible for JAK Inhibitor Therapy

Wade, S. W.

892 - Hospital Costs and Healthcare Resource Utilization (HRU) for Chimeric Antigen (CAR) T-Cell Therapy and Stem Cell Transplant (SCT) in Patients with Large B-Cell Lymphoma (LBCL) in the United States (US)
1581 - Chimeric Antigen Receptor T-Cell Therapy Setting of Care: A Retrospective Cohort Analysis of MCL and FL Patients in the US
3346 - Network Meta-Analysis (NMA) of Chimeric Antigen Receptor (CAR) T-Cell Therapy for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) after 2 Prior Treatments Using Published Comparative Studies

Wadelin, F.

4369 - Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib

Wader, K. F.

76 - Venetoclax, Lenalidomide and Rituximab for Patients with Relapsed or Refractory Mantle Cell Lymphoma - the Nordic Lymphoma Group NLG-MCL7 (VALERIA) Phase Ib-II Trial

Wadham, C.

331 - Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors
1704 - Clonal Hematopoiesis Detected at the Time of Tyrosine Kinase Inhibitor Cessation Is Associated with Delayed Molecular Recurrence after Treatment-Free Remission in Patients with CML

Wadhwa, A.

903 - Poverty during Maintenance and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): A Report from Children’s Oncology Group Study (COG-AALL03N1)

Wadleigh, M.

1370 - Body Mass Index Effect on Survival and Toxicities Differs between Age Groups Among Adolescents and Young Adults Treated on DFCI Consortium ALL Trials
2702 - Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML)
4004 - Intensity of Induction Regimen and Outcomes Among Adults with Ph+ ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4013 - Adolescent and Young Adults with ALL Who Complete Therapy on DFCI Consortium ALL Trials Have Excellent Long-Term Overall Survival
4030 - FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3-wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study

Wadleigh, M.

377 - Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study

Wagenaar, T.

3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Wagenblast, E.

920 - Discovery of a New Human Hematopoietic Stem Cell Involved with Aging That Retains Memory of Immune Activation

Wagener, R.

1506 - A Human iPSC Model Reveals Specific Upregulation of Linker Histone H1‑0 in ETV6::RUNX1⁺ Preleukemia and B Cell Precursor Acute Lymphoblastic Leukemia
3939 - The Role of Adult Cancer Predisposition Genes in Hematological Malignancies of Childhood
4148 - Deciphering the Somatic and Germline Structural Variation Landscape in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia By Whole Genome Optical Mapping

Wagenführ, L.

1499 - Prevalence, Clinical and Molecular Features, and Prognostic Value of Tetraploidy/Near-Tetraploidy in Patients with Acute Myeloid Leukemia

Wagner, C. B.

252 - Racial and Ethnic Differences in Clinical Outcomes Among Multiple Myeloma Patients Treated with CAR T Therapy
766 - Idecabtagene Vicleucel (Ide-cel) Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Who Have Received a Prior BCMA-Targeted Therapy: Real World, Multi-Institutional Experience
1406 - Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia
2027 - Factors Associated with Refractoriness or Early Progression after Idecabtagene Vicleucel (Ide-cel) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): U.S. Myeloma CAR T Consortium Real World Experience
4226 - Real World Outcomes of Brentuximab Vedotin Maintenance after Autologous Stem Cell Transplant in Relapsed/Refractory Classical Hodgkin Lymphoma: An Time-Variable Analysis of the Effect of Dose on Progression Free Survival
4296 - CAR-T Therapy in Patients with Relapsed or Refractory Diffuse Large B Cell Lymphoma: Real World Outcomes Based on Tumor Biology
4659 - Idecabtagene Vicleucel Chimeric Antigen Receptor T-Cell Therapy for Relapsed/Refractory Multiple Myeloma with Renal Insufficiency: Real World Experience
4677 - Absolute Lymphocyte Count and Outcomes of Multiple Myeloma Patients Treated with Idecabtagene Vicleucel: The U.S. Myeloma CAR T Consortium Real World Experience

Wagner, C.

4093 - IMA402, an Off-the-Shelf, Next-Generation TCR Bispecific (TCER^®) for Efficiently Targeting an HLA-Presented Peptide from the Pan-Cancer Antigen PRAME

Wagner, E.

2725 - A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations

Wagner, E. M.

871 - Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation – a Registry Study on Behalf of the EBMT Acute Leukemia Working Party
957 - Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
988 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Wagner, E. M.

4 - In Patients with Relapsed/Refractory AML Sequential Conditioning and Immediate Allogeneic Stem Cell Transplantation (allo-HCT) Results in Similar Overall and Leukemia-Free Survival Compared to Intensive Remission Induction Chemotherapy Followed By Allo-HCT: Results from the Randomized Phase III ASAP Trial
771 - Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309

Wagner, J. R.

2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

Wagner, J. E.

114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
2055 - Phase II Study Optimizing Engraftment in Radiation-Sparing Myeloablative Umbilical Cord Blood Transplant for Hematologic Malignancies in Infants
4775 - Lentiviral-mediated Gene Therapy for Patients with Fanconi Anemia [Group A]: Updated Results from Global RP-L102 Clinical Trials

Wagner, K.

3947 - Dormancy Is a Feature of Therapy Resistant Mouse and Human Leukemia-Initiating Cells in T-ALL

Wagner, K.

1189 - Clinical Characteristics and Acute Management of Pediatric Pulmonary Embolism
3733 - Analysis of Clinical Cytokine Panel Profiles As Diagnostic and Prognostic Biomarkers in Pediatric Hyperinflammatory Conditions

Wagner, L.

3971 - The Novel Bispecific Innate Cell Engager (ICE^®) AFM28 Efficiently Directs Allogeneic NK Cells to CD123+ Leukemic Stem- and Progenitor Cells in AML

Wagner, L. I.

77 - Randomized Phase 2 Trial of First-Line Bendamustine-Rituximab (BR)-Based Induction Followed By Rituximab (R) ± Lenalidomide (L) Consolidation for Mantle Cell Lymphoma ECOG-ACRIN E1411
421 - A Simplified Patient Care Strategy to Decrease Early Deaths in Acute Promyelocytic Leukemia (APL): Results of the ECOG-ACRIN EA9131 Trial
3612 - Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma: Insights from the Connect^® MM Registry

Wagner, S.

3814 - Evaluation of Anti-PF4 Positivity and Platelet Activation after COVID-19 Vaccination with Ad26.COV2.S in Brazil

Wagner, S.

2995 - Non-Canonical Gli1 Activation Mediates Profibrotic Hematopoiesis-Stroma Crosstalk in MPN

Wagner, S.

1519 - Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
1619 - First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
2947 - Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Wagner, T. R.

245 - Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma

Wagner-Ballon, O.

3886 - Rare PNH Cells May be Considered As Genuine PNH Clone: Insights from Analysis of the 5-Year French Nation-Wide Multicenter Observational Study

Wagner-Drouet, E. M.

713 - Use of an Allogeneic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML-Patients Results in MRD Conversion, Improved Relapse-Free Survival and Vaccine Induced Immune Responses to Tumor Antigens
1480 - Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Wagner-Johnston, N. D.

2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)

Waheed, A.

2204 - Cost to Treat Newly Diagnosed Patients with Paroxysmal Nocturnal Hemoglobinuria: A Retrospective Analysis

Wahl, D.

3757 - Neural Network Diagnoses the Antiphospholipid Syndrome without Interrupting Anticoagulant Therapy

Wåhlander, K.

2484 - Mim8 Clinical Development Program: An Overview of the Frontier Studies

Wahle, R.

781 - Successful Ex Vivo Telomere Elongation with Exg-001 in a Patient with a Dyskeratosis Congenita

Wahlin, B. E.

611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R²) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1572 - Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study
4845 - Rituximab Infusion in 30 Minutes' Is Safe and Improves the Flow of Outpatients with Lymphoma Treatment (SPEEDR)

Wahlster, L.

4003 - Racial and Ethnic Disparities in Childhood Acute Lymphoblastic Leukemia Risk Due to an IKZF1 Noncoding Regulatory Variant

Wahlstrom, J.

3349 - Updated Efficacy and Safety of Tabelecleucel in Patients with Epstein–Barr Virus-Positive (EBV⁺) Leiomyosarcomas (LMS)

Wahlstrom, S. K.

1808 - Comparing Acalabrutinib and Ibrutinib in the Real World: A Study of 2,509 Patients with Chronic Lymphocytic Leukemia

Wain, L. C.

391 - AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model
3686 - Specific Alterations in Membrane Lipid Levels Correlate with the Degree of Sickling in a Humanized Mouse Model

Wais, V.

3385 - Feasibility and Efficacy of Romiplostim for the Treatment of Persistent Thrombocytopenia after Allogeneic Stem Cell Transplantation. a Single Centre Experience

Wais, V.

3350 - Monitoring the in-Vivo Expansion and Persistence of CAR-T Cells As a Tool to Help Decision Making in Patients with Aggressive B-Cell Lymphoma

Wajant, H.

1945 - Harnessing the Expression of TNFR2 on Tregs to Prevent Agvhd

Wajnberg, A.

1903 - Cellular Immune Composition in Multiple Myeloma Patients Associated with Variable Humoral Responses to Sars-Cov-2 Vaccination

Wajon, D.

2821 - MLL (KMT2A)-rearranged Acute Lymphoblastic Leukemias Are Addicted to S-Adenosyl Methionine (SAM): Implications for Therapy

Wakabayashi, A.

1041 - Regulation of Fetal Hemoglobin Production in Adult Erythroid Cells By Protein Phosphatase 6C (PPP6C)

Wakabayashi, Ｍ.

1570 - Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Wakahashi, K.

524 - Neutrophils Regulate Bone Formation Via IL-1b Secretion

Wakasa, K.

321 - Novel Simple Prognostic Index (NJHSG-PI) Can Effectively Predict Prognosis in Patients with Newly Diagnosed DLBCL : A Real World Analysis across 14 Cancer Centers in Japan
324 - Incidentally Detected Complex Karyotypic Abnormalities in the Bone Marrow Provide a Clue to Diagnosing Intravascular Large B-Cell Lymphoma
2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma
4095 - Subclinical Minute FLT3-ITD Clone Can be Detected in Clinically FLT3-ITD-Negative Acute Myeloid Leukemia

Wakatsuki, S.

2161 - Novel Small Molecule and Peptide Inhibitors of CREB in Leukemia Cells

Wakefield, C.

2465 - Unravelling the Effect of Blood Type on FVIII:C Levels and Response to DDAVP in 20 Males with a Single Genotype (Twillingate Variant) Causing Mild Hemophilia Α
3790 - A Real-World Population Pharmacokinetic (PK) Study of Two Recombinant Factor VIII (rFVIII) Concentrates in Boys with Severe Hemophilia a without Inhibitors

Wakita, S.

4019 - Mutational Analysis of DNMT3A Improves the Prognostic Stratification Using NPM1/FLT3-ITD Genotypes in Patients with Acute Myeloid Leukemia

Wakui, H.

2658 - STAT3 Is a Potential Therapeutic Target for Histone Deacetylase Inhibitor-Resistant Cutaneous T-Cell Lymphoma

Walchack, R.

1406 - Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia

Walcheck, B.

4605 - Multi-Antigen Targeting By Novel Combination of CAR-T Cells and hnCD16 Transgene, Yields in Complete Tumor Clearance Via Antibody Dependent Cellular Cytotoxicity

Walcheck, M.

3847 - Bnip3lb Regulated Mitophagy Maintains the Embryonic Pool of Hematopoietic Stem Cells By Protecting Them from ROS Induced Apoptosis

Wald, D.

833 - Oral Realgar-Indigo Naturalis Formula Versus Intravenous Arsenic Trioxide for Non-High-Risk Patients with Acute Promyelocytic Leukemia: Interim Results of a Multicenter Randomized Controlled Trial APL16
3300 - Sequential Administration of Selinexor then CD19 CAR-T Cells Exhibits Enhanced Efficacy in a Mouse Model of Human Non-Hodgkin’s Lymphoma

Wald, D.

4620 - Non-Invasive Tracking of Nanobubble Tagged Natural Killer Cells Using Clinical Ultrasound

Walding, C.

4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Waldman, A.

21 - Do Children with Immune Thrombocytopenia Have Cerebral Microbleeds?
2447 - Cognitive Impairment in Patients with Immune Thrombocytopenia

Waldron, R.

1848 - A Multiomic Approach to Reversing Therapy Resistance in Multiple Myeloma Using Paired Ex Vivo Drug Sensitivity Measures and RNA Sequencing Data

Waldron-Lynch, M.

1619 - First-Mind: Final Analysis from a Phase Ib, Open-Label, Randomized Study to Assess Safety of Tafasitamab or Tafasitamab + Lenalidomide in Addition to R‑CHOP in Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma
2947 - Frontmind: A Phase III, Multicenter, Randomized, Double-Blind Study of Tafasitamab + Lenalidomide + R-CHOP Versus R-CHOP Alone for Newly Diagnosed High-Intermediate and High-Risk Diffuse Large B-Cell Lymphoma

Waldschmidt, J. M.

4456 - Nivolumab-Based Salvage Therapy to Restore T Cell Fitness in Penta-Refractory Multiple Myeloma with Relapse to Anti-BCMA CAR T Cell Therapy

Waldvogel, S.

3857 - Clonal Competition: Cisplatin Treatment Drives Dominance of TP53- over Tet2-Mutant Stem Cell Clones

Walewski, J.

1 - Efficacy and Safety of Ibrutinib Combined with Standard First-Line Treatment or As Substitute for Autologous Stem Cell Transplantation in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial By the European MCL Network

Walewski, J.

444 - Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Prespecified Analysis of the Pivotal Phase II Study ELM-2
607 - Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy

Walgren, R. A.

229 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Relapsed / Refractory Waldenström Macroglobulinemia: Results from the Phase 1/2 BRUIN Study
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Walia, A.

4120 - Multiomic Single-Cell Sequencing of Mixed Phenotypic Acute Leukemia (MPAL) Reveals Complex Immunophenotypic, Transcriptional, and Genetic Heterogeneity

Walia, M.

79 - Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML – Interim Results from ALLG CML13 Ascend-CML

Walji, M.

263 - Inflammatory Biomarker Clusters Are Predictive of Response and Toxicity in Large B-Cell Lymphoma Treated with CD19 CAR-T Cell Therapy
2036 - Predictors and Implications of Renal Injury in Large Cell Lymphoma Patients Receiving CD19 CAR T Cell Therapy
4767 - Allogeneic Hematopoietic Cell Transplantation in Patients with Relapsed or Refractory Acute Leukemia
4950 - Association of Linguistic Barriers and Survival in Allogeneic Hematopoietic Cell Transplantation

Walkama, D. M.

4804 - Causal AI in silico Patient Model Identifies Minichromosome Maintenance (MCM) Family Genes As Novel Predictors for Overall Survival in Multiple Myeloma

Walker, A. R.

1484 - Secondary AML Mutations Confer Poor Prognosis in Patients with ELN Favorable Risk NPM1-Mutated AML
- Malignant Hematology
- Blood Drop: Malignant Hematology

Walker, B. A.

174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
242 - Single Cell Multiomic Analysis Reveals Relapsed and Refractory Multiple Myeloma Cells Associated with 1q, TP53, and PHF19 alterations That Affect Subclonal Chromatin Accessibility
243 - Multiomics Analysis of IMiD/CELMoD Resistant Multiple Myeloma Models Uncovers Novel and Targetable Vulnerabilities in the SREBP Lipid Synthesis Pathway
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
1842 - The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma
1852 - Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma
1855 - The Frequency of Alternative Splicing in Multiple Myeloma Is Determined By the Non-Homologous End Joining Pathway
4453 - The Pre-Existing T Cell Landscape Is Associated with Response to High Dose Melphalan and Autologous Stem Cell Transplant in Multiple Myeloma
4479 - Patient Derived Xenografts Highlight Mouse-Specific Tumor Evolution Patterns and Genomic Diversity of Multiple Myeloma

Walker, C. J.

386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])

Walker, D. B.

1363 - PIT565, a First-in-Class Anti-CD19, Anti-CD3, Anti-CD2 Trispecific Antibody for the Treatment of B Cell Malignancies

Walker, I.

4474 - Development of the First SEMA4A CAR-T Cell Targeting Multiple Myeloma
4540 - Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma

Walker, J. S.

276 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD⁺ Acute Myeloid Leukemia
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma

Walker, L.

2049 - Strategies to Optimize the Utilization of Stored Autologous Peripheral Blood Stem Cells for Second Transplantation in Multiple Myeloma

Walker, M.

2280 - Isatuximab with Pomalidomide and Dexamethasone Provides Comparable Efficacy Outcomes in Frail Routine Care Myeloma Patients in a UK-Wide Cohort

Walker, M.

684 - NEO-TRA1: A CD25-Targeted De Novo non-Alpha Agonist of the IL-2 Receptor Selectively Expands Regulatory T Cells

Walker, P.

234 - Long-Term Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory (R/R) Marginal Zone Lymphoma (MZL): Final Analysis of the Magnolia (BGB-3111-214) Trial

Walker, S. K.

849 - Predictors of Adverse Clinical Outcome in Diffuse Large B-Cell Lymphoma Richter Transformation of CLL/SLL: A Consortium of Richter Transformation Investigators (CORTI) Multicenter Study across 8 US, UK, and Australian Academic Centers

Walker, S.

3481 - Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Walker, T.

- Update on the Approaches for GATA2 and RUNX1 Variant Curations By the MM-VCEP
- Q&A

Walker, Z. J.

3157 - High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Walkley, C. R.

90 - Genome-Wide CRISPR-Cas9 Screening Identifies a Synergy between Hypomethylating Agents and Sumoylation Blockade in Myelodysplastic Syndromes and Acute Myeloid Leukemia

Walkovich, K. J.

588 - Mavorixafor for Patients with Chronic Neutropenic Disorders: Results from a Phase 1b, Open-Label, Multicenter Study
1086 - Real-World Demographics, Clinical Characteristics, and Treatment Patterns of Patients Treated with Emapalumab for Primary Hemophagocytic Lymphohistiocytosis in the United States: The Real-HLH Study
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector

Wall, D. A.

2137 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Transfusion-Dependent β-Thalassemia

Wall, E.

22 - Arterial Thromboembolism Is Prevalent and Often Suboptimally Managed in Immune Thrombocytopenia
24 - Management and Outcomes of Venous Thromboembolism in Adults with Immune Thrombocytopenia

Wall, M.

1779 - Favorable Outcomes of DDX41-Mutated MDS and Low Blast Count AML Treated with Azacitidine with or without Lenalidomide (ALLG MDS4 Trial)

Wall, S.

- Biomarkers of Aging in Allogeneic Stem Cell Transplant

Wall, S. A.

777 - Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial
3442 - Haploidentical Donor Transplantation with Posttransplantation Cyclophosphamide in Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Institutional Collaboration of 14 Centers

Wallace, D. S.

1814 - Rituximab Induces an Inflammatory Cytokine Response with Increased IP-10 (CXCR10) in Patients with Infusion Reactions

Wallace, E. L.

667 - The Performance of Electronic Consultation in Non-Malignant Hematology in a Fee-for-Service Care Delivery Model

Wallace, J.

2003 - Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial

Wallace, L.

2602 - A Murine Model Harboring Cooperating DNMT3A and SF3B1 Mutations Phenocopies SF3B1 Driven Myelodysplastic Syndrome

Walldin, G.

2418 - Somatic Mutations in T Cells in Patients with Hematological Diseases
3068 - Long-Term Clonal Inversion in an MDS-RS Case with Dual SF3B1 Mutations
3097 - Transfusion Patterns during Early Follow-up Predict Overall Survival Independently of IPSS-M in Patients with Myelodysplastic Syndromes

Waller, A.

2227 - Safety and Feasibility of Outpatient High-Dose Cytarabine Consolidation in AML Patients

Waller, A. P.

696 - Hypoalbuminemia Increases Clot Fibrin Network Density and Impairs Fibrinolysis during Glomerular Proteinuria

Waller, D. K.

3697 - Reduction in Opioid Use and Clinical Complications in Vitamin D Deficient Pediatric SCD Patients Following Vitamin D Replacement

Waller, E. K.

265 - Precision-Engineered Cell Therapy Orca-T Demonstrates High Relapse-Free Survival at 1 Year While Reducing Graft-Versus-Host Disease and Toxicity
769 - Orca-Q Demonstrates Favorable GvHD-and-Relapse-Free Survival in Haploidentical Transplants without Post-Transplant Cyclophosphamide
1941 - Indole-3-Carbinol Supplement Reduces GvHD Related Mortality in Allogeneic Hematopoietic Stem Cell Transplant Recipients
2164 - High Potency Vasoactive Intestinal Peptide Receptor Antagonists Induce Durable Antileukemia/Tumor T Cell Memory in Mice with Once Daily Dosing
4588 - Dual Inhibition of PI3K Delta and PI3K Gamma Isoforms to Prevent Graft-Versus-Host Disease By Limiting T Cell Expansion In Vivo
4629 - CTX110 Allogeneic CRISPR-Cas9–Engineered CAR T Cells in Patients (Pts) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL): Results from the Phase 1 Dose Escalation Carbon Study
4709 - Neihulizumab (ALTB-168) in Patients with Steroid-Refractory Acute Graft-Versus-Host-Disease (SR-aGVHD) or Treatment-Refractory Acute Graft-Versus-Host-Disease (TR-aGVHD)

Waller, J.

3427 - Autologous Hematopoietic Stem Cell Transplantation Improves Survival in Patients with Multiple Myeloma and End Stage Renal Disease

Waller, L.

213 - Ponatinib and Blinatumomab for Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Subgroup Analysis from a Phase II Study
2729 - A Phase II Study of the Sequential Combination of Low-Intensity Chemotherapy (mini-hyper-CVD) and Ponatinib Followed By Blinatumomab and Ponatinib in Patients with Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)
2761 - A Phase I/II Study of Combination of Azacitidine, Venetoclax and Pevonedistat in Patients with Newly-Diagnosed Secondary Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) with Hypomethylating Agent (HMA) Failure
4046 - Ponatinib and Blinatumomab for Patients with Relapsed/Refractory Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myeloid Leukemia in Lymphoid Blast Phase: A Subgroup Analysis from a Phase II Study

Wallington, M.

4855 - Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study

wallington-Gates, C.

4568 - Secondary Analysis of the MM21 Trial: Response Adaptive Salvage Treatment with Daratumumab-Lenalidomide-Dexamethasone (DRd) for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients Failing Front-Line Bortezomib-Based Induction Therapy

Wallis, L.

4369 - Disease Characteristics and Outcomes of Non-Melanoma Skin Cancers in Myeloproliferative Neoplasm (MPN) Patients Treated with Ruxolitinib

Wallisch, M.

3781 - Antiplatelet Effects of Inhibiting Coagulation Factor XI in a Diet-Induced Obesity Model of Early Atherosclerosis

Wallner, B.

2638 - Epichaperome Inhibition Targets Kinase and TP53 Mutant Therapy Resistant AML

Walsh, A.

687 - Endothelial-Targeted CD39 Ameliorates Pulmonary Hypertension in a Murine Model of Endothelial Toxin Administration

Walsh, D.

2313 - Measuring the Incidence of Distress and Supportive Oncology Utilization Among Patients with Myeloproliferative Neoplasms: A Single Center Experience
3637 - Self-Reported Distress Is Associated with Decreased Survival in Patients with Newly Diagnosed Acute Myeloid Leukemia

Walsh, J.

880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Walsh, M. P.

2589 - Comprehensive Genomic Landscape and Clonal Architecture in Pediatric Patients with Monosomy 7
3906 - Tracking Clonal Evolution in Pediatric AML
3930 - UBTF-TD Expression Is Necessary and Sufficient for Myeloid Cell Expansion
4141 - The Rise and Fall of Leukemia Clones in Longitudinal Samples from Diagnosis to Relapse in KMT2A-rearranged Infant and Childhood Leukemia

Walter, C.

2813 - Molecular Relapse in Pediatric AML: Clinical Relapse May be Predicted By Increasingin MRD Level - Experiences from Real-World Data in Patients with Inv(16), t(8;21), t(9;11), t(10;11) or NPM1

Walter, H. S.

1659 - Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Walter, J. E.

588 - Mavorixafor for Patients with Chronic Neutropenic Disorders: Results from a Phase 1b, Open-Label, Multicenter Study
1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency
1102 - Circulating B-Cell Precursor Cells As Potential Diagnostic and Therapeutic Biomarker in Patients with WHIM Syndrome
2414 - The Morphologic Spectrum of Myelokathexis in WHIM Syndrome and Germline CXCR4 Variants: New Insights into Cellular Changes in the Bone Marrow and Peripheral Blood
3739 - Investigating Biomarkers for Primary Immunodeficiency Disorders in Patients with Autoimmune Cytopenia
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector

Walter, M. J.

89 - Therapeutic Targeting of Spliceosome Mutant Myeloid Neoplasms Via PARP1 Inhibition
773 - Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant
1225 - Clonal Myeloid Heterogeneity in Older Autopsy Patients Determined By Multiple Bone Marrow Site Sequencing
1243 - Spatial Organization of Hematopoietic Clones in the Bone Marrow of a Patient with Polycythemia Vera
3072 - Nonsense-Mediated RNA Decay Disruption Induces Altered Splicing in Spliceosome Mutant Cells
3100 - Dynamics of Mortality and Transformation Risk within Different Risk Groups of Patients with Myelodysplastic Syndromes Stratified According to the IPSS-R - Comparison of Treated and Untreated Patients and Consequences for the Description of Risk Categories

Walter, R. B.

57 - Time-Dependent Prediction of Relapse in Patients with Acute Myeloid Leukemia
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
64 - Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
496 - Long-Term Outcomes of a Clinical Trial of Molecular and Functional Drug Screening for Individualized Therapy in Relapsed and Refractory (R/R) Acute Leukemia (AL)
1385 - Revised Prognostic Index for Patients with Acute Myeloid Leukemia and Other High-Grade Myeloid Neoplasms in First Relapse
1423 - Lower-Intensity CPX-351 + Venetoclax for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Post Hoc Analysis By Disease Risk Subgroups
2694 - Dose-Adjusted EPOCH Versus Hypercvad As Initial Treatment for Adults with Acute Lymphoblastic Leukemia (ALL): A Retrospective Matched Cohort Comparison
2708 - Time to Count Recovery after Post-Remission Chemotherapy in AML Patients
4057 - Addition of Sorafenib to Cladribine, High-Dose Cytarabine, G-CSF, and Mitoxantrone (CLAG-M) in Adults with Newly-Diagnosed Acute Myeloid Leukemia (AML) and High-Grade Myeloid Neoplasms Independent of FLT3-Mutation Status: Final Results of a Phase 1/2 Study

Walter, W.

438 - A Multi-Cohort Gene Expression Classifier (ALLCatchR) Identifies B-Precursor ALL Subtypes and Their Developmental Trajectories across Age Groups
466 - Risk Prediction in MDS: A Validation of the IPSS-M and Comparison to IPSS-R and to Two Other Personalized Prediction Tools
856 - Interplay of TP53 Allelic State, Blast Count and Karyotype on Survival of Patients with AML and MDS
1281 - RUNX1 Mutated AML and MDS: Similarities, Differences and Molecular Factors Leading to Disease Progression
1477 - IDH2 mutations in Hematological Malignancies: Distribution, Hot Spots, Clonal Development and Identification of a Novel (cyto-)Genetically Defined Subgroup
1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing
2166 - Detecting the Unusual without Compromising Diagnostic Accuracy - a Prospective WGS/Wts Pilot Study in Acute Leukemias Provided Additional Information for Diagnosis, Prognosis and Treatment
2643 - Polyploidy Is Necessary for Apoptotic Cell Death in TP53-Mut AML in Response to Polo-like-Kinase 4 (PLK4) Inhibition and Results in Caspase 3 Cleavage
2823 - Proximally Biased V(D)J Recombination and Evolution of Non-Productive Clones in B-Cell Precursor Acute Lymphocytic Leukemia with KMT2A::AFF1 Fusion Genes
3486 - How Whole Genome and Transcriptome Sequencing (WGTS) Can Contribute to Unsolved Cases in Hematology That Have Undergone Extensive Standard Diagnostic Workup: A Prospective Head-to-Head Study
3487 - Benchmarking of Whole Genome Sequencing (WGS) and Whole Transcriptome Sequencing (WTS) As Diagnostic Tools for Determining the Mutation Status of IGHV Genes in CLL
4016 - Identification of Phenotypic Subgroups of Acute Myeloid Leukemia, Defined By Differentiation According to Who 2022 Classification
4118 - Myeloid Neoplasms with MYC-Positive Double Minutes, a Specific Subgroup?

Walters, M. C.

2140 - Interim Safety and Efficacy Results from a Phase 1/2 Study of Zinc Finger Nuclease-Modified Autologous Hematopoietic Stem Cells for Sickle Cell Disease (PRECIZN-1)

Walters, M. C.

11 - Lovo-cel (bb1111) Gene Therapy for Sickle Cell Disease: Updated Clinical Results and Investigations into Two Cases of Anemia from Group C of the Phase 1/2 HGB-206 Study
12 - Efficacy and Safety of a Single Dose of Exagamglogene Autotemcel for Severe Sickle Cell Disease
2348 - Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials
3665 - Long-Term Patient-Reported Outcomes Following Treatment with betibeglogene autotemcel in Patients with Transfusion-Dependent β-Thalassemia

Walther, P.

2828 - Venetoclax Resistance in B-Cell Precursor Acute Lymphoblastic Leukemia Is Characterized By Increased Mitochondrial Metabolism and Can be Overcome By Co-Targeting Oxidative Phosphorylation

Waltl, E. E.

1656 - Management of Canadian Patients (Pts) with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) in the Real-World

Waltner, O.

3499 - Single-Cell Multiomics of Pre- and Post- Remission Bone Marrow from a Pediatric Patient with JMML Reveal Distinct Progenitors and Inflammatory Monocytes Which Are Eliminated By Chemotherapy
3849 - Clonal Analysis Reveals Functional and Transcriptional Heterogeneity of Self-Renewing Fetal Liver Hematopoietic Stem Cells
4586 - Single-Cell Multiomics for Residual Disease Detection in Acute Myelogenous Leukemia after Allogeneic Hematopoietic Cell Transplantation

Walton, J.

1067 - Incidence of VTE in Pregnant Women with Sickle Cell Gene Mutation(s): A Retrospective Database Analysis
4881 - Outcomes in Pregnant HbSS and HbSβ0-Thalassemia Sickle Cell Disease Patients Receiving Scheduled Exchange Transfusions: A Retrospective Study

Walulik, S.

1275 - TRIM13 Is a Novel Cell Cycle Hub Regulated By CHAF1B to Promote Acute Myeloid Leukemogenesis

Wan, B.

3362 - Clinical Outcomes in Fresh Versus Cryopreserved Hematopoietic Stem Cell Products in British Columbia: A Retrospective Study

Wan, C.

1391 - Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study

Wan, D.

2064 - Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Wan, H.

1122 - Hyperglycemia Induces Endothelial Dysfunction through Hedgehog Signaling-Mediated TNF-α Production

Wan, J. Y.

1595 - Elevated CCL22 and sIL2Rα Levels Precede the Diagnosis of Young Adult Classical Hodgkin Lymphoma: A Nested Case-Control Study from the DoD Serum Repository

Wan, J.

4580 - The in Vitro and In Vivo Effects of DPP-4 Inhibition with Sitagliptin, Alone and in Combination with Bortezomib, on T Cell Activation: Rationale for GvHD Prevention

Wan, L.

44 - The Role of GATA2 in Drug Resistance in AML
- Chromatin Reader in Cancer: Molecular Mechanisms and Therapeutic Opportunities
- Q&A

Wan, L.

2059 - Metagenomic Next-Generation Sequencing for Pathogens in Bronchoalveolar Lavage Fluid Improve the Survival of Patients with Pulmonary Complications after Allogeneic Hematopoietic Stem Cell Transplantation
3394 - Phase I Study of SHR0302, a Selective JAK1 Inhibitor, Combined with Prednisone for First-Line Treatment of Chronic Graft-Versus-Host Disease after Allo-HSCT

Wan, L.

4697 - Low-Dose Antithymocyte Globulin Plus Low-Dose Post-Transplant Cyclophosphamide for Prevention of Graft-Versus-Host Disease after Haploidentical Peripheral Blood Stem Cell Transplants: A Large Sample, Long-Term Follow-up Retrospective Study

Wan, X.

3991 - 26S Proteasome Non-Atpase Subunit 1, PSMD1/Rpn2, Is a Potential Therapeutic Target in Multiple Myeloma

Wan, Y.

459 - Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed/Refractory (R/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study
1713 - MYF1001: An Open Label, Dose Escalation and Expansion, Phase 1/1b Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination with Ruxolitinib in Patients with Intermediate 1, Intermediate 2 or High-Risk Myelofibrosis
3037 - MYF3001: A Randomized Open Label, Phase 3 Study to Evaluate Imetelstat Versus Best Available Therapy in Patients with Intermediate-2 or High-Risk Myelofibrosis Relapsed/Refractory to Janus Kinase Inhibitor

Wan, Y.

2409 - Microglia Regulating Neuronal Apoptosis Via Alpha7 Nicotinic Acetylcholine Receptor in HIV-Associated Neurocognitive Disorders

Wan, Z.

2670 - TBL1 Inhibitor, Tegavivint, Supresses Cell Survival and Promotes Sensitivity to Chemotherapy in ALL and AML
3963 - The Role of Integrin Beta-1 in the Chemoresistance of Acute Myeloid Leukemia

Wanchai, V.

106 - A 12 Gene Signature Accurately Predicts Multiple Myeloma Progression from Monoclonal Gammopathy of Undetermined Significance

Wandke, A.

15 - PRMT5 Inhibition Reduces Autoinflammation in a Murine Model of Secondary Hemophagocytic Lymphohistiocytosis
1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease

Wandler, A.

2659 - Opposing Effects of KDM6A and JDP2 on Glucocorticoid Sensitivity in T-ALL

Wang, A.

2916 - XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study

Wang, A.

2215 - Health Care Resource Utilization and Costs of CAR T Therapy in Patients with Large B-Cell Lymphoma: A Retrospective US Claims Database Analysis
2296 - Follicular Lymphoma Treatment Patterns and Outcomes over Time: A Real-World Analysis in the United States
2978 - Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis
3580 - Improvements in Lymphoma Symptoms and Health-Related Quality of Life in Patients with Relapsed or Refractory Large B-Cell Lymphoma Treated with Subcutaneous Epcoritamab (EPCORE NHL-1)
4912 - Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Wang, B.

330 - Jak2^V617F Reversible Activation Shows an Essential Requirement for Jak2^V617F in Myeloproliferative Neoplasms (MPNs)

Wang, B.

1951 - Distinct Immune Homeostasis Remodeling Patterns after HLA-Matched and Haploidentical Transplantation

Wang, B.

4591 - Targeting Intestinal Epithelial Ceacam1 Expands Peripheral Tregs and Prevents Steroid-Refractory Acute Gut Graft-Versus-Host Disease

Wang, B.

3283 - Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma

Wang, B.

2790 - Single Cell RNA-Seq Reveals Intra-Tumoral Heterogeneity Relevant to Differentiation States and Outcomes Among Newly Diagnosed Acute Myeloid Leukemia Patients
4119 - Single-Cell Profiling of CD8 Landscape in Treatment Naïve and Relapsed/Refractory AML Patients Reveals Distinct Effector Cellular States Predictive of Outcomes

Wang, C.

1186 - Assessing the Rate of Compliance with the Revised Sapporo/Sydney Criteria in Diagnosing Antiphospholipid Syndrome: A Multicenter Retrospective Analysis

Wang, C.

3283 - Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma

Wang, C.

4293 - Efficacy and Safety of Zanubrutinib Combined with R-CHOP Regimen in the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma with Extranodal Involvement: A Single-Arm, Prospective Phase II Trial

Wang, C.

1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency
1894 - Efficacy of Frontline Treatments for Newly Diagnosed Transplant-Ineligible Multiple Myeloma, a Network Meta-Analysis
2794 - Drivers of Deep Molecular Response and Outcomes in Patients with Core Binding Factor Acute Myeloid Leukemia
3084 - Clinical Characterization and Outcomes of Patients with NPM1-Mutated Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia
4633 - Phase 1/1b Safety Study of Prgn-3006 Ultracar-T in Patients with Relapsed or Refractory CD33-Positive Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Wang, C.

1417 - The First Report of Third-Generation TKI Olverembatinib in Adult Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed Disease
4049 - A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia in Adults：Preliminary Results from RJ-ALL2020.2A Trial

Wang, C.

1313 - EZH1-PRC2 Identifies a Potential Reservoir for Disease Relapse in Quiescent Cancer Cells Refractory to EZH2 Enzymatic Inhibition

Wang, C.

2553 - Sex Dimorphism in the Bone Marrow Niche Contributes to Gender Difference in Mouse Hematopoiesis

Wang, C. C.

4854 - Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Wang, C. Y.

2338 - ALK2 Inhibition and a Modified Activin Receptor Type Iia Ligand Trap Cotherapy Maximized Hematologic Improvements in a Mouse Model of Anemia of Inflammation

Wang, C. K.

1802 - Real-World First-Line Treatment and Outcomes of Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Bruton Tyrosine Kinase Inhibitor (BTKi) or B-Cell Lymphoma 2 (BCL2) Therapy
2234 - Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)
3183 - Patient- and Clinician-Reported Performance Status in Patients with Multiple Myeloma Treated in the United States Using Real World Data

Wang, C.

1526 - Dynamic Response Assesment Combining Liquid Biopsy MRD and PET/CT in Follicular Lymphoma Patients Including CAR-T Cell Therapy

Wang, C.

3422 - Efficacy and Safety of Gilteritinib Vs. Sorafenib As Post-Transplant Maintenance in Patients with FLT3-ITD Acute Myeloid Leukemia

Wang, C.

347 - Efficacy of Pirtobrutinib, a Highly Selective, Non-Covalent (Reversible) BTK Inhibitor in Richter Transformation: Results from the Phase 1/2 BRUIN Study
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Wang, C.

4386 - High Expression of Plasma IL-1β Levels and Transition of Regulatory T-Cell Subsets Correlate with Disease Progression in Myelodysplastic Syndrome

Wang, C.

1532 - Circulating Tumor DNA Clearance during Treatment As a Predictive and Prognostic Biomarker for Diffuse Large B-Cell Lymphoma Patients Receiving First-Line Therapy

Wang, C.

1560 - Identification of Pyroptosis-Related Signature and Development of a Novel Prognostic Model in Diffuse Large B-Cell Lymphoma

Wang, C.

82 - Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Wang, D.

1100 - GATA2-TGF-b Axis in Human NK Cell Development

Wang, D.

1532 - Circulating Tumor DNA Clearance during Treatment As a Predictive and Prognostic Biomarker for Diffuse Large B-Cell Lymphoma Patients Receiving First-Line Therapy

Wang, D.

1295 - Metabolic Biomarkers Affecting Cell Proliferation and Prognosis in Polycythemia Vera

Wang, D.

1202 - CD4+ T Cells Are Required for Production of Disease-Causing Antibodies in an Alloantigen-Specific Murine Model of Fetal/Neonatal Alloimmune Thrombocytopenia
4461 - Genomic and Transcriptional Profiling Stratifies Vq Myeloma Lines into Two Clusters with Distinct Risk Signatures and Drug Responses

Wang, D.

961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study

Wang, D.

3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Wang, D.

3192 - Dose Optimization to Mitigate the Risk of CRS with Elranatamab in Multiple Myeloma
4509 - A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

Wang, D.

1632 - Combination of Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine and Prednisone (CMOP) in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial

Wang, D.

4289 - Demographic Features, Clinical Characteristics and Survival Outcomes of Primary Cutaneous Gamma-Delta T Cell Lymphoma, a Retrospective National Cancer Database Analysis

Wang, E.

1760 - Treatment Patterns and Characteristics Among Patients with Myelodysplastic Syndromes Initiating Oral Decitabine and Cedazuridine or Intravenous/Subcutaneous Hypomethylating Agents in a Real-World Setting

Wang, E.

750 - Kinase Dead BTK Mutations Confer Resistance to Covalent and Noncovalent BTK Inhibitors but Are Susceptible to Clinical Stage BTK Degraders
934 - Systematic Evaluation of AML-Associated Antigens Identifies Novel Anti-U5 snRNP200 Therapeutic Antibodies for the Treatment of AML

Wang, E.

236 - Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study

Wang, E. S.

58 - Gemtuzumab Ozogamicin Plus Standard Induction Chemotherapy Improves Outcomes in Intermediate Risk Cytogenetic Acute Myeloid Leukemia
62 - Broad Activity for the Pivekimab Sunirine (PVEK, IMGN632), Azacitidine, and Venetoclax Triplet in High-Risk Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
64 - Update on a Phase 1/2 First-in-Human Study of the Menin-KMT2A (MLL) Inhibitor Ziftomenib (KO-539) in Patients with Relapsed or Refractory Acute Myeloid Leukemia
128 - Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies
305 - Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia
981 - Ameli-01: A Phase I Trial of UCART123v1.2, an Anti-CD123 Allogeneic CAR-T Cell Product, in Adult Patients with Relapsed or Refractory (R/R) CD123+ Acute Myeloid Leukemia (AML)
1244 - Autophagy Plays a Role in the Maintenance of Acute Myeloid Leukemia Stem Cells in the Hypoxic Bone Marrow Microenvironment
2302 - Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms
2740 - Tagraxofusp, a CD123-directed Therapy, in Patients with Blastic Plasmacytoid Dendritic Cell Neoplasm and Prior or Concomitant Hematologic Malignancies: Subgroup Analysis of a Pivotal Trial
4061 - MRD Status and ELN 2022 Predicts for Outcomes of Venetoclax + Hypomethylating Therapy in AML: Single-Center Real-World Analysis

Wang, F.

4622 - Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions

Wang, F.

2635 - Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia through Ubiquitination and Degradation of PML-RARα

Wang, F.

2788 - Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
2812 - Characterization of Dysregulated Transcription in TP53-Mutated AML Subpopulations

Wang, F. R.

2111 - Worldwide Network for Blood and Marrow Transplantation (WBMT) Global Study on Baseline Characteristics and Clinical Outcomes in NEWLY Diagnosed Multiple Myeloma Patients Undergoing Upfront Autologous STEM Cell Transplantation, a Study Off 61,725 Patients from 629 Centers
2289 - International Differences in Baseline Characteristics and Practice Patterns in Patients with NEWLY Diagnosed Multiple Myeloma Undergoing Upfront Autologous STEM Cell Transplantation

Wang, F.

957 - Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party

Wang, F.

2051 - Thrombopoietin Levels Predict the Response to Avatrombopag Treatment in Patients with Persistent Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplantation
2081 - Efficacy and Safety of MSCs Plus Basiliximab for the Treatment of Steroid-Resistant aGVHD after Haploidentical Stem Cell Transplantation: A Multicenter, Randomized, Open-Label Trial
2454 - Real-World Study of the Use of Iguratimod to Treat Chronic/Refractory ITP
3424 - Machine Learning Algorithm As a Prognostic Tool for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation
4772 - A Prospective Study of Short-Term Chemotherapy Bridging Allogeneic-SCT in High Risk Peripheral T-Cell Lymphoma

Wang, F.

2113 - A Phase IV, Multicenter, Open-Label, Safety, and Efficacy Study of High-Dose, Propylene Glycol-Free Melphalan Hydrochloride for Injection (EVOMELA) As a Myeloablative Conditioning Regimen in Chinese Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation

Wang, G.

2012 - Be Cautious to Adopt a Second CAR T-Cell Infusion after Failure of CD19/CD22 Cocktail CAR T-Cell Therapy in Relapsed/Refractory B-NHL
2021 - The Safety and Efficacy of p CAR-19B, a Scfv Humanized CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL
4632 - Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma

Wang, G. M.

3502 - Artificial Intelligence to Assess the Systemic Impact of Malignant Plasma Cell Clone in Patients with Plasma Cell Dyscrasia

Wang, G.

4346 - BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Wang, G.

4470 - MDM2-p53 Inhibitor Alrizomadlin (APG-115) Enhances Antitumor Activity of Pomalidomide in Multiple Myeloma (MM)

Wang, G.

698 - Human Bone Marrow Organoids Enable the Study of Hematopoietic Cell-Stromal Interactions and Support the Survival of Malignant Cells from Patients

Wang, G.

453 - Cross-Talk between Hematopoietic Cells and Fibroblast Subsets Drives Inflammation and Remodelling of the Bone Marrow Microenvironment in Myeloproliferative Neoplasms

Wang, G.

2559 - ROBO4 Inhibits Irradiation-Induced Microvascular Permeability, Endothelial to Mesenchymal Transition, and Improves Hematopoietic Reconstitution

Wang, H. L.

765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy

Wang, H.

2074 - Individualized Dosing of Anti-Thymocyte Globulin Led to Reduced CMV/EBV Reactivation and Superior Overall Survival in Adult Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Phase II Study

Wang, H.

1635 - Preliminary Results of a Phase Ⅱ Study of Zanubrutinib Combined with Immunochemotherapy in Patients with CD79A/CD79B-Mutant Diffuse Large B-Cell Lymphoma
2928 - Phase II Clinical Trial of Camrelizumab Combined with AVD (Epirubicin, Vincristine and Dacarbazine) in the First-Line Treatment for Patients with Advanced Classical Hodgkin's Lymphoma

Wang, H.

955 - Sintilimab Plus P-Gemox (Pegaspargase, Gemcitabine and Oxaliplatin) Regimen for Newly-Diagnosed Advanced, Extranodal Natural Killer/T Cell Lymphoma, Nasal Type: A Multicenter, Phase 2 Cohort of the Open-Label Spirit Study

Wang, H. W.

1512 - Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition
3310 - T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Wang, H.

3762 - Low-Dose Rhein Sensitizes Platelet Production to Thrombopoietin Receptor Agonists (TPO-RA) in Immune Thrombocytopenia

Wang, H.

3764 - Rapamycin Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction in Immune Thrombocytopenia

Wang, H. C.

1954 - KMT2C/MLL3 Attenuates Committed Myeloid Progenitor Self-Renewal Capacity and Balances Granulocyte and Monocyte/Dendritic Cell Output

Wang, H.

81 - A Five-Year Follow-up on Safety and Efficacy of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML) in China
82 - Olverembatinib (HQP1351) Overcomes Ponatinib Resistance in Patients with Heavily Pretreated/Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)
964 - Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Wang, H.

3931 - Activating a Non-Genetic MYC-Regulating Pathway Sensitizes Acute Myeloid Leukemia to Bromodomain Inhibition

Wang, H.

2754 - Outcomes of Adults Treated with a Hypomethylating Agent Plus Venetoclax for Relapsed/Refractory Acute Myeloid Leukemia: A Multicenter Retrospective Study

Wang, H.

4623 - A Novel Dual-Antigen Targeting Approach Enables Off-the-Shelf CAR NK Cells to Effectively Recognize and Eliminate the Heterogenous Population Associated with AML

Wang, H.

3157 - High Ex Vivo Response Rates to CD38/CD28xCD3 Trispecific T Cell Engager in Patients Relapsed after Anti-CD38 and Anti-BCMA Targeted Immunotherapies

Wang, H.

2682 - Targeted Nanotherapy of Hematologic Malignancies Using Gold Nanoframework-Based Delivery of a Novel NF-Kb Inhibitor

Wang, H.

2741 - Venetoclax in Combination with Hypomethylating Agents Compared to Standard Chemotherapy in Relapsed/Refractory Acute Myeloid Leukemia

Wang, H.

2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1
3805 - Eptacog Beta (rFVIIa) Has a Low Incidence of Spontaneous Rebleeding through 24 and 48 Hours in Adult and Adolescent Patients with Hemophilia A or B with Inhibitors

Wang, H.

2831 - Biologic Relevance of Variable Immunoglobulin Gene Diversity in B-Lymphoblastic Leukemia

Wang, H.

4694 - Fludarabine, Busulfan and Melphalan Based Conditioning Reduced Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myeloid Malignancies: A Multicenter Retrospective Analysis

Wang, H.

146 - BRD9 Facilitates Oncogenic Nrf2 Pathway and Dampens Venetoclax Sensitivity By Remodeling Chromatin Accessibility in Chronic Lymphocytic Leukemia
2664 - APG115 Enhances the Sensitivity of Ibrutinib Via Promoting p53 to Target MCL-1 in Chronic Lymphocytic Leukemia

Wang, H.

942 - Homoharringtonine Synergizes Strongly with Venetoclax Against the Early T-Cell Progenitor Acute Lymphoblastic Leukemia：from Bench to Bed
1450 - Venetoclax Plus “2 + 5” Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis

Wang, H.

1629 - The ZR2-Minichop Study：Zanubrutinib, Lenalidomide, Rituximab, Cyclophosphamide, Vincristine, Epirubicin and Prednisone in Elderly Patients with Previously Untreated Diffuse Large B-Cell Lymphoma
2152 - Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity

Wang, H.

833 - Oral Realgar-Indigo Naturalis Formula Versus Intravenous Arsenic Trioxide for Non-High-Risk Patients with Acute Promyelocytic Leukemia: Interim Results of a Multicenter Randomized Controlled Trial APL16

Wang, H.

1994 - Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Wang, H.

3283 - Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma

Wang, H.

3267 - Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice

Wang, H.

2020 - SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up
4622 - Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions

Wang, H.

2945 - Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma

Wang, H. H.

1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Wang, H.

4184 - Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Wang, H.

3209 - The Value of PET/CT Combined with Next-Generation Flowcytometry in Minimal Residual Disease Detection and Prognostic Evaluation of Multiple Myeloma

Wang, H.

560 - Validation of the 5^th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute
1764 - Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates
2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma

Wang, H.

4933 - A Comparison of Financial Hardship Among Survivors of Childhood Cancer Treated with and without Hematopoietic Cell Transplantation: A Report from the Childhood Cancer Survivor Study

Wang, J. F.

4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Wang, J. C.

1332 - Targeting N-Myristoylation for Adult Acute Myeloid Leukemia Therapy
4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis

Wang, J. C.

2633 - A Novel Role for PLK1 in Leukemia Stem Cell Function in Acute Myeloid Leukemia
4109 - The LSC17 Score Correlates with the ELN 2022 Classification of AML and Is an Independent Predictor of Detectable Measurable Residual Disease after Induction Chemotherapy

Wang, J.

2152 - Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity

Wang, J.

31 - Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study
1201 - Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Wang, J.

518 - Factor XI Inhibition for the Prevention of Catheter-Associated Thrombosis in Cancer Patients Undergoing Central Line Placement: A Phase 2 Clinical Trial

Wang, J. Y.

1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency

Wang, J.

1711 - Safety and Efficacy of Fedratinib in Patients with Primary (P), Post-Polycythemia Vera (Post-PV), and Post-Essential Thrombocythemia (Post-ET) Myelofibrosis (MF) Previously Treated with Ruxolitinib: Primary Analysis of the FREEDOM Trial

Wang, J.

4778 - Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34⁺ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Wang, J.

2950 - Preliminary Result of Lenalidomide Combined with R-CHOP(R2-CHOP) in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma: A Prospective Phase II Clinical Trial

Wang, J.

4243 - Outcomes of PD-1 Inhibitors Treatment of Chronic Active Epstein Barr Virus Infection : A Single Center Retrospective Analysis

Wang, J.

3997 - β2-AR Signaling Enhances MDSC Survival through Metabolic Reprograming and Impairs Therapeutic Efficacy in Hematologic Malignancies

Wang, J.

3399 - Decoding the Immune Landscape of Pathogenic T Cells in Acute Graft-Versus-Host Disease By Single-Cell RNA-Seq

Wang, J.

4691 - Improved Grfs Observed in a Multicenter Prospective Study of Tcrαβ- and CD45RA-Depleted Haploidentical Transplant in Children with Acute Leukemia

Wang, J.

219 - Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
223 - Molecular Characterization of Clinical Response and Relapse in Patients with IDH1m ND-AML Treated with Ivo+AZA in the AGILE Study
225 - Quantum-First Trial: FLT3-ITD–Specific MRD Clearance Is Associated with Improved Overall Survival
255 - Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies
660 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China
816 - Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial
839 - Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)
878 - Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3–Internal Tandem Duplication: Results from the Quantum-First Trial
918 - _{Predictive Factors of Relapse for Primary Immune Thrombocytopenia in Adults: A Single-Center Retrospective Cohort Analysis}
1290 - Investigation of Impact Induced By AML1-ETO on Self-Renewal and Differentiation of Hematopoietic Stem and Progenitor Cells in Pre-Leukemic Stage
1297 - The Characteristics of AML1-ETO Fusion Gene Induced Pre-Leukemia Immune Microenvironment
1419 - Construction of Dual- and Enhanced Dual-Antibodies Targeting CD19 in the Treatment of B-ALL and Investigation of the Relevant Mechanisms
1776 - Combination Therapy of Eltrombopag and Cyclosporine a Improves Hematopoiesis in Patients with Lower-Risk Myelodysplastic Syndrome
1980 - Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells
2009 - CNCT19 CAR T-Cell Therapy in Relapsed or Refractory B-Cell Lymphoma: Long-Term Results of a Pilot Prospective Clinical Study
2020 - SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up
2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma
3295 - The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma
3327 - Long-Term Activity of Combining CNCT19 with HDT/ASCT in Refractory Large B-Cell Lymphoma: Two-Year Follow-up of a Prospective Phase 1/2 Clinical Trial
3491 - Predicting Response to FLT3 Inhibitors Using Genomics-Based Computational Bio-Simulation Platform
3797 - Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study
4263 - First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies
4309 - Molecular Analysis of JAK2V617F-Positive Myeloproliferative Neoplasms Reveals Wnt/β-Catenin As a Potential Target for Therapy
4339 - Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN
4622 - Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions

Wang, J.

918 - _{Predictive Factors of Relapse for Primary Immune Thrombocytopenia in Adults: A Single-Center Retrospective Cohort Analysis}

Wang, J.

292 - Real-World Evidence of Incidence and Outcomes of Aplastic Anemia Following Administration of Immune Checkpoint Inhibitors
600 - Racial Disparities in Mortality Trends from Acute Myeloid Leukemia: A Population-Based Study in the United States between 2000 and 2019
778 - Multicenter Phase I Study of Post-Transplant Low-Dose Inotuzumab Ozogamicin to Prevent Relapse of Acute Lymphoblastic Leukemia
1006 - Autoimmune Hemolytic Anemia and Increased Stroke Risk in the United States: A Population-Based Study
1768 - The Risk of Cerebrovascular Accident in Patients with Myelodysplastic Syndrome in the United States: A Nationwide Population-Based Study
3215 - The Risk of Stroke and Myocardial Infarction in Multiple Myeloma: A Population-Based Study in the United States
4439 - Retrospective Comparison of Patients with Chronic Lymphocytic Leukemia Receiving BTK Inhibitors Versus Obinutuzumab/Venetoclax As Frontline Therapy
4513 - Race-Specific Mortality from Multiple Myeloma: A CDC Database Population Study in the United States between 2000 and 2020

Wang, J.

2944 - Phase 1 Safety and Dose Escalation of Purinostat Mesylate, a Uniquely Potent and Selective Inhibitor of HDAC I and IIb in Relapsed or Refractory Lymphoma and Multiple Myeloma

Wang, J.

1417 - The First Report of Third-Generation TKI Olverembatinib in Adult Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed Disease
4049 - A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia in Adults：Preliminary Results from RJ-ALL2020.2A Trial

Wang, J.

3264 - Functional Human iPSC-Derived Thymic Epithelial Progenitor Cells Reconstitute T Cell Development and Function in an In Vivo Model of Thymic Aplasia

Wang, J.

1885 - TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing
4518 - The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Wang, J.

1381 - Homoharringtonine-Based Induction Regimens Combined with ATRA-Based Maintenance in Chinese Pediatric AML: A Report from the Cclg-AML 2015 Protocol Study

Wang, J. Z.

3424 - Machine Learning Algorithm As a Prognostic Tool for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation

Wang, J.

3322 - Sequential GD2 Chimeric Antigen Receptor T Cell Therapy (4SCAR2.0-GD2) for the Treatment of Refractory/Relapsed Neuroblastoma

Wang, J.

3922 - High Expression of BCAT1 Affects DNA Damage Response By Inhibiting α-KG-Dependent Histone Demethylase

Wang, J.

3425 - Profiles of Germline Predisposition Gene Variants in Hematologic Disorders and Its Impact on Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation

Wang, J.

813 - Platelet ERO1α Is Crucial for Ca²⁺ Mobilization and Platelet Activation in Atherothrombosis

Wang, J.

2720 - Establishment of Mortality Risk Prediction Model for Bloodstream Infections in Patients with Hematological Diseases

Wang, J.

2682 - Targeted Nanotherapy of Hematologic Malignancies Using Gold Nanoframework-Based Delivery of a Novel NF-Kb Inhibitor

Wang, J.

1759 - A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome
2944 - Phase 1 Safety and Dose Escalation of Purinostat Mesylate, a Uniquely Potent and Selective Inhibitor of HDAC I and IIb in Relapsed or Refractory Lymphoma and Multiple Myeloma
3406 - Phase II Multicenter, Randomized Controlled Study on Infusion of MSCs at 45 Days after Haplo-Hematopoietic Stem Cell Transplantation in the Prophylaxis of Gvhd
3732 - Nrf2 Overexpression Increases Risk of Venetoclax Resistance in Acute Myeloid Leukemia By Promoting Glycolysis

Wang, J.

2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)

Wang, J.

2940 - Phase I Study of Tq-B3101 in Pediatric Patients with Relapsed/Refractory Anaplastic Lymphoma Kinase Positive Anaplastic Large Cell Lymphoma

Wang, J.

3762 - Low-Dose Rhein Sensitizes Platelet Production to Thrombopoietin Receptor Agonists (TPO-RA) in Immune Thrombocytopenia
3767 - Eltrombopag Plus Diacerein Versus Eltrombopag in Adult Primary Immune Thrombocytopenia: Interim Analysis of a Multicenter, Randomized, Controlled, Phase 2 Trial

Wang, J.

3767 - Eltrombopag Plus Diacerein Versus Eltrombopag in Adult Primary Immune Thrombocytopenia: Interim Analysis of a Multicenter, Randomized, Controlled, Phase 2 Trial

Wang, J.

1588 - An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy

Wang, J.

1990 - Allogeneic CAR-T Therapy Enabled By Base Editing of Lck to Resist Dasatinib Used to Prevent Rejection Mediated through Both T and NK in Host
3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Wang, J.

307 - Longitudinal Single Cell Analyses Reveal the Co-Evolutionary Dynamics of the Tumor and Microenvironment Accompanying Follicular Lymphoma Transformation
429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML

Wang, J.

4760 - Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT

Wang, J.

1381 - Homoharringtonine-Based Induction Regimens Combined with ATRA-Based Maintenance in Chinese Pediatric AML: A Report from the Cclg-AML 2015 Protocol Study

Wang, J.

1240 - Increased Tumor-Associated CD66b+ Myeloid-Derived Suppressor Cells in Waldenstrom Macroglobulinemia Inhibit T-Cell Immune Function
3899 - Longitudinal Single Cell Multiomic Analysis of a Patient with GATA2 Haploinsufficiency with ASXL1 Mutant Clonal Hematopoiesis

Wang, K.

3994 - Elucidating the Molecular Mechanisms of Action of CC-99282, a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent, Via Genome-Wide CRISPR Screen in a Preclinical Model of Non-Hodgkin Lymphoma (NHL)

Wang, K.

3772 - Combination of Thrombopoietin Receptor Agonist and Recombinant Human Thrombopoietin for Treating Cancer Therapy Induced Thrombopenia

Wang, K.

4651 - CAR-T Therapy for a Child with Refractory Inflammatory Myofibroblastic Tumor

Wang, K.

2011 - Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r/r T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Interim Analysis from a Phase 2 Trial

Wang, K.

3641 - DISC-0974, an Anti-Hemojuvelin (HJV) Monoclonal Antibody, Reduced Hepcidin and Improved Anemia in a Rat Model of Chronic Kidney Disease

Wang, K.

4506 - A Retrospective Study of Antibody Titers in Patients with Plasma Cell Disorders

Wang, K.

1393 - Prognostic Impact of WT1 Mutation on AML of Different Risk Groups Based on 2022 European Leukemianet (ELN) Risk Classification

Wang, K.

2185 - Retrospective Assessment of Total Cost of Care in Non-Dialysis Dependent Chronic Kidney Disease Patients Receiving Parenteral Iron Therapy for Iron Deficiency Anemia

Wang, K.

415 - Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia
1274 - TET2-Mediated mRNA and DNA Oxidation in Leukemia Homing and Immune Evasion

Wang, K.

2234 - Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)

Wang, L.

1324 - The Aryl Hydrocarbon Receptor Defines a Unique Genomic and Immune Signature in AML Characterized By Monocytic Differentiation, Venetoclax Resistance and Is Targetable By Ahr Antagonist

Wang, L.

663 - Efficient and Specific Multi-Locus Editing of Allogeneic CAR T Cells for Hypoimmunity during Large Scale Manufacture Using Cas12b

Wang, L.

4268 - Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial

Wang, L.

4294 - Selinexor in Combination with R-GDP/R-ICE Regimen for Refractory Aggressive Large B-Cell Lymphoma Patients with TP53 Alterations

Wang, L.

1381 - Homoharringtonine-Based Induction Regimens Combined with ATRA-Based Maintenance in Chinese Pediatric AML: A Report from the Cclg-AML 2015 Protocol Study

Wang, L.

3050 - Phase Ⅱ,Open-Label, Multicenter, Single-Arm Study Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea(HU)

Wang, L.

1660 - Preliminary Results of Penpulimab Combined with RMA (rituximab, methotrexate, and cytarabine) for Newly Diagnosed Primary Central Nervous System Lymphoma
1792 - Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)
1811 - Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia
3104 - Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
3108 - Single-Cell RNA Sequencing Reveals the Characteristics of High Proliferating Tumor Cells in Btki-Resistant Progression to Richter Transformation and Accelerated CLL

Wang, L. L.

2565 - Immune Checkpoint Molecules Regulate Paroxysmal Nocturnal Hemoglobinuria Clonal Evolution

Wang, L. L.

2635 - Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia through Ubiquitination and Degradation of PML-RARα

Wang, L.

1624 - A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Dignosed Primary Central Nervous System Lymphoma

Wang, L.

2953 - A Phase I Trial of PI3Kαδ Inhibitor Copanlisib in Combination with Nivolumab in Patients with Richter’s Transformation (RT) or Transformed Non-Hodgkin Lymphoma (tNHL)
4421 - Disrupting MGA-MYC Driven Metabolic Reprogramming in Richter’s Syndrome Pre-Clinical Models Via Novel Therapeutic Approaches

Wang, L.

2074 - Individualized Dosing of Anti-Thymocyte Globulin Led to Reduced CMV/EBV Reactivation and Superior Overall Survival in Adult Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Phase II Study

Wang, L.

1327 - C/EBPα-p30 Confers AML Cell Susceptibility to the Terminal Unfolded Protein Response and Resistance to Venetoclax By Activating DDIT3 Transcription

Wang, L.

1023 - Iron Overload and Iron-Induced Microbiome Changes May Affect Lymphoid Levels Post Bone Marrow Transplant and Graft-Versus-Host Disease Survival in Mice

Wang Lin, S. X.

97 - Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC‑1
1911 - Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
3228 - Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Wang, L.

4184 - Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Wang, L.

2020 - SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up

Wang, L.

2632 - CD123 Directed IgM Antibody-based T-cell Engager, IGM-2537, Demonstrates Potent in vitro and in vivo Activity with Minimal Cytokine Release

Wang, L.

2519 - Sec14l4 SNP Mice Have Increased Susceptibility to Oxidative Hemolysis through Modulation of G6PD and the Pentose Phosphate Pathway
3838 - Sec14-like-Lipid-Binding-4 Enables Hemoglobin Clearance By Liver Sinusoidal Endothelial Cells

Wang, L.

3169 - Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment

Wang, L.

3764 - Rapamycin Inhibits Cytotoxic T Lymphocytes-Mediated Platelet Destruction in Immune Thrombocytopenia

Wang, L.

1636 - Efficacy and Safety of Lenalidomide, Anti-PD-1 Antibody Combined with Orelabrutinib or Rituximab in the Treatment of Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Wang, L.

1381 - Homoharringtonine-Based Induction Regimens Combined with ATRA-Based Maintenance in Chinese Pediatric AML: A Report from the Cclg-AML 2015 Protocol Study

Wang, L.

2021 - The Safety and Efficacy of p CAR-19B, a Scfv Humanized CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL
3298 - A Novel Platform to Manufacture High-Efficient “Off-the-Shelf” CAR-NK Products from Peripheral Blood Mononuclear Cells (PBMC)

Wang, L.

22 - Arterial Thromboembolism Is Prevalent and Often Suboptimally Managed in Immune Thrombocytopenia
24 - Management and Outcomes of Venous Thromboembolism in Adults with Immune Thrombocytopenia

Wang, L.

443 - Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results
609 - Subcutaneous Epcoritamab with Rituximab + Lenalidomide in Patients with Relapsed or Refractory Follicular Lymphoma:Phase 1/2 Trial Update
611 - Subcutaneous Epcoritamab in Combination with Rituximab + Lenalidomide (R²) for First-Line Treatment of Follicular Lymphoma: Initial Results from Phase 1/2 Trial

Wang, L.

- Integrating Whole-Genome and Whole-Transcriptome Sequencing for Molecular Diagnosis, Classification and Risk Stratification of Pediatric and Adolescent AML

Wang, L.

3066 - The M6A Methyltransferase METTL14 Promotes Myelodysplastic Syndromes Development Via PI3K/Akt Signaling Pathway
4389 - EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

Wang, L.

2088 - Efficiency and Toxicity of Imatinib Mesylate Combined with Atorvastatin Calcium for Steroid-Refractory Chronic Graft-Versus-Host Disease
2134 - Combination Azacitidine and Lenalidomide: A Novel Relapse Prophylaxis Option in Patients after Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia

Wang, L.

1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Wang, L.

4184 - Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes
4268 - Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial

Wang, L.

3399 - Decoding the Immune Landscape of Pathogenic T Cells in Acute Graft-Versus-Host Disease By Single-Cell RNA-Seq

Wang, L.

3929 - Targeting HIF-Hydroxylases Compromises Disease Initiation and Propagation, and Synergises with Current Therapies to Eliminate Cancer Stem Cells in AML

Wang, M. (. Y.

LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Wang, M.

2912 - Preliminary Biomarker Data from a Phase 1/2 Study of Golidocitinib Demonstrates Targeting JAK/STAT Pathway to Treat Peripheral T-Cell Lymphoma

Wang, M.

1865 - The Association between Body Mass Index Trajectory and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
1899 - The Association of Agent Orange Exposure Duration with Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma Progression: A Population-Based Study
3489 - Racial Difference in Dynamic Markers for Progression of MGUS Using Machine Learning Approaches
4503 - Association between SLGT2 Inhibitor Use and the Progression of Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma

Wang, M.

2021 - The Safety and Efficacy of p CAR-19B, a Scfv Humanized CD19-Directed CAR-T for Patients with Relapsed/Refractory (R/R) CD19+ B-ALL
3298 - A Novel Platform to Manufacture High-Efficient “Off-the-Shelf” CAR-NK Products from Peripheral Blood Mononuclear Cells (PBMC)

Wang, M.

2668 - Selinexor-Loaded Polymeric Micelles for Multiple Myeloma Therapy
2720 - Establishment of Mortality Risk Prediction Model for Bloodstream Infections in Patients with Hematological Diseases
4796 - Study of Fabrication of Two Novel Methotrexate-Loaded Micelles and Their Anti-Lymphoma Effects

Wang, M.

28 - U.S. Cohort Study of Previously Untreated Patients with Congenital Hemophilia (ATHN 8: PUPs Study): Inhibitor Development and Treatment Characteristics
2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Wang, M.

662 - Clinical Development of Senza5^TMCART5: a Novel Dual Population CD5 CRISPR-Cas9 Knocked out Anti-CD5 Chimeric Antigen Receptor T Cell Product for Relapsed and Refractory CD5+ Nodal T-Cell Lymphomas

Wang, M. L.

Wang, M.

255 - Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies
1290 - Investigation of Impact Induced By AML1-ETO on Self-Renewal and Differentiation of Hematopoietic Stem and Progenitor Cells in Pre-Leukemic Stage
1297 - The Characteristics of AML1-ETO Fusion Gene Induced Pre-Leukemia Immune Microenvironment
1419 - Construction of Dual- and Enhanced Dual-Antibodies Targeting CD19 in the Treatment of B-ALL and Investigation of the Relevant Mechanisms
1980 - Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells
3295 - The Investigation of Antitumor Effect of Humanized Bispecific BCMA/CD38 CAR-T Cells on Multiple Myeloma

Wang, M.

276 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD⁺ Acute Myeloid Leukemia
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma

Wang, M. H.

4431 - Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up
4434 - Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Wang, M.

1951 - Distinct Immune Homeostasis Remodeling Patterns after HLA-Matched and Haploidentical Transplantation

Wang, M. C.

853 - Primary Results of Stimulus-MDS1: A Randomized, Double-Blind, Placebo-Controlled Phase II Study of TIM-3 Inhibition with Sabatolimab Added to Hypomethylating Agents (HMAs) in Adult Patients with Higher-Risk Myelodysplastic Syndromes (MDS)
4364 - Safety and Effectiveness of Ruxolitinib in Real-World Patients with Myelofibrosis: A 2-Year Observational Study from Taiwan

Wang, M.

2066 - Herombopag for Enhancement of Platelet Engraftment in Patients Undergoing Hematopoietic Stem Cell Transplantation
3439 - Impact of HLA-B Leader Mismatching on Outcomes after Haploidentical Transplantation with Antithymocyte Globulin

Wang, M.

1327 - C/EBPα-p30 Confers AML Cell Susceptibility to the Terminal Unfolded Protein Response and Resistance to Venetoclax By Activating DDIT3 Transcription

Wang, N.

4611 - MIP3α As an Early Prognostic Predictor for Patients with B-Cell Malignancies Receiving CD19/CD22-Redirected CAR T-Cell Cocktail Therapy
4632 - Radiation Prior to Chimeric Antigen Receptor T-Cell Therapy Is an Optimizing Bridging Strategy in Relapse/Refractory Aggressive B-Cell Lymphoma

Wang, N.

574 - Addition of Ruxolitinb to Corticosteroids As First-Line Therapy for High-Risk Acute Graft Versus Host Disease in Allogeneic Peripheral Blood Stem Cell Transplantation
2074 - Individualized Dosing of Anti-Thymocyte Globulin Led to Reduced CMV/EBV Reactivation and Superior Overall Survival in Adult Unmanipulated Haploidentical Peripheral Blood Stem Cell Transplantation: A Prospective Phase II Study

Wang, N.

2733 - Pediatric Acute Lymphoblastic Leukemia with Pdgfrb Fusions: A Multicenter Retrospective Study

Wang, P.

1885 - TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing
4518 - The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Wang, P.

331 - Additional Mutational Events at Diagnosis of CML Confer Inferior Failure-Free Survival and Molecular Response for Patients Treated with Frontline Imatinib but Not for Patients Treated with Frontline Second-Generation Tyrosine Kinase Inhibitors
4403 - TP53 Mutation Status Defines a Distinct Clinicopathological Entity of Therapy-Related Myeloid Neoplasm, Characterized By Genomic Instability and Extremely Poor Outcome

Wang, P.

1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41

Wang, P.

2031 - Matching-Adjusted Indirect Comparison (MAIC) of Lisocabtagene Maraleucel (Liso-cel) Versus Axicabtagene Ciloleucel (Axi-cel) for Second-Line (2L) Treatment of Patients (Pt) with Refractory/Early Relapsed (R/R) Large B-Cell Lymphoma (LBCL)

Wang, P.

4400 - Application of Newly Developed IPSS-M and Comparison of Different Prognostic Systems in Patients with Myelodysplastic Syndrome

Wang, P.

2873 - Nuclear NPM-ALK Protects Myc from Proteosomal Degradation and Contributes to High Protein Expression in Cancer Stem-like Cells in ALK-Positive Anaplastic Large Cell Lymphoma
3324 - Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)
4125 - The Application of the SORE6 Reporter in the Studies of Acute Myeloid Leukemia - a Novel Model for Disease Relapses

Wang, P.

437 - Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis

Wang, P.

2185 - Retrospective Assessment of Total Cost of Care in Non-Dialysis Dependent Chronic Kidney Disease Patients Receiving Parenteral Iron Therapy for Iron Deficiency Anemia

Wang, P.

1632 - Combination of Mitoxantrone Hydrochloride Liposome with Cyclophosphamide, Vincristine and Prednisone (CMOP) in Treatment-Naïve Patients with Peripheral T-Cell Lymphoma: A Multicenter, Open-Label, Single-Arm, Phase Ib Clinical Trial

Wang, P. F.

1891 - Treatment Patterns and Patient Outcomes in Relapsed/Refractory Multiple Myeloma (RRMM) Stratified By Exposure to Lenalidomide or Anti-CD38 Therapy and Double-Class Refractory Status: A Retrospective Electronic Health Record Database Study

Wang, P. N.

225 - Quantum-First Trial: FLT3-ITD–Specific MRD Clearance Is Associated with Improved Overall Survival

Wang, P. N.

878 - Impact of Allogeneic Hematopoietic Cell Transplantation in First Complete Remission in Addition to FLT3 Inhibition with Quizartinib in Acute Myeloid Leukemia with FLT3–Internal Tandem Duplication: Results from the Quantum-First Trial

Wang, P.

4536 - Update on the Outcome of M-Protein Screening Program of Multiple Myeloma in China: A 7-Year Cohort Study

Wang, Q.

3018 - First-in-Human Study of Elvn-001, a Highly Selective BCR::ABL1 Tyrosine Kinase Inhibitor, in Patients with Chronic Myeloid Leukemia Who Failed Previous Tyrosine Kinase Inhibitor Therapies

Wang, Q.

2951 - Preliminary Result of Phase 1 Trial of Orelabrutinib in Combination with Rituximab, Methotrexate, and Dexamethasone in Patients with Newly Diagnosed Primary CNS Lymphoma Implementing Bayesian Design for Dose-Seeking
4146 - Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia
4647 - Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1-like Acute Lymphoblastic Leukemia

Wang, Q.

2971 - The Impact of Chimeric Antigen Receptor T Cell Quality to Clinical Safety and Efficacy in Non-Hodgkin Lymphomas

Wang, Q. F.

2533 - SETD2 Regulates Nuclear Division to Achieve Polyploidization in Megakaryocyte
4102 - Identification of a Novel FAM135B Cancer Susceptibility Mutation in a Family with Multiple Cases of MLL-Rearranged AML

Wang, Q.

3007 - Single-Cell RNA Profiling of Primary Myelofibrosis Reveals RUX Resistance Decreasing Mononuclear Phagocytes in Peripheral Blood
4869 - Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia

Wang, Q.

2324 - Endogenous Endothelial Nitric Oxide Synthase (eNOS) Modulates Oxygen (O₂) Responsive Control of Red Blood Cell (RBC) Energy Metabolism and Antioxidant Systems
2360 - Compound Nanoparticle 5HMF-Prodrug Formulations for Optimized Anti-Sickling Therapy
3683 - Modified and Novel Lorrca Oxygenscan Measurement Parameters with Physiological Relevance

Wang, Q.

3283 - Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma

Wang, Q.

417 - Native Stem Cell Transcriptional Circuits in Normal and Malignant Early-Stage T Cells
418 - Polymerase-Associated Factor Complex (PAFc) Protects Notch-Induced Leukemia Cells from DNA Damage and Mitochondrial Stress

Wang, Q.

3102 - Resistance to the Non-Covalent BTK Inhibitor Pirtobrutinib

Wang, Q.

2783 - Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia

Wang, Q. S.

2542 - Detailed Analysis of the Impact of Clonal Hematopoiesis on the Risk of Severe COVID-19 Infection

Wang, Q.

4565 - Renal Response of Pomalidomide with Bortezomib and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients with Renal Impairment: A Prospective, Open-Label, Multicenter, Phase 2 Study

Wang, Q.

1885 - TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing
3226 - Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma
4518 - The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Wang, Q.

3283 - Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma

Wang, Q.

4146 - Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Wang, R.

2309 - Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma
4899 - Real-World Practice Patterns and Outcomes Following Bruton Tyrosine Kinase Inhibitors (BTKi) in Older Patients with Mantle Cell Lymphoma (MCL): A Population-Based Analysis
4943 - Second Malignancies Among Older Patients with Classical Myeloproliferative Neoplasms Treated with Ruxolitinib

Wang, R.

3589 - Real-World Assessment of Second Primary Malignancies in a Treated and Untreated Chronic Lymphocytic Leukemia Population in the United States

Wang, R.

3578 - Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib

Wang, R.

4587 - Efficient Multiplex Gene Editing of CD33 and CLL-1 in Human Hematopoietic Stem Cells Enables the Potential of Next-Generation Transplants for AML Treatment

Wang, R.

1972 - Initial Characterization of Nexi-001, a Donor-Derived T-Cell Product, for the Treatment AML Patients That Have Relapsed after Allogeneic Hematopoietic Stem Cell Transplant

Wang, R.

276 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD⁺ Acute Myeloid Leukemia

Wang, R.

3762 - Low-Dose Rhein Sensitizes Platelet Production to Thrombopoietin Receptor Agonists (TPO-RA) in Immune Thrombocytopenia

Wang, S. A.

95 - Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
224 - Clinical Outcomes and Impact of Therapeutic Intervention in Patients (pts) with Acute Myeloid Leukemia (AML) with Recurrence of Measurable Residual Disease (MRD) after Achievement of MRD-Negative Remission
709 - Venetoclax Combined with Cladribine, Idarubicin, Cytarabine (CLIA) As Induction Therapy in Patients with Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
944 - Achievement of Measurable Residual Disease (MRD) Negativity Supersedes Treatment Intensity in Predicting the Outcome of Patients with Acute Myeloid Leukemia
2805 - The Adverse Effect of Myelodysplasia-Related Mutations in De Novo Acute Myeloid Leukemia Is Associated with Higher Variant Allelic Frequency (VAF): A Proposal for a Numeric Cutoff for Variant Allelic Frequency
4224 - Utility of Flow Cytometry in Monitoring of Measurable Residual Disease in Patients with Hairy Cell Leukemia

Wang, S.

3406 - Phase II Multicenter, Randomized Controlled Study on Infusion of MSCs at 45 Days after Haplo-Hematopoietic Stem Cell Transplantation in the Prophylaxis of Gvhd
4694 - Fludarabine, Busulfan and Melphalan Based Conditioning Reduced Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myeloid Malignancies: A Multicenter Retrospective Analysis

Wang, S. Y.

4102 - Identification of a Novel FAM135B Cancer Susceptibility Mutation in a Family with Multiple Cases of MLL-Rearranged AML

Wang, S.

2537 - Loss of DHX15 Function Impairs Hematopoiesis in Vav-Dhx15-KO Mice and Cause DNA Damage-Induced Cell Cycle Arrest and Apoptosis in Leukemia Cell Lines
3731 - Recombinant Mouse GM-CSF Enhances the Bactericidal Ability of Pmns and Improves the Prognosis of Secondary Pseudomonas Aeruginosa Pneumonia By Intracellular IL-1β

Wang, S.

3770 - Efficiency and Safety of Avatrombopag in the Management of Thrombocytopenia with TPO or Tpora Ineffective：a Prospective, Single Arm, Exploratory Clinical Study

Wang, S. Y.

2309 - Racial Difference in Part D Enrollment and Survival Among Older Patients with Multiple Myeloma

Wang, S.

1488 - Cell-Free DNA (cfDNA)-Based Measurable Residual Disease (MRD) Detection As a Predictor of Relapse Post-Allogeneic Blood or Marrow Transplant (alloBMT) in Patients with Myeloid Malignancies

Wang, S.

2182 - Utilization of the Tapestri Platform for Quantification of Single Cell Vector Copy Number in CAR T Cell Products

Wang, S. Y.

1928 - Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Wang, S.

1941 - Indole-3-Carbinol Supplement Reduces GvHD Related Mortality in Allogeneic Hematopoietic Stem Cell Transplant Recipients
2164 - High Potency Vasoactive Intestinal Peptide Receptor Antagonists Induce Durable Antileukemia/Tumor T Cell Memory in Mice with Once Daily Dosing
4588 - Dual Inhibition of PI3K Delta and PI3K Gamma Isoforms to Prevent Graft-Versus-Host Disease By Limiting T Cell Expansion In Vivo

Wang, S.

1148 - Rituximab and Bortezomib for Patients with Newly Diagnosed Acquired Haemophilia: Single Arm, Single Center, Prospective Phase 2 Study

Wang, S.

2064 - Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Wang, S.

2574 - Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study

Wang, S.

3745 - Uncovering Transcriptome Characteristics in Bone Marrow Hematopoiesis in Immune Thrombocytopenia at Single-Cell Resolution

Wang, S.

1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Wang, S.

2956 - Waveline-001: Updated Results from a Phase 1 Dose Escalation and Cohort Expansion Study of Zilovertamab Vedotin (MK-2140) in Non-Hodgkin Lymphoma

Wang, S.

1989 - PI3K and BTK Inhibition Induces the Upregulation of CD19 and Increases Sensitivity to CAR T Cells in a Model of Marginal Zone Lymphoma (MZL)

Wang, S. Y.

1829 - Single-Cell Multi-Omics of Peripheral Blood Reveals Tiding and Evolution of Responsive and Resistant Clones upon Daratumumab-Based Treatments in Multiple Myeloma and Plasma Cell Leukemia

Wang, S. Y.

4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Wang, S.

1530 - Plasma Extracellular Vesicle-Associated microRNAs for Early Response Prediction in Patients with High-Grade B-Cell Lymphoma
1533 - Harnessing Cell-Free DNA Biological Features for Early Treatment Response Prediction in High Grade B-Cell Lymphoma

Wang, T.

113 - Development of a Validated Clinical Risk Score to Predict the Incidence of Acute Graft Versus Host Disease after Allogeneic Hematopoietic Cell Transplantation: A CIBMTR Analysis
278 - Does Race/Ethnicity Impact Umbilical Cord Blood Transplant Outcomes in a Contemporary Era?
373 - JAK2 ^V617F Mutation and Associated Chromosomal Alterations Involving JAK2 in Pre-HCT Blood Samples and Transplant Outcomes in Myelofibrosis Subtypes
2237 - Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis

Wang, T.

4713 - JAK/Rock Inhibitor TQ05105 for Glucocorticoid-Refractory or -Dependent Chronic Graft-Versus-Host Disease：Preliminary Analysis Results of a Phase 1b/2 Study

Wang, T.

1225 - Clonal Myeloid Heterogeneity in Older Autopsy Patients Determined By Multiple Bone Marrow Site Sequencing

Wang, T.

3141 - Association between Bone Marrow Immune Microenvironment Following Autologous Stem Cell Transplant and Duration of Response for Multiple Myeloma
4466 - Needle in a Haystack: A Pilot Study Combining Single-Cell Multiomics with Clinical NGS-MRD Sequencing to Search for Circulating Clonotypic Dedifferentiated Myeloma Cells

Wang, T.

1917 - Phase I Study of a Novel Oral Proteasome Inhibitor TQB3602 in Relapsed/Refractory Multiple Myeloma

Wang, T.

1626 - Zanubrutinib Plus Rituximab for the Treatment of Elderly Unfit Patients with Previously Untreated Diffuse Large-B Cell Lymphoma
4630 - Phase I Study of a BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <3 Days Using the High-Performance Platform

Wang, T.

350 - PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment

Wang, T.

1559 - Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study
2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma
3161 - Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment
4749 - A Retrospective, Matched Paired Analysis Comparing GBM/GBC Versus BEAM/Beac Conditioning Regimen for Autologous Stem Cell Transplantation in Non-Hodgkin’s Lymphoma

Wang, T.

254 - Functional Disruption of TET2-Mediated Cytosine Oxidation in CAR-T Cells Using IDH1 Neomorph

Wang, T.

2978 - Real-World Outcomes in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Treated with Standard of Care: A Cota Database Analysis

Wang, T. F.

509 - Risk of Venous Thromboembolism or Hemorrhage Among Individuals with Chronic Kidney Disease Taking a Direct Oral Anticoagulant Compared to Low-Molecular-Weight Heparin after a Hip or Knee Arthroplasty
1184 - Thrombophilia Gene Mutations for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy
2517 - Blood Biomarkers for the Prediction of Venous Thromboembolism in Perioperative or Hospitalized Cancer Patients: A Systematic Review
3752 - Evaluating Doac Efficacy and Safety Against Vka/LMWH in Patients with Atrial Fibrillation and Malignancies: A Systemic Review and Meta-Analysis
3827 - The Safety and Efficacy of Anticoagulation for the Management of Isolated Distal Deep Vein Thrombosis in Patients with Cancer
3830 - Management of Anticoagulation and Related Outcomes in Patients with Cancer-Associated Thrombosis and Thrombocytopenia: A Systematic Review and Meta-Analysis
- Frequently Asked Questions about Factor Xa Inhibitors

Wang, W.

1994 - Phase Ⅱ Study of Fully Human BCMA-Targeting CAR-T Cells (Zevorcabtagene Autoleucel) in Patients with Relapsed/Refractory Multiple Myeloma

Wang, W.

3050 - Phase Ⅱ,Open-Label, Multicenter, Single-Arm Study Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea(HU)

Wang, W.

1525 - Targeting the HSP90-MYC-CDK9 Axis to Overcome Dual Resistance to BTK Inhibition and CAR-T Therapy in Mantle Cell Lymphoma
1615 - Clinical Outcomes of Patients with Breast Implant- Associated Anaplastic Large- Cell Lymphoma (BIA-ALCL) Treated with Chemotherapy and Brentuximab Vedotin
2850 - HSP27 Promotes Mantle Cell Lymphoma Growth and Mediates Resistance to Venetoclax
4155 - Establishment of a Patient-Derived Organoid Culture Platform for Mantle Cell Lymphoma Drug Sensitivity and CAR T Cell Anti-Tumor Activity Assay

Wang, W.

3492 - Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

Wang, W.

2942 - Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Wang, W.

1254 - Differental Distribution of Hematopoietic Cells in Bone Marrow of PNH Patients Were Showed By Single-Cell Sequencing

Wang, W.

4295 - Orelabrutinib in Combination with Rituximab and Chemotherapy for Newly Diagnosed Aggressive B-Cell Lymphoma: A Multicenter, Single-Arm, Prospective Study

Wang, W.

4778 - Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34⁺ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Wang, W.

1884 - Effect of Predicted Fludarabine Lymphodepletion Exposure on Clinical Outcomes in Myeloma Patients Undergoing BCMA-CAR-T: An Exploratory Analysis from CARTITUDE-1

Wang, W.

3880 - NLRP6 in the Bone Marrow Microenvironment Regulates HSPC Quiescence Via MGP/RUNX2

Wang, W.

2682 - Targeted Nanotherapy of Hematologic Malignancies Using Gold Nanoframework-Based Delivery of a Novel NF-Kb Inhibitor

Wang, W.

4778 - Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34⁺ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Wang, W.

3981 - Pharmacologic Inhibitors of STAT3 or BCL6 Transcriptional Function Sensitize Lymphoma Cells to the Novel PD-1 Cis-Targeted PD1-IL2v Immunocytokine in a Murine Model

Wang, W.

3311 - Updated Results of Fumanba-1: A Phase 1b/2 Study of a Novel Fully Human B-Cell Maturation Antigen-Specific CAR T Cells (CT103A) in Patients with Relapsed and/or Refractory Multiple Myeloma

Wang, W.

1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency

Wang, W.

1853 - Single-Cell Analyses of Immune Microenvironment Informs Potential Benefits of Dual Macrophage-Targeted Therapy in Multiple Myeloma
4536 - Update on the Outcome of M-Protein Screening Program of Multiple Myeloma in China: A 7-Year Cohort Study

Wang, W.

816 - Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial

Wang, W. C.

181 - Hydroxyurea Dosing in Very Young Children with Sickle Cell Anemia: A Multicenter, Randomized, Controlled Trial (HUGKISS)
289 - Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial
883 - Optimizing the Frequency of Transcranial Doppler (TCD) Exams in Children with Sickle Cell Anemia

Wang, X.

2876 - Immune Checkpoints Involving the PD-1/PD-L1/L2 and CD73/A2aR Axes and the Immunosuppressive Microenvironment in DLBCL
4162 - Comprehensive Analysis of TP53 and CD58 Mutations and Identification of Patients with Inferior Prognosis and Enhanced Immune Escape in Diffuse Large B Cell Lymphoma
4174 - PIM1 Genetic Alterations Associated with Distinct Molecular Profiles, Phenotypes and Drug Responses in Diffuse Large B-Cell Lymphoma

Wang, X.

3425 - Profiles of Germline Predisposition Gene Variants in Hematologic Disorders and Its Impact on Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation

Wang, X. D.

4268 - Chidamide Plus Prednisone, Cyclophosphamide, and Thalidomide (CPCT) for Relapsed or Refractory Peripheral T-Cell Lymphoma: A Multicenter Phase II Trial

Wang, X.

558 - Orelabrutinib, Rituximab, and High-Dose Methotrexate (HD-MTX) in Newly Diagnosed Primary Central Nervous System Lymphoma (PCNSL): A Retrospective Analysis on Efficacy, Safety, and Biomarker
1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe

Wang, X.

1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency

WANG, X.

335 - Is the 2^nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy

Wang, X.

2756 - Bmf-500: An Orally Bioavailable Covalent Inhibitor of FLT3 with High Selectivity and Potent Antileukemic Activity in FLT3-Mutated AML

Wang, X.

1532 - Circulating Tumor DNA Clearance during Treatment As a Predictive and Prognostic Biomarker for Diffuse Large B-Cell Lymphoma Patients Receiving First-Line Therapy

Wang, X.

4312 - Transcriptional and Epigenetic Dysregulation Drives Erythroid and Megakaryocyte Differentiation Bias in the Spleens of Patients with Advanced Myelofibrosis

Wang, X.

4652 - Safety, Tolerability, PK/PD and Preliminary Efficacy of NKTR-255, a Novel IL-15 Receptor Agonist, in Patients with Relapsed/Refractory Hematologic Malignancies

Wang, X.

2288 - Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy

Wang, X.

3797 - Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Wang, X.

1288 - PHF6 Maintains Acute Myeloid Leukemia Via Regulating NF-Κappab Signaling Pathway

Wang, X.

3800 - Factor X Activator for Hemophilia Patients with Inhibitors: A Phase 1, First-in-Human, Multi-Center, and Open-Label Trial

Wang, X.

3925 - Inhibiting the Mitochondrial RNA Degradosome Complex SUV3 and Pnpase Increases dsRNA in the Cytoplasm, Triggers a Viral Mimicry Response and Kills AML Cells and Progenitors

Wang, X.

4258 - Phase II Study of Zanubrutinib in Combination with Rituximab and Methotrexate, Followed By Zanubrutinib Maintenance in Patients with Secondary Central Nervous System Lymphoma

Wang, X.

3317 - Off-the-Shelf CD33 CAR-NK Cell Therapy for Relapse/Refractory AML: First-in-Human, Phase I Trial
3475 - Amplifying Sting Activation By Bio-Inspired Nanomedicine for Targeted Acute Myeloid Leukemia Chemo- and Immunotherapy

Wang, X.

1990 - Allogeneic CAR-T Therapy Enabled By Base Editing of Lck to Resist Dasatinib Used to Prevent Rejection Mediated through Both T and NK in Host

Wang, X.

2841 - Single-Cell Transcriptome Analysis Reveals Stem Cell-like Subsets in the Progression of Waldenström’s Macroglobulinemia

Wang, X.

4869 - Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia

Wang, X.

687 - Endothelial-Targeted CD39 Ameliorates Pulmonary Hypertension in a Murine Model of Endothelial Toxin Administration

Wang, X.

1621 - Combination Anti-PD1 Antibody and Rituximab Followed By R-CHOP for Elderly Patients with Newly Diagnosed DLBCL: Analysis of the Phase II TREND Trial
2941 - A Prospective Study of Methotrexate in Combination with Ibrutinib and Temozolomide (MIT) in Newly Diagnosed Primary CNS Lymphoma
4227 - DNA-Demethylating Agents Combined with Anti-PD-1 Inhibitors Showed Activity in Patients with Relapsed or Refractory Extranodal NK/T Cell Lymphoma Who Have Failed Immunotherapy: An Exploratory Study

Wang, X.

1847 - Clinical Genomic Analyses Demonstrate t(11;14) Multiple Myeloma Retains B-Cell Biology and Distinct Mitochondrial Metabolism That Convey Increased Sensitivity to BCL-2 Inhibition By Venetoclax

Wang, X.

3762 - Low-Dose Rhein Sensitizes Platelet Production to Thrombopoietin Receptor Agonists (TPO-RA) in Immune Thrombocytopenia
3767 - Eltrombopag Plus Diacerein Versus Eltrombopag in Adult Primary Immune Thrombocytopenia: Interim Analysis of a Multicenter, Randomized, Controlled, Phase 2 Trial

Wang, X.

146 - BRD9 Facilitates Oncogenic Nrf2 Pathway and Dampens Venetoclax Sensitivity By Remodeling Chromatin Accessibility in Chronic Lymphocytic Leukemia
1560 - Identification of Pyroptosis-Related Signature and Development of a Novel Prognostic Model in Diffuse Large B-Cell Lymphoma
1671 - Global Burden, Risk Factors, and Trends of Non-Hodgkin Lymphoma in 2020 and Projections to 2040: A Population-Based Study
2664 - APG115 Enhances the Sensitivity of Ibrutinib Via Promoting p53 to Target MCL-1 in Chronic Lymphocytic Leukemia
2879 - Identification of Histone Acetylation Regulator KAT2A As a Potential Prognostic Biomarker in Diffuse Large B-Cell Lymphoma
3474 - AT56 Exerts Anti-Tumor Effects in Peripheral T Cell Lymphoma By Regulating HMOX1-Mediated Ferroptosis
3745 - Uncovering Transcriptome Characteristics in Bone Marrow Hematopoiesis in Immune Thrombocytopenia at Single-Cell Resolution
3980 - NAT10 Promotes Tumorigenesis of Diffuse Large B-Cell Lymphoma By ac4C-Dependent Acetylation of SLC30A9
4190 - Comprehensive Analysis of the Prognosis and Immune Infiltrates of Ferroptosis-Related Genes in Diffuse Large B-Cell Lymphoma
4295 - Orelabrutinib in Combination with Rituximab and Chemotherapy for Newly Diagnosed Aggressive B-Cell Lymphoma: A Multicenter, Single-Arm, Prospective Study
4305 - Incidence and Mortality of Second Primary Malignancies after Lymphoma

Wang, X.

1101 - Flonoltinib, a Novel JAK2/FLT3 Inhibitor, Potently Treats Hemophagocytic Lymphohistiocytosis and Increases Sensitivity to Dexamethasone

Wang, X.

257 - Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
4626 - BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System

Wang, X.

4267 - The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

Wang, X.

4168 - The Clinical and Translational Exploration of the Role of S1P/SPHK1 Pathway in Non-Hodgkin Lymphoma with Obesity

Wang, X.

2855 - Prompt Assessment of Tumor Load and Treatment Response in Patients with Lymphoma By a Blood-Based Multi-Omics Approach

Wang, X.

253 - MEK Inhibition in CAR-T Cells Prevents Exhaustion and Terminal Differentiation Via Downregulating C-Fos and JunB

Wang, X.

2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells
4776 - Antimetabolite Resistant CAR T Cells through the Suppression of Hypoxanthine Phosphoribosyltransferase 1

Wang, X.

163 - A Phase I Study of CD19-Targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
358 - Target Densities in Malignant and Normal Cells Determine CAR T Cell Efficacy and Off-Target Hematotoxicity

Wang, X.

918 - _{Predictive Factors of Relapse for Primary Immune Thrombocytopenia in Adults: A Single-Center Retrospective Cohort Analysis}

Wang, X.

354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells

Wang, X.

3907 - Loss of FBXO11 Function Establishes a Stem Cell Program in Acute Myeloid Leukemia through Dysregulation of the Mitochondrial Protease LONP1

Wang, X. C.

4102 - Identification of a Novel FAM135B Cancer Susceptibility Mutation in a Family with Multiple Cases of MLL-Rearranged AML

Wang, X.

2537 - Loss of DHX15 Function Impairs Hematopoiesis in Vav-Dhx15-KO Mice and Cause DNA Damage-Induced Cell Cycle Arrest and Apoptosis in Leukemia Cell Lines
3731 - Recombinant Mouse GM-CSF Enhances the Bactericidal Ability of Pmns and Improves the Prognosis of Secondary Pseudomonas Aeruginosa Pneumonia By Intracellular IL-1β

Wang, X.

4400 - Application of Newly Developed IPSS-M and Comparison of Different Prognostic Systems in Patients with Myelodysplastic Syndrome

Wang, X.

1467 - Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup
2039 - Baseline CRP and Ferritin Identify Patients at High Risk of Poor Outcomes after Axicabtagene Ciloleucel Despite Corticosteroid Prophylaxis

Wang, X.

3464 - The Experimental Gene Therapy on Type 2A/Iic VWD Mouse Model with AAV Vector Delivering Only VWF Propeptide Expression cassette4
3776 - Single-Cell Sequencing of Immune Cells from Hemophilia a Patients with Inhibitors and Acquired Hemophilia a Patients

Wang, X.

95 - Combined Ibrutinib and Venetoclax for First-Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL): 4-Year Follow-up Data
2746 - Phase Ib/2 Study of Oral Decitabine/Cedazuridine (ASTX727) and Venetoclax in Combination with the Targeted Mutant IDH1 Inhibitor Ivosidenib or the Targeted Mutant IDH2 Inhibitor Enasidenib in IDH Mutated Acute Myeloid Leukemia
3341 - Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30

Wang, X.

2841 - Single-Cell Transcriptome Analysis Reveals Stem Cell-like Subsets in the Progression of Waldenström’s Macroglobulinemia

Wang, X.

1734 - A Phase 1, Open-Label, Dose-Escalation Study of Selinexor Plus Ruxolitinib in Patients with Treatment-Naïve Myelofibrosis

Wang, X.

393 - Pklr Variants Associated with Acute Pain in Sickle Cell Disease Influence ATP Concentrations in Red Blood Cells
1044 - The Pyruvate Kinase Activator Mitapivat Improves Red Blood Cell Deformability and Sickling Kinetics in Adult Patients with Sickle Cell Disease
2367 - Activating Pyruvate Kinase Improves Red Blood Cell Integrity By Reducing Band3 Tyrosine Phosphorylation
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Wang, Y. L.

1624 - A Multicenter, Single-Arm, Prospective Phase II Study of Orelabrutinib Combined with High-Dose Methotrexate and Rituximab Sequential Autologous Hematopoietic Stem Cell Transplantation in Newly-Dignosed Primary Central Nervous System Lymphoma
2945 - Zanubrutinib PLUS RCHOP(ZR-CHOP) Regimen Achieves High Complete Response Rate in the Treatment of Newly-Diagnosed Double-Expression Diffuse Large B Cell Lymphoma

Wang, Y. P.

4102 - Identification of a Novel FAM135B Cancer Susceptibility Mutation in a Family with Multiple Cases of MLL-Rearranged AML

Wang, Y.

3797 - Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Wang, Y.

1178 - Use of Plasmic Scores to Aid Diagnosis of aHUS: A Real-World Analysis of Hospitalized Patients from the Premier Healthcare Database

Wang, Y.

1759 - A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Wang, Y.

2017 - Consolidation with Allogeneic Hematopoietic Cell Transplant Improved Survival Outcomes of Adults with Relapsed / Refractory Acute Lymphoblastic Leukemia Following Response to Memory-Enriched CD19CAR T Cells

Wang, Y.

1722 - Comparison of the Efficacy and Safety of Pegylated Interferon Alpha-2b and Common Interferon Alpha in Patients with Myeloproliferative Neoplasms

Wang, Y.

3767 - Eltrombopag Plus Diacerein Versus Eltrombopag in Adult Primary Immune Thrombocytopenia: Interim Analysis of a Multicenter, Randomized, Controlled, Phase 2 Trial

Wang, Y.

268 - Allogeneic but Not Autologous Stem Cell Transplantation Improves Outcome in HTLV-1-Associated North American Adult T-Cell Leukemia/Lymphoma
1512 - Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling Inhibition
2783 - Oncogenic JAK2/STAT Signaling Molecules Activation Is Associated with PD-L1 Upregulation in Acute Myeloid Leukemia
3946 - Adult T-Cell Leukemia/Lymphoma Diagnosed in North American Is Characterized By a Requirement for BCL6 and a Cell Cycle Program Associated with DNA Replication Stress

Wang, Y.

4817 - CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer ⁸⁹Zr-Crefmirlimab Berdoxam

Wang, Y.

2013 - Outcome of Tandem CD19/CD20 CAR Therapy with 3-Year Follow-up in R/R B-NHL

Wang, Y.

4536 - Update on the Outcome of M-Protein Screening Program of Multiple Myeloma in China: A 7-Year Cohort Study

Wang, Y.

2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma

Wang, Y.

2020 - SC-gtCAR19, a Non-Viral Genome Targeting Anti-CD19 CAR-T Candidate in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia: Updated Results from Long-Term Follow-up
2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial
2574 - Iron Chelation of Hetrombopag in Aplastic Anemia: A Post Hoc Analysis of a Phase II Study
4622 - Clinical Efficacy Observation of Humanized BCMA-CAR-T in the Treatment of Relapsed/Refractory Multiple Myeloma Complicated with Extramedullary Lesions

Wang, Y. C.

306 - Characteristics and Prognostic Effects of DNMT3A Co-Mutations
1467 - Transcriptome Analysis and Machine Learning Prioritize Therapeutic Strategies for High-Risk Pediatric AML Patients of the KMT2A-Fusion Subgroup
1471 - Expanding the High-Risk Definition for Children with Newly Diagnosed Acute Myeloid Leukemia
1498 - CXCR4 (CD184) Expression in Pediatric AML Is Associated with Bone Marrow Retention, Specific Disease Characteristics, and Worse Outcomes: A Report of 1004 Patients from the Children’s Oncology Group AAML1031 Protocol
4133 - A Robust Long Non-Coding RNA Expression Classifier for Risk Stratification in Pediatric AML

Wang, Y.

4801 - Identification of a Novel Nucleoside Prodrug with Preferential Activity in Lymphoma and Leukemia Subtypes

Wang, Y.

3283 - Allogeneic CAR-NK Cell Therapy Targeting Both BCMA and GPRC5D for the Treatment of Multiple Myeloma

Wang, Y.

1622 - Zanubrutinib, Lenalidomide, Rituximab, Temozolomide and Methotrexate (RLZT±MTX) As First-Line Treatment for Newly Diagnosed PCNSL: A Prospective, Open-Lable, Multicenter Clinical Trial

Wang, Y.

1381 - Homoharringtonine-Based Induction Regimens Combined with ATRA-Based Maintenance in Chinese Pediatric AML: A Report from the Cclg-AML 2015 Protocol Study

Wang, Y.

3372 - Allogeneic Peripheral Blood Stem Cell Transplantation for Bone Marrow Failure Syndromes Using CD34⁺-Selected Progenitor Cells Co-Infused with a Reduced Number of Non-Mobilized T-Cells

Wang, Y.

255 - Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies
660 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China
839 - Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)
1428 - Preclinical Studies and Phase II Trial of Venetoclax in Combination with Chidamide and Azacitidine in Relapsed/Refractory Acute Myeloid Leukemia
1980 - Universal Anti-CD7 CAR-T Cells Targeting T-ALL and Functional Analysis of CD7 Antigen on T/CAR-T Cells

Wang, Y.

2635 - Targeting HDAC3 to Overcome the Resistance to ATRA or Arsenic in Acute Promyelocytic Leukemia through Ubiquitination and Degradation of PML-RARα

Wang, Y.

4297 - CD19 Expression by IHC Alone Is Not a Predictor of Response to Loncastuximab Tesirine: Results from the LOTIS-2 Clinical Trial and Quantitative Systems Pharmacology Modeling

Wang, Y.

3285 - Development of a mRNA Lipid Nanoparticle (mRNA-LNP) Cancer Vaccine to Prevent Leukemia Relapse after Stem Cell Transplant

Wang, Y.

2386 - A Novel Finding in Cerebral Blood Flow in Patients with Sickle Cell Disease Using Bold Functional MRI
2392 - Acupuncture Alleviates Pain and Improves Quality of Life in Patients with Sickle Cell Disease
3490 - Association of Noninvasive Peripheral Blood Hemoglobin Assessments with Venous Blood Draws Among Sickle Cell Patients

Wang, Y.

132 - A Patient-Centered Communication Tool for Older Patients with Acute Myeloid Leukemia, Their Caregivers, and Oncologists: A Single Arm Pilot Study

Wang, Y.

601 - Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial
4146 - Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia

Wang, Y.

4562 - Sea-BCMA Mono- and Combination Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Updated Results of a Phase 1 Study (SGNBCMA-001)

Wang, Y.

1284 - CBFB-MYH11 Is Required for the Maintenance of Inv(16) AML

Wang, Y.

2892 - Pharmacokinetics, Safety, and Efficacy of Acalabrutinib in Chinese Patients with Relapsed/Refractory Mantle Cell Lymphoma and Other B-Cell Malignancies: An Open-Label, Multicenter Phase 1/2 Trial

Wang, Y.

270 - Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
4760 - Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT

Wang, Y.

702 - Using Spatial Transcriptomics to Reveal Fetal Liver Hematopoietic Stem Cell-Niche Interactions
3846 - Characterization of Dynamic Niche Signaling Modules during Embryonic Hematopoietic Development Using Spatial Transcriptomics

Wang, Y.

2944 - Phase 1 Safety and Dose Escalation of Purinostat Mesylate, a Uniquely Potent and Selective Inhibitor of HDAC I and IIb in Relapsed or Refractory Lymphoma and Multiple Myeloma

Wang, Y.

255 - Structural Optimization of Dual-Target CD22/CD19 CAR-T and Its Anti-Tumor Effects on B Cell Malignancies
660 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China

Wang, Y.

373 - JAK2 ^V617F Mutation and Associated Chromosomal Alterations Involving JAK2 in Pre-HCT Blood Samples and Transplant Outcomes in Myelofibrosis Subtypes
1264 - Telomere Shortest Length Assay (TeSLA) Defines the Distribution and Accumulation of the Shortest Telomeres in Dyskeratosis Congenita

Wang, Y.

780 - Development and Validation of a Prognostic Model Based on Clinical Biomarkers for Heart Failure in Adult Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
989 - Effect of Two Conditionings on Relapse in Myelodysplastic Syndrome and Secondary Acute Myeloid Leukemia Undergoing Allogeneic Hematopoietic Cell Transplantation
1393 - Prognostic Impact of WT1 Mutation on AML of Different Risk Groups Based on 2022 European Leukemianet (ELN) Risk Classification
1951 - Distinct Immune Homeostasis Remodeling Patterns after HLA-Matched and Haploidentical Transplantation
2051 - Thrombopoietin Levels Predict the Response to Avatrombopag Treatment in Patients with Persistent Thrombocytopenia after Haploidentical Hematopoietic Stem Cell Transplantation
2081 - Efficacy and Safety of MSCs Plus Basiliximab for the Treatment of Steroid-Resistant aGVHD after Haploidentical Stem Cell Transplantation: A Multicenter, Randomized, Open-Label Trial
2107 - Mutations of TP53 Gene in Acute Lymphoblastic Leukemia Do Not Affect the Survival Outcomes after Haploidentical Stem Cell Transplantation
3270 - Exploring the Effects of G-CSF Mobilization on the Immune Function of Mucosal-Associated Invariant T Cell Subsets By Single-Cell RNA-Seq
3423 - The FLT3-ITD Allelic Ratio and NPM1 Mutation Do Not Impact Outcomes in AML Patients with FLT3-ITD after Allo-HSCT: A Retrospective Propensity-Score Matching Study
3424 - Machine Learning Algorithm As a Prognostic Tool for Epstein-Barr Virus Reactivation after Haploidentical Hematopoietic Stem Cell Transplantation
4772 - A Prospective Study of Short-Term Chemotherapy Bridging Allogeneic-SCT in High Risk Peripheral T-Cell Lymphoma

Wang, Y.

4263 - First in Human (FIH) Study of GFH009, a Highly Selective Cyclin-Dependent Kinase 9 (CDK9) Inhibitor, in Patients with Relapsed/Refractory (r/r) Hematologic Malignancies

Wang, Y.

1230 - Primary HSPC-Derived Monocytes with DNMT3A p.R882H Exhibit Activated Myeloid Cell Gene Signatures

Wang, Y. H.

87 - Integrative Analysis of Blast Phase Chronic Myelomonocytic Leukemia Reveals Distinct Transformation Phenotypes Predictive of Drug Response
458 - A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia

Wang, Y. T.

2255 - Validation of the Impede VTE Score for Prediction of Venous Thromboembolism in Chinese Patients with Multiple Myeloma: A Retrospective Cohort Study

Wang, Y.

1960 - Novel Anti-CD117 Antibodies for Rapid and Efficient Hematopoietic Stem Cell Depletion and Safe Bone Marrow Conditioning

Wang, Y.

100 - Fc-Mediated Antibody Effector Function, Inflammation Resolution and Oligoclonality on TCR Rearrangements Predict Sustained MRD Negativity in Newly Diagnosed Multiple Myeloma Treated with Immunotherapy Regimens
174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
470 - Genomic Determinants of Resistance in Newly Diagnosed Multiple Myeloma Treated with Targeted-Immunotherapy
1852 - Structural Heterogeneity of Chromosome 1q Drives Outcome in Newly Diagnoses Myeloma

Wang, Y.

264 - The CAR-Hematotox Score Identifies Patients at High Risk for Hematological Toxicity, Infections and Poor Clinical Outcomes Following Brexucabtagene Autoleucel in Relapsed/Refractory Mantle Cell Lymphoma
798 - Incidence of Second Primary Malignancies in Lymphoma Survivors: A Prospective Cohort Study in the Modern Treatment Era
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
1664 - Outcomes with Immunochemotherapy Plus Radiation Versus Immunochemotherapy Alone in Stage I Diffuse Large B-Cell Lymphoma: A Retrospective Study
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
2957 - Outcomes and Prognostic Factors of Transformed Follicular Lymphoma: An Analysis from the LEO Consortium
4156 - Molecular Landscape of Primary Refractory DLBCL
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4276 - Prognosis Score for Overall Survival with CAR-T Therapy in Aggressive Lymphoma
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Wang, Y.

2182 - Utilization of the Tapestri Platform for Quantification of Single Cell Vector Copy Number in CAR T Cell Products

Wang, Y.

3797 - Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Wang, Y.

2803 - Survival Prediction Optimization of Acute Myeloid Leukemia Based on T-Cell Function-Related Genes and Plasma Proteins
3180 - Identification of a Novel Drug Sensitivity Biomarker SUMF2 for Carfilzomib/Bortezomib Dual-Drug Resistance MM
4532 - Predicting Survival of Persons with Newly-Diagnosed Plasma Cell Myeloma

Wang, Y.

3325 - Trial in Progress: A Phase 1 Umbrella Study of TCR-Engineered T Cells That Target HA-1 (TSC-100) and HA-2 (TSC-101) to Treat Residual Leukemia after Hematopoietic Cell Transplantation

Wang, Y.

1450 - Venetoclax Plus “2 + 5” Modified Intensive Chemotherapy with Daunorubicin and Cytarabine in Fit Elderly Patients with Untreated De Novo Acute Myeloid Leukemia: A Single-Center Retrospective Analysis
3922 - High Expression of BCAT1 Affects DNA Damage Response By Inhibiting α-KG-Dependent Histone Demethylase

Wang, Y.

3921 - RIPK3 Deficiency Caused By DNA Hypermethylation Blocks R-2-Hydroxyglutarate Induced Necroptosis in AML with IDH Mutation
4389 - EZH2 Inhibition Mediates Proptosis Via DHX9 and S100A9 in Myelodysplastic Syndromes

Wang, Y.

912 - Terminal Erythroid Differentiation Is Regulated By Mitochondrial Translation Via Maintenance of Iron Homeostasis

Wang, Z.

4184 - Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Wang, Z.

2011 - Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r/r T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Interim Analysis from a Phase 2 Trial

Wang, Z.

1766 - Alterations of Gut Microbiota in Myelodysplastic Syndromes and Aplastic Anemia: Potential Relationship with Inflammatory Response

Wang, Z.

1027 - A Systematic Review and Indirect Treatment Comparison of Ferric Carboxymaltose Versus Iron Isomaltoside in Correcting Iron Deficiency Anemia
1627 - Preliminary Safety and Efficacy of Zanubrutinib in Combination with Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Wang, Z.

902 - Epigenetic Age Acceleration and Neurocognitive Function Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

Wang, Z.

2048 - Development of a Novel Platform for in-Vitro Immune-Monitoring of Antigen-Specific T Cells and Discovery of Novel Antigen-Specific TCRs Using Immortalized B Cells Transfected with mRNA of Antigen Fused to Mitd (IBMAM)

Wang, Z.

4200 - Preliminary Safety and Efficacy Evaluation of IMM0306, a CD47 and CD20 Bispecific Monoclonal Antibody-Trap (mAb-Trap), from an Ongoing Phase I Dose-Escalation Study in Patients with Relapsed or Refractory B-Cell Non- Hodgkin's Lymphoma (R/R B-NHL)
4228 - A Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Wang, Z.

525 - Stromal STAT5-Mediated Trophic Activity Regulates Hematopoietic Multipotent Progenitor Niche Factors

Wang, Z.

3974 - Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)
4462 - Exploration of the Therapeutic Effects of CD47 and CD38 Antibody Combination in Relapsed or Refractory Multiple Myeloma (rrMM) and the Correlation with CD47 and CD38 Expression

Wang, Z.

1951 - Distinct Immune Homeostasis Remodeling Patterns after HLA-Matched and Haploidentical Transplantation
3270 - Exploring the Effects of G-CSF Mobilization on the Immune Function of Mucosal-Associated Invariant T Cell Subsets By Single-Cell RNA-Seq

Wang, Z.

4131 - Whole Genome Sequencing Comparison of Acute Myeloid Leukemia at Presentation and Remission Predicts Patient Outcome

Wang, Z.

1295 - Metabolic Biomarkers Affecting Cell Proliferation and Prognosis in Polycythemia Vera

Wang, Z.

2409 - Microglia Regulating Neuronal Apoptosis Via Alpha7 Nicotinic Acetylcholine Receptor in HIV-Associated Neurocognitive Disorders

Wange, L.

2606 - Synergistic Antileukemic Effect of Mek and Lsd1 Inhibitors Correlates with Decreased Phospho-Serine 315 of TP53
2811 - Uncovering the Enemy: Single-Cell Transcriptional Profiling of Measurable Residual Disease (MRD) Cells

Wangondu, R.

52 - IKZF1^plus Confers a Strong Adverse Prognostic Effect in Total Therapy Studies (XV/XVI)
- The Role of Ikaros (IKZF1) Alterations in B-Acute Lymphoblastic Leukemia

Wani, K.

3564 - Factors Associated with in-Hospital Mortality in Patients with Hemophagocytic Lymphohistiocytosis: A 5-Year Analysis from the National Inpatient Sample

Wani, R.

3680 - An Endogenous Metabolic Modulator Composition Improves Hydration Status and Decreases Adhesion Properties of Red Blood Cells from Patients with Sickle Cell Disease

Wanjari, P.

437 - Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis

Wanjiku, C. M.

3634 - The Role of a Multi-Center Tumor Board Discussion in Managing Acute Leukemia in Under-Resourced Settings
- Prevalence of Impairment in Activities of Daily Living in Adults with Sickle Cell Disease and Its Association with Disease Complications

Warburton, P.

4381 - Clinical Response to Azacytidine (AZA) Is Associated with Increased Contribution from Mutated Blood Progenitors: Insights from Single Cell Genotyping of Matched Stem/Progenitor and Mature Blood Cells from MDS/CMML Patients Pre- and Post-AZA Treatment

Ward, R.

4832 - “It’s Kind of a Hidden Code”: An Exploratory Study of Residents’ Experiences Caring for People with Sickle Cell Disease on the Internal Medicine Wards

Ward, S.

2356 - Blood Transfusion Ameliorates Free Haem-Induced Loss of Thrombomodulin and Endothelial Cell Activation in Paediatric Sickle Cell Anaemia

Wardecki, M.

31 - Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study
1201 - Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Wardell, C. P.

1842 - The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma

Ware, R. E.

182 - Hydroxyurea with Dose-Escalation to Reduce Primary Stroke Risk in Children with Sickle Cell Anemia in Tanzania: Primary Results of the Sphere Trial
184 - Hydroxyurea with Dose Escalation to Reduce Primary Stroke Risk in Children with Sickle Cell Anemia in Dominican Republic: The Sacred Trial
2400 - Hydroxyurea Pharmacokinetics and Fetal Hemoglobin Response in Ugandan Children with Sickle Cell Anemia
3649 - Hydroxyurea Pharmacokinetics in Young Children with Sickle Cell Anemia: Results from the Therapeutic Response Evaluation and Adherence Trial (TREAT)
3691 - Evaluation of Dosage and Food Effect on L-Glutamine Exposure for Sickle Cell Anemia: A Population Pharmacokinetic Analysis
- Global Hematology

Warlick, E. D.

1444 - Initial Results from SELECT-AML-1, a Phase 2 Study of Tamibarotene in Combination with Venetoclax and Azacitidine in RARA-Positive Newly Diagnosed AML Patients Ineligible for Standard Induction Chemotherapy

Warm, M.

1399 - Trial in Progress: An Open-Label Phase II Study of Relatlimab with Nivolumab in Combination with 5-Azacytidine for the Treatment of Patients with Relapsed/Refractory and Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia (AARON)

Warmack, A.

1141 - Pathogenicity of Sars-Cov-2 Spike Protein Variants Correlates with Coagulation and Complement Assays

Warnatz, H. J.

363 - Phase I/II Clinical Trials of Donor-Derived Purified Regulatory T Cells for the Treatment of Steroid-Refractory Chronic Graft Versus Host Disease

Warnatz, K.

1102 - Circulating B-Cell Precursor Cells As Potential Diagnostic and Therapeutic Biomarker in Patients with WHIM Syndrome

Warne, R.

4472 - CD73 Inhibition Reverses Immunosuppression and Has Potential As an Immunomodulatory Therapy in Patients with Multiple Myeloma

Warnecke, B.

852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

Warner, S. L.

1315 - Activin-like Kinase 2 (ALK2/ACVR1) Is a Resistance Factor and Therapeutic Vulnerability to FLT3 Inhibition in Acute Myeloid Leukemia

Warnqvist, A.

1572 - Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Warren, E. H.

2913 - Circulating Tumor DNA in Untreated Classical Hodgkin Lymphoma Patients Treated with Pembrolizumab and Chemotherapy: Dynamic Response Assessment and Correlation with Baseline Metabolic Tumor Volume
4031 - Clinical Outcome and Treatment-Related Mortality in Patients with Acute Myeloid Leukemia Treated at the Uganda Cancer Institute

Warren, J. T.

588 - Mavorixafor for Patients with Chronic Neutropenic Disorders: Results from a Phase 1b, Open-Label, Multicenter Study

Warrington, J.

973 - Costimulatory Domains Direct Distinct Fates of CAR T Cell Dysfunction

Warrington, K.

2541 - Clonal Hematopoiesis in Vexas Syndrome

Warsame, R. M.

768 - Prognostic Value of Month 1 Bone Marrow and PET MRD Status in CAR-T Therapy for Myeloma
970 - Persistance or Reappearance of Serum Monoclonal Protein Detected By Mass Spectrometry Is a Major Prognostic Factor in Patients with Newly Diagnosed Multiple Myeloma
993 - Outpatient Practice Pattern for Recently Approved CAR-T in Patients with Lymphoma and Multiple Myeloma
3177 - Muscle and Fat Composition in Patients with Newly Diagnosed Multiple Myeloma
3196 - Outcomes of Allogeneic Stem Cell Transplant for Multiple Myeloma
3220 - Therapeutic Outcomes of Relapsed-Refractory Multiple Myeloma Patients with 1q21+Treated with Daratumumab-Based Regimens: A Retrospective Analysis
3613 - Immunoglobulin Heavy Chain Amyloidosis: Patient Characteristics and Outcomes
4492 - Outcomes of Multiple Myeloma Patients Refractory to Standard Dose Vs Low Dose Lenalidomide
4501 - Patients with Monoclonal Gammopathy Have a High Rate of Second Symptomatic COVID-19 Infection Even after a Prior COVID-19 Infection and Vaccination
4523 - Evidence Supporting Light Chain Cast Nephropathy As a Myeloma Defining Event
4556 - Fixed Duration Daratumumab, Ixazomib, Lenalidomide, and Dexamethasone Quadruplet for Newly Diagnosed Multiple Myeloma – MRD Negativity and Survival Outcomes
4916 - Performance of Glomerular Filtration Rate Estimating Equations in Cancer Patients Evaluated for Chimeric Antigen Receptor T-Cell Therapy

Wartewig, T.

1303 - IFITM3 Acts As a PIP₃ Scaffold in TCR-PI3K Signaling
2660 - CD25 As Feedback Regulator of Oncogenic TCR Signaling in T-Cell Lymphoma

Wartiovaara-Kautto, U.

46 - Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia
2724 - Fractionated Inotuzumab Ozogamicin Combined with Low-Intensity Chemotherapy in Older Patients with Newly Diagnosed CD22+ Philadelphia Chromosome (Ph)-Negative B-Cell Precursor (BCP) Acute Lymphoblastic Leukemia (ALL): Results of the EWALL-INO Study
4249 - Subsequent Malignant Neoplasms after Primary Hematological Malignancy in Adult Patients (Aged ≥20 Years) – High Risk of Hodgkin Lymphoma in Patients with Chronic Lymphocytic Leukemia

Warwick, L. E.

3537 - Patient Reported Experience with Fatigue, a Cross Sectional Study Examining Indolent and Aggressive Lymphomas

Wäsch, R.

51 - Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL
212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)
4092 - Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial)

Wasef, B.

1406 - Assessment of Midostaurin in Combination with Idarubicin-Based Induction Treatment in Acute Myeloid Leukemia

Washio, K.

2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission

Wasifuddin, M.

2293 - Epidemiology of Non-Hodgkin Lymphoma: Global Patterns of Incidence, Mortality, and Trends

Wasik, M.

3280 - Overcoming CD19-Negative Relapses in Patients with B-Cell Lymphomas Treated with Tisagenlecleucel

Wasik, M. A.

1273 - DNA Polymerase Theta Protects Leukemia Cells from Metabolic-Induced DNA Damage

Wasik-Szczepanek, E.

966 - Differences in Clinical Course and Management of Sars-CoV2 Infection in Patients with Chronic Lymphocytic Leukemia between the Sequential Pandemic Phases: An Eric Study
1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL

Wasinski, D.

1159 - Real Pandemic World Results of Personalized Prophylaxis of Bleeds in Polish Children and Adolescents with Severe Hemophilia a

Wasmuth, R.

1326 - The Multi-CDK Inhibitor Dinaciclib Shows Synergistic Activity with the BET Inhibitor PLX51107 and Reverses BET Resistance through Inhibition of Canonical Wnt Signaling in Acute Myeloid Leukemia (AML)

Wass, M.

1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Wassef, M.

88 - DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation

Wasserman, G.

4736 - Impact of FDA-Approved Novel Agents for Steroid-Refractory Chronic Graft-Vs. Host Disease on Treatment Patterns and Outcomes – a Single Center Longitudinal Cohort Analysis

Wasswa, P.

4012 - High Preponderance of High-Risk Phenotypes of Acute Leukemias Among Ugandan Children

Wästerlid, T.

1572 - Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study

Watabe, S.

2630 - TPL2, a New Prognostic Factor and a Potential Therapeutic Target in ABC-DLBCL

Watanabe, A.

2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission

Watanabe, A.

1460 - Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)–Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)

Watanabe, A.

54 - Risk Stratified Therapy with Nelarabine and Intensified Administration of L-Asparaginase for Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia in Adolescents and Young Adults (JPLSG T-11/JALSG T-ALL-211-U): An Intergroup Phase 2 Study

Watanabe, E.

311 - Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy

Watanabe, K.

2706 - Prognostic Factors in Children with Acute Myeloid Leukemia Receiving the First Hematopoietic Stem Cell Transplantation in Second Remission

Watanabe, M.

3260 - Allogeneic Donor T Cells Directly Attack Renal Endothelial and Epithelial Cells in Mice

Watanabe, M.

3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

Watanabe, M.

3070 - Molecular Landscape of Myeloid Neoplasms with Der(1;7)(q10;p10)

Watanabe, S.

2987 - Elevated FDG Uptake in the Lung Is a Characteristic Finding of Intravascular Large B-Cell Lymphoma

Watanabe, T.

1570 - Final Analysis of JCOG0203 for Advanced-Stage Indolent B-Cell Lymphoma 15 Years after the End of Enrollment: Pooled Analysis of Arms a and B for Follicular Lymphoma

Watanabe, T.

1337 - Biomarkers of Clinical Resistance to Decitabine and Venetoclax Therapy Inferred By Transcriptome and Methylation Analyses

Watanabe, T.

311 - Durable Clinical Impacts and Mechanisms of Action and Resistance in EZH1/2-Targeting Epigenetic Therapy

Watber, P.

4157 - HTLV-1 Carriers with Circulating Dominant Clones Harbor ATL-like Mutational and Transcriptomic Profiles Which Identify an Ultra-High Risk Group for Disease Transformation

Watek, M.

1388 - A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL – a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Waters, N.

1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials

Wathan, T. K.

405 - The Impact of Dnmt3a or Tet2 CH on Alzheimer’s Disease in a Murine Model
3857 - Clonal Competition: Cisplatin Treatment Drives Dominance of TP53- over Tet2-Mutant Stem Cell Clones

Watke, J.

3918 - Lactate Utilization Provides a Metabolic Escape to Resist the Antileukemic Activity of BET Inhibition in Acute Myeloid Leukemia

Watkins, B.

109 - Single-Cell RNA-Seq Reveals an Interferon-Driven Inflammatory CD4 Naïve T Cell Subpopulation at Day 100 in Hematopoietic Stem Cell Transplant Patients That Ultimately Develop Chronic Gvhd
111 - Early Breakthrough T Cell Proliferation Despite CNI/MTX Prophylaxis Is a Harbinger of Acute Gvhd (AGVHD) and Is Controlled By Abatacept: Mechanism of Success of the ABA2 Agvhd Prevention Trial
3407 - Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis

Watkins, B.

925 - Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation
2545 - Dynamics of Clonal Hematopoiesis Inferred By Modelling Deep Bulk Whole-Genome Sequencing Data at a Single Time Point

Watkins, K.

4050 - Pediatric Preclinical Testing Consortium Evaluation of the Anti-CD123 Antibody-Drug Conjugate, IMGN632, Against Patient-Derived Xenograft Models of Pediatric Acute Lymphoblastic Leukemia

Watkins, M. P.

1539 - Mutations Associated with Progression in Follicular Lymphoma Predict Inferior Outcomes in Newly Diagnosed Patients (Alliance 151303)
4664 - Outcomes of Relapsed Refractory Double Hit Lymphoma: A Multicenter Observational Cohort

Watkins, N.

392 - Inhibition of MRP1 Induces Fetal Hemoglobin through NRF2 Activation to Protect Human Erythroid Cells from Sickling

Watowich, S. S.

1221 - STAT3 Protects Hematopoietic Stem and Progenitor Cell Function in Non-Inflamed Conditions

Watrin, T.

1343 - Targeting Hyperactivated Lck in PAX5 Rearranged Pediatric B-Cell Precursors Acute Lymphoblastic Leukemia
3977 - The RNA Binding Protein Musashi-2 (MSI2) Sustains the Growth and the Leukemogenic Potential of MLL-Rearranged Acute Lymphoblastic Leukemia, and It Is Involved in Glucocorticoid Resistance

Watson, A. M.

1716 - Phase 1/2a Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of Pxs-5505 in Patients with Primary, Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis

Watson, D.

3530 - The Cost of Cellular Therapy in the Treatment of Pediatric Acute Lymphoblastic Leukemia: A Commercial Insurance Claims Database Analysis

Watson, E.

4868 - Adaptation of the Serious Illness Care Program for Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndromes

Watson, E.

4699 - A Primed Neutrophil Subset Predicts the Risk of Bloodstream Infections in Allogenic Bone Marrow Transplant Patients: A Prospective Study

Watson, G.

1963 - Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy

Watson, R.

936 - MP0533: A Multispecific Darpin CD3 Engager Targeting CD33, CD123, and CD70 for the Treatment of AML and MDS Designed to Selectively Target Leukemic Stem Cells

Watt, E.

915 - CD8⁺TEMRA Clones Cause Platelet Lysis in Immune Thrombocytopenia

Wattad, M.

832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia

Wattad, N.

1022 - The Effect of Monoferric Transferrins on Hypoferremia in a Murine Model of Inflammation

Watts, J.

862 - Tracking the Evolution of Therapy-Related Myeloid Neoplasms Using Chemotherapy Signatures
1434 - Toxicity and Outcomes in Octo- and Nonagenarians with AML Treated with Venetoclax and Hypomethylating Agent Therapy
1460 - Phase 1/2, Open-Label, Dose Escalation, Dose Expansion Study of Menin Inhibitor DSP-5336 in Adult Patients with Acute Leukemia with and without Mixed-Lineage Leukemia (MLL)–Rearrangement (R) or Nucleophosmin 1 (NPM1) Mutation (m)
2760 - Updated Results from a Phase 1 Study of APVO436, a Novel Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecule, in Relapsed/Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome
4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes
4358 - INCB057643 Monotherapy in Patients with Relapsed or Refractory Myelofibrosis: A Phase 1 Study
4368 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Advanced Myelofibrosis (MF): Updated Results and Genomic Analyses

Watts, K.

663 - Efficient and Specific Multi-Locus Editing of Allogeneic CAR T Cells for Hypoimmunity during Large Scale Manufacture Using Cas12b

Watts, K.

997 - Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure
4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Watts, N.

1916 - Stem Cell Mobilization Characteristics for Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma (NDMM) Treated with Carfilzomib, Lenalidomide, Dexamethasone, and Daratumumab (KRd-Dara)
2299 - Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant

Waugh, R.

4265 - Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Waukau, J.

4391 - A Phase I/II Study of Seclidemstat, an LSD1 Inhibitor, and Azacitidine for Patients with Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
4411 - A Phase I Open Label Study of Fostamatinib, a SYK Inhibitor, in Patients with Lower-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia

Waultier, A.

3356 - Efficacy of CAR-T Cells in Primary Central Nervous System Lymphomas: The French Experience of the National LOC Network

Wawrzyniecka, P.

258 - A Novel Protein-Based Approach to Generate Allogeneic CAR-T Cells with Simultaneous TCR and MHC Class 1 Downregulation

Waxman, A.

4529 - Infectious Complications of B-Cell Maturation Antigen (BCMA)-Targeted Therapies for Relapsed/Refractory Multiple Myeloma

Wayant, C.

4866 - Hype, Spin or Accurate Reporting: The Quality of Reporting on Oncology News Website

Wayi-Wayi, G.

4890 - Exploratory Validation of a Bespoke International Patient Symptom Survey in Idiopathic Multicentric Castleman’s Disease Using Psychometric Testing: Implications for Clinical Practice and Routine Data Collection

Wayne, A. S.

2718 - Phase I Study of Tagraxofusp with or without Chemotherapy in Pediatric Patients with Relapsed or Refractory CD123-Expressing Hematologic Malignancies: A Therapeutic Advances in Childhood Leukemia and Lymphoma (TACL) Consortium Trial

Wayser, G. R.

4855 - Clinician and Patient Factors Influencing Treatment Decisions in Front-Line Chronic Lymphocytic Leukemia: A Qualitative Research Study

Wazir, M.

452 - Mutant Srsf2 Diminishes Jak2^V617F-Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2-Mutant MPN
3178 - Plasma Cell Leukemia: A Multicenter Retrospective Study of 130 Patients

Weaver, K. B.

667 - The Performance of Electronic Consultation in Non-Malignant Hematology in a Fee-for-Service Care Delivery Model

Weaver, M. S.

2220 - Understanding the Treatment Preferences of Adults with Cancer

Webb, A.

270 - Associations of Minor Histocompatibility Antigens with Clinical Outcomes Following Allogeneic Hematopoietic Cell Transplantation
1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT
4760 - Genome-Wide Non-HLA Mismatches Improve Risk Stratification for Overall Survival and Cause Specific Mortality after Unrelated Donor Allogeneic HCT

Webb, M. W.

3750 - Theme and Variation: Structuring Thrombus Formation from Jugular/Arterial Puncture Wounds to Occlusive Clots in a Mouse Model

Weber, A.

2097 - Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd

Weber, D.

2709 - Second Malignancy after Childhood AML Treatment – a Retrospective Analysis of the AML-BFM Stud

Weber, D. S.

2393 - Natural History of Pediatric Patients with Sickle Cell Disease and Concurrent Cerebral Vasculopathies: Report of 62 Cases from a Single Institution

Weber, D.

832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
2799 - Analysis of Patient-Level Data from 3 Cooperative Group Trials Confirms a Survival Advantage for NPM1m Patients Achieving MRD-Negative CR after Intensive Induction

Weber, D.

3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients

Weber, D. M.

115 - Impact of Presence and Amount of Clonal Plasma Cells in Autografts Affect Outcomes in High-Risk Multiple Myeloma Patients Undergoing Autologous Hematopoietic Stem Cell Transplant
1929 - Initial Results of a Phase 1 Study of Daratumumab, Ixazomib, and Dexamethasone in Newly Diagnosed and Previously Treated AL Amyloidosis
3169 - Single Cell Profiling of BCMA Naïve Vs Refractory Relapsed Myeloma Patients Reveals Unique Transcriptomic Profiles in Tumor and Microenvironment
4751 - Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4:14): The MD Anderson Cancer Center Experience

Weber, D.

220 - A Randomized Comparison of the Fractionated Versus Single Dose Schedule of Gemtuzumab Ozogamicin at Induction with Determinants of Benefit for Older AML Patients: UK NCRI AML18 Trial Results

Weber, E.

- An Integrated View of T-Cell Exhaustion

Weber, G. M.

1198 - Antiplatelet Medications and Intracranial Hemorrhage in Patients with Primary Brain Tumors

Weber, H. J. J.

4033 - Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse

Weber, K.

1531 - EFS24 Failure, BRD4 Expression, and TP53 Are Linked to Reduced CDKN1A Expression in DLBCL and May be Targeted By Single-Agent Protac ARV-825 or in Synergistic Combination with the CDK4/6 Inhibitor Abemaciclib
2848 - The DLBCL Axis of Low TNFRSF10B Expression, TP53 Loss, and a Cold Immune Microenvironment May be Addressed By the Synergistic Combination of Eprenetapopt and Idasnutlin

Weber, T.

LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Webster, J. A.

2101 - Allogeneic Blood or Marrow Transplantation (AlloBMT) with High-Dose Post-Transplantation Cyclophosphamide (PTCy) for Acute Lymphoblastic Leukemia (ALL) in Patients Aged ≥ 55: Best Results in B ALL in First Remission (CR1) with Reduced-Intensity Conditioning (RIC)
4015 - Impact of Inotuzumb Ozogamicin on Outcome in Relapsed or Refractory Acute B-Lymphoblastic Leukemia Patients Prior to Allogeneic Hematopoietic Stem Cell Transplantation
4768 - Outcomes of Patients with TP53-Mutated Myeloid Neoplasms (TP53-MN) and the Role of Allogenic Blood or Marrow Transplantation (alloBMT)

Webster, J.

3259 - Inhibition of the Receptor Interactive Protein Kinase 1 (RIP1) Pathway Prevents Acute Gvhd

Webster, N.

91 - MRD4 Eradication at 6 Months and Early Clearance of MRD with Combination of Ibrutinib Plus Venetoclax Results in Sustained Clinical and MRD Responses: Exploratory Analysis of the Blood Cancer UK TAP Clarity Study
3125 - High-Sensitivity Analysis of Normal B-Cell Subsets in MBL and Untreated CLL Identifies Patients with Sub-Optimal Sars-Cov-2 Antibody Responses

Webster, S.

680 - Interim Analysis of Safety and Hematological Parameters of an Ongoing Long-Term Open-Label Extension Study of Investigational PI3Kδ Inhibitor Leniolisib for Patients with Activated PI3K Delta Syndrome (APDS) through December 2021

Wechalekar, A. D.

972 - Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis
1586 - Type 1 Cryoglobulinaemia Associated with Waldenström Macroglobulinemia, IgM MGUS or Non-Hodgkin Lymphoma
1887 - Evaluation of the Path to Diagnosis and Time to Treatment in Patients with Light-Chain Amyloidosis Using the Komodo Claims Database
3244 - Efficacy and Safety of Belantamab Mafodotin Monotherapy in Patients with Relapsed or Refractory Light Chain Amyloidosis: A Phase 2 Study By the European Myeloma Network

Wechsler, D. S.

948 - A Single Cell Atlas and Interactive Web-Resource of Pediatric Cancers and Healthy Bone Marrow
1412 - A Pilot Study of Azacitidine As Epigenetic Priming for Chemotherapy in Infants Less Than 1 Year of Age with KMT2A-Rearranged Acute Lymphoblastic Leukemia (ALL); Results from the Children’s Oncology Group (COG) Trial AALL15P1

Wedge, D. C.

3938 - Genomic Panorama and Clonal Evolutionary Trajectory of Classical Hairy Cell Leukemia

Weeks, L. D.

437 - Molecular Characterization of Adult Acute Lymphoblastic Leukemia Identifies a Subgroup with Myeloid Mutations and Pre-Existing Clonal Hematopoiesis
452 - Mutant Srsf2 Diminishes Jak2^V617F-Induced Erythrocytosis in Mice and Is Associated with Lower Hemoglobin in Patients with Chronic Phase JAK2-Mutant MPN
926 - Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis
4053 - Nelarabine Combination Therapy for Relapsed or Refractory T-Cell Acute Lymphoblastic Lymphoma/Leukemia
- How to Transition from Trainee to Faculty

Weerasathain, R.

1032 - Plasma Metabolomic Profiles Are Imbalanced in Adults Thalassemia Patients with Malnutrition and That Imbalance Is Alleviated By Oral Nutritional Supplements: A Prospective Randomized Controlled Trial

Wehmeyer, G.

323 - Tafasitamab and Lenalidomide in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL): Real World Outcomes in a Multicenter Retrospective Study

Wei, A. H.

606 - A Prospective Phase 2 Study of Venetoclax and Low Dose Ara-C (VALDAC) to Target Rising Molecular Measurable Residual Disease and Early Relapse in Acute Myeloid Leukemia
711 - High Response and Prolonged Treatment-Free Remission after a Short-Course of Modified Intensive Chemotherapy and Venetoclax in Elderly AML: An Updated Analysis of the Caveat Trial
840 - Molecular MRD Assessment Is Strongly Prognostic in Patients with NPM1 Mutated AML Receiving Venetoclax Based Non-Intensive Therapy
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
1456 - High Deliverability of a Midostaurin Triplet Regimen Incorporating Venetoclax and Low Dose Cytarabine in Non-Adverse Cytogenetic Risk Acute Myeloid Leukaemia: A Sub-Analysis of the Australasian Leukaemia Lymphoma Group (ALLG) Intervene Study
2784 - Intensified Induction Chemotherapy Results in More Rapid Early NPM1 Mutant (mut) Measurable Residual Disease (MRD) Clearance but Similar Disease Outcomes
3329 - An Open-Label, First-in-Human, Dose-Escalation Study of SAR443579 Administered As Single Agent By Intravenous Infusion in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-Cell Acute Lymphoblastic Leukemia (B-ALL) or High-Risk Myelodysplasia (HR-MDS)

Wei, A. H.

1226 - Allogeneic Hematopoietic Cell Transplantation (HCT) and Impact on Clonal Haematopoiesis and Post-HCT Therapy-Related Myeloid Neoplasm in Heavily Treated and Poor Risk Patients with Plasma Cell Myeloma
1443 - Preliminary Safety and Efficacy of Bgb-11417, a Novel Bcl-2 Inhibitor, in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML)
1754 - Somatic Mutational Landscape of Hereditary Hematopoietic Malignancies Associated with Germline Variants in RUNX1, GATA2 and DDX41
2757 - Olutasidenib (FT-2102) Induces Durable Complete Remissions in Patients with Relapsed/Refractory mIDH1 Acute Myeloid Leukemia. Results from a Planned Interim Analysis of a Phase 2 Pivotal Clinical Trial

Wei, A.

138 - Silent Cerebral Infarction during Immune TTP Remission – Prevalence, Predictors and Impact on Cognition

Wei, B.

1635 - Preliminary Results of a Phase Ⅱ Study of Zanubrutinib Combined with Immunochemotherapy in Patients with CD79A/CD79B-Mutant Diffuse Large B-Cell Lymphoma

Wei, C.

2942 - Phase Ib/II Study of Rituximab, Lenalidomide and Methotrexate Followed By Lenalidomide Maintenance in Patients with Newly Diagnosed Primary CNS Lymphoma: The Remla Trial

Wei, C.

2922 - A Multicenter, Phase III Study of Chidamide, Azacitidine Combined with CHOP Versus CHOP in Patients with Untreated Peripheral T-Cell Lymphoma

Wei, C.

253 - MEK Inhibition in CAR-T Cells Prevents Exhaustion and Terminal Differentiation Via Downregulating C-Fos and JunB

Wei, D.

4778 - Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34⁺ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Wei, F. Y.

912 - Terminal Erythroid Differentiation Is Regulated By Mitochondrial Translation Via Maintenance of Iron Homeostasis

Wei, G.

3336 - High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study
4642 - Safety and Efficacy of CD19 CAR-T Cells for Refractory Systemic Sclerosis: A Phase I Clinical Trial

Wei, H.

839 - Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)
3491 - Predicting Response to FLT3 Inhibitors Using Genomics-Based Computational Bio-Simulation Platform

Wei, J.

2989 - A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data
3067 - Soluble PD-L1 Predict Poor Outcome and Disease Progression in Patients with De Novo Myelodysplastic Syndrome
4386 - High Expression of Plasma IL-1β Levels and Transition of Regulatory T-Cell Subsets Correlate with Disease Progression in Myelodysplastic Syndrome

Wei, J.

3435 - Combination of Cytogenetic Classification and MRD Status Correlates with Outcomes of Autologous Versus Allogeneic Stem Cell Transplantation in Adults with B Cell-Acute Lymphoblastic Leukemia in First Remission

Wei, J.

253 - MEK Inhibition in CAR-T Cells Prevents Exhaustion and Terminal Differentiation Via Downregulating C-Fos and JunB

Wei, J. X.

4948 - Factors Associated with Early Mortality in Patients with Multiple Myeloma: A SEER Analysis

Wei, J.

816 - Multi-Omics Analysis of Human Mesenchymal Stem Cell Guides Perinatal MSC Based Cellular Therapy for Splenectomy-Nonresponsive Refractory Immune Thrombocytopenia: A Phase I Clinical Trial

Wei, J.

1603 - Tucidinostat Maintenance after Achieving Objective Response to First-Line Therapy in Peripheral T-Cell Lymphoma: A Single-Center Retrospective Case-Control Study

Wei, J.

1099 - Ruxolitinib Combined with Dexamethasone in Adult Patients with Newly Diagnosed Hemophagocytic Lymphohistiocytosis: A Prospective, Single-Center, Single-Arm, Phase 2 Clinical Trial

Wei, L.

777 - Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with Aggressive T-Cell Malignancies in a Phase I/II Trial
2891 - Extended Follow up of a Phase 2 Study of Ibrutinib in Hairy Cell Leukemia

Wei, M. C.

1544 - Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide
1588 - An External Control for Mosunetuzumab Using Real-World Data in Follicular Lymphoma in the Third or Subsequent Lines of Systemic Therapy
1630 - Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
2871 - Pharmacodynamic Biomarkers of Mosunetuzumab Efficacy and Safety in Patients with Relapsed/Refractory Non-Hodgkin Lymphoma: Results from a Phase I/II Study

Wei, M. C.

610 - Mosunetuzumab Monotherapy Demonstrates Durable Efficacy with a Manageable Safety Profile in Patients with Relapsed/Refractory Follicular Lymphoma Who Received ≥2 Prior Therapies: Updated Results from a Pivotal Phase II Study
1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study
1637 - SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Wei, M.

4267 - The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Orelabrutinib in Chinese Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma: Updated Results of a Multicenter, Phase I/IIa Trial

Wei, M.

1274 - TET2-Mediated mRNA and DNA Oxidation in Leukemia Homing and Immune Evasion

Wei, Q.

257 - Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
4636 - Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL

Wei, Q.

2007 - Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

Wei, R.

3669 - Erythroid Response in Patients with Non-Transfusion-Dependent β-Thalassemia Treated with Luspatercept: Long-Term Data from the BEYOND Trial

Wei, S.

839 - Prognostic Effect and Clinical Application of Early Measurable Residual Disease (MRD) By Flow Cytometry on De Novo Acute Myeloid Leukemia (AML)

Wei Teik, V. L.

4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore

Wei, W.

4212 - An Open-Label, Multicenter,Single-Arm, Phase I Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 in Patients with Relapsed or Refractory Hematologic Malignancies

Wei, W.

3151 - Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma
4091 - A Multi-Center Phase Ib Trial of the Histone Deactylase Inhibitor (HDACi) Entinostat in Combination with Anti-PD1 Antibody Pembrolizumab in Patients with Refractory/Relapsed Myelodysplastic Syndromes (RR-MDS) or Oligoblastic Acute Myeloid Leukemia (RR-AML) after Hypomethylating Agent (HMA) Failure

Wei, W.

1199 - Efficacy of the Hepcon System in Reducing Hemorrhagic and Thrombotic Complications in Antiphospholipid Syndrome Patients Undergoing Cardiac Surgery Requiring Cardiopulmonary Bypass
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Wei, W.

2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)

Wei, W.

4778 - Preliminary Safety and Efficacy Results of EDI001: An Investigator Initiated Trial on CRISPR/Cas9-Modified Autologous CD34⁺ Hematopoietic Stem and Progenitor Cells for Patients with Transfusion Dependent β-Thalassemia

Wei, W.

3922 - High Expression of BCAT1 Affects DNA Damage Response By Inhibiting α-KG-Dependent Histone Demethylase

Wei, X.

3161 - Multiple Myeloma-Derived Mir-27b-3p Facilitates Tumor Progression Via Promoting Tumor Cell Proliferation and Immunosuppressive Microenvironment

Wei, X.

660 - Sustained Remission and Decreased Severity of CAR T-Cell Related Adverse Events: A Pivotal Study Report of CNCT19 (inaticabtagene autoleucel) Treatment in Adult Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia (R/R B-Cell ALL) in China
3974 - Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)
4090 - Phase I Study of TQB3455, a Selective Inhibitor of IDH2 with Favorable Safety and More Potent Efficacy to IDH2-R172K Mutation, for Acute Myeloid Leukemia and Myelodysplastic Syndrome

Wei, Y.

1204 - Machine Learning Applications for Prediction of Blood Transfusion and Survival in Acute Myeloid Leukemia
2745 - High Efficacy of Azacitidine Plus Hag in Acute Myeloid Leukemia: A Multi-Center, Phase 2 Clinical Trial
4400 - Application of Newly Developed IPSS-M and Comparison of Different Prognostic Systems in Patients with Myelodysplastic Syndrome

Wei Ying, J.

3494 - An Ex-Vivo Combination Drug Sensitivity Platform for Predicting Sensitivity to FLT3 Inhibitor-Based Combination in Acute Myeloid Leukemia

Wei, Y.

1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe
4184 - Oligosecretory Waldenström Macroglobulinemia Patients Exhibit Excellent Treatment Response and Outcomes

Wei, Y.

3061 - Downregulation of UBA1 in Myelodysplastic Syndrome
3090 - Impact of Spliceosome Mutations on the Prognosis of Myelodysplastic Syndrome (MDS)
3496 - Combined Structural Variant and Mutation Profiling for Comprehensive Characterization of Chromoanagenesis and TP53 Mutations in Myelodysplastic Syndromes with Complex Karyotype
4392 - Genomic Evolution of Patients with Myelodysplastic Syndrome after Hypomethylating Agent Failure

Wei, Z.

575 - Basiliximab in the Prevention of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Thalassemia Major: A Prospective, Multicenter, Open-Label, Randomized Controlled Study

Wei, Z.

2096 - Analysis Benefits of a Second Allo-HSCT after CAR-T Cell Therapy in 97 Patients with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Who Relapsed after a First Transplant

Wei, Z.

4668 - High Metabolic Tumor Volume Is Associated with Higher Toxicity and Decreased Efficacy of BCMA CAR-T Cell Therapy in Multiple Myeloma

Weibl, K.

3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success

Weibull, C. E.

448 - Reproduktiv Patterns Among Non-Hodgkin Lymphoma Survivors By Subtype in Sweden, Denmark and Norway
953 - FLIPI24: An Improved International Prognostic Model Developed on Early Events in Follicular Lymphoma
1572 - Treatment Sequencing and Survival in Follicular Lymphoma: A National Population-Based Study
4236 - Treatment-Related Circulatory Diseases and Mortality in Hodgkin Lymphoma Patients Using Multi-State Modelling and Relative Survival

Weich, K.

3749 - Platelet Phosphatidylserine Is the Critical Mediator of Increased Thrombus Formation in Heparin-Induced Thrombocytopenia

Weigand, M.

3842 - Magnetic Fractionation of Red Blood Cells Based on Oxygen Saturation in Sickle Cell Disease

Weigel, B. J.

2762 - Safety and Activity of Flotetuzumab in Pediatric and Young Adult Patients with Relapsed/Refractory Acute Myeloid Leukemia: Results from the COG PEPN1812 Phase 1 Trial

Weigel, C.

1347 - PRMT5 Inhibition Potentiates Anti-Tumor Immune Targeting of EBV-Driven B Cell Lymphoproliferative Disease
3950 - Methylome Analysis of Epstein-Barr Virus with Nanopore Sequencing Reveals Viral State Dynamics

Weigert, A.

2099 - Outcomes Following Hypomethylating Agent / Venetoclax Combination-Therapy for MDS or AML Relapse after Allogeneic Hematopoietic Stem Cell Transplantation
3364 - Collections of Autologous Lymphocytes for Treatment with Chimeric Antigen Receptor (CAR) T-Lymphocytes – No Association of Clonal Hematopoiesis (CH) with Manufacturing Success
4077 - Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Weigert, O.

4106 - Computational Tool for Assessing Differential Cell Type to Cell Type Communication in Case-Control Studies Using Single-Cell RNA-Seq

Weiler, M.

1677 - Metaphyseal Stromal Progenitor Cells Are Skewed Via Wnt-Activation Towards Osteogenesis in Progressed Myelofibrosis

Weiliang, S.

2011 - Efficacy and Safety of Donor-Derived CD7 CAR T Cells for r/r T-Cell Acute Lymphoblastic Leukemia/Lymphoma: Interim Analysis from a Phase 2 Trial

Weill, S.

3155 - Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma

Weimer, E. T.

1948 - Shared Graft Versus Leukemia Minor Histocompatibility Antigens in DISCOVeRY-BMT

Weimer, N.

1316 - Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms
1744 - Direct Comparison of NSG and NBSGW Mice for MDS Patient-Derived Xenograft Models
4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Wein, A.

4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Weinacht, K. G.

3264 - Functional Human iPSC-Derived Thymic Epithelial Progenitor Cells Reconstitute T Cell Development and Function in an In Vivo Model of Thymic Aplasia

Weinberg, J. B.

1799 - Chronic Lymphocytic Leukemia in African Ancestry Population Is Characterized By Increased Telomere Erosion

Weinberg, K. I.

3265 - Non-Genotoxic Restoration of the Hematolymphoid System in Fanconi Anemia Mice through Antibody-Mediated Hematopoietic Stem Cell Transplantation
3459 - Hematopoietic and Immunological Assessment in Fanconi Anemia after Ex Vivo Lentiviral FANCA Gene Therapy with RP-L102

Weinberg, R. S.

4681 - Recovery of Highly Functional Human Hematopoietic Stem and Progenitor Cells from 27-Year Old Cryopreserved Umbilical Cord Blood

Weiner, A.

1928 - Daratumumab Carfilzomib Lenalidomide Dexamethasone Provides Effective Salvage for Functionally and Cytogenetically High-Risk Myeloma Patients, Except Those Expressing Module-1 Transcriptional Signature: Extended Follow-up from Kydar Multicenter Clinical/Translational Trial.

Weinhaeuser, I.

523 - M2 Macrophages Drive Resistance to Phagocytosis and Improve Mitochondrial Metabolism in Acute Myeloid Leukemia Facilitating Leukemic Transformation and In Vivo Engraftment
2787 - High MN1 Expression Is Associated with an Lspc-Enriched Phenotype and Glycolysis Representing a New Vulnerability in Acute Myeloid Leukemia
3960 - Functional Drug Screen Identifies Thiostrepton, NAMPT Inhibitors and Metformin As Potential Candidates to Target the Macrophage Tumor Microenvironment in Acute Myeloid Leukemia
3970 - Impaired Metabolic Plasticity Under Stress Constitutes a Therapeutic Vulnerability in IDH1/2-Mutant Acute Myeloid Leukemia

Weinhäuser, I.

2655 - Targeting PIP4K2 Lipid Kinases through Thz-P1-2 Reveals Vulnerabilities Related to Mitochondrial Homeostasis and Autophagy in Acute Leukemia

Weinhold, N.

174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
245 - Discovery of Tumor Reactive T Cell Receptors in Newly Diagnosed Multiple Myeloma
643 - Tracking the Earliest Genomic Events in Multiple Myeloma Life-History
644 - Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients – Meta-Analysis of 5,808 Trial Patients
646 - Individualized Treatment-Adjusted Risk Stratification in Newly Diagnosed Multiple Myeloma
860 - Bone Marrow Immune Signatures in Multiple Myeloma Are Linked to Tumor Heterogeneity and Treatment Outcome
968 - Implications and Prognostic Impact of Mass Spectrometry in Patients with Newly-Diagnosed Multiple Myeloma
1842 - The Impact of Autologous Stem Cell Transplantation on the Genetics of High-Risk Relapsed Multiple Myeloma
3170 - The Mutagenic Impact of Radiotherapy in Multiple Myeloma
4487 - Single-Cell Multi-Omics Reveal Longitudinal Dynamics of Clonal Architecture and Microenvironment Interactions in Relapsed-Refractory Myeloma
4499 - The Landscape of Small Nucleolar RNA Expression in Multiple Myeloma

Weinkove, R.

LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Weinlich, K.

935 - Spatially Confined T-Cell Mediated Anti-AML Tumor Immunity By Dual Recognition Antibodies (CD123/CD200)

Weinschenk, T.

4093 - IMA402, an Off-the-Shelf, Next-Generation TCR Bispecific (TCER^®) for Efficiently Targeting an HLA-Presented Peptide from the Pan-Cancer Antigen PRAME

Weinstein, B.

2018 - A Phase 1 Study of ADI-001: Anti-CD20 CAR-Engineered Allogeneic Gamma Delta1 (γδ) T Cells in Adults with B-Cell Malignancies

Weinstein, S.

3726 - The Optimized HLH Inflammatory Index Is Associated with a Higher Stage of Lymphoma, but an Unexpected High Mortality Associated with Inflammation

Weinstock, D. M.

1502 - Cellular Plasticity As Mechanisms to Escape from NOTCH1-Inhibition in T-ALL

Weinstock, D. M.

207 - Combinatorial Effects of BH3 Mimetics and CAR T Cells Targeting T-Cell Lymphomas
706 - TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2
937 - KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas
1556 - Cell Mass and Stiffness As Integrative Biomarkers of Cell State in Mantle Cell Lymphoma

Weinstock, M. J.

344 - Updated Results from a Multicenter, Phase 2 Study of Acalabrutinib, Venetoclax, Obinutuzumab (AVO) in a Population of Previously Untreated Patients with CLL Enriched for High-Risk Disease
2295 - G-CSF Administration Is Associated with Worse Treatment Response and Survival after CAR T-Cell Therapy

Weis, C. A.

1316 - Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Weisberg, D.

782 - Biochemical Engraftment and Clinical Outcomes Following Ex-Vivo Autologous Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA

Weisdorf, D. J.

114 - Phase II Study of Myeloablative 8/8- or 7/8-Matched Allotransplantation with Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil: Marked Reduction in Gvhd Risk without Increased Relapse Risk Compared to Historical Cyclosporine/Methotrexate
119 - Specific Clonal Mutations Are Predictive of Therapy-Related Myeloid Neoplasms (tMN) after Autologous Peripheral Blood Stem Cell Transplantation (aPBSCT) for Lymphoma
492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4708 - Chronic Gvhd Following Steroid Sensitive, Dependent, and Refractory Acute Gvhd: Incidence and Clinical Outcomes
- Transplant in Those with High Burden Disease: Refractory AML and High Risk MDS

Weisel, J. W.

586 - Aggregation of Enveloped Viruses By Platelet Factor 4 (PF4) and Neutrophil Extracellular Traps (NETs): Implications for the Anti-Viral Properties of NETs

Weisel, K. C.

Weisman, H.

901 - The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children’s Oncology Group Study

Weisnicht, A.

904 - Severe Adverse Events Associated with Concentrations of High Dose Methotrexate in Pediatric Acute Lymphoblastic Leukemia Patients

Weiss, C.

4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Weiss, D.

2653 - Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents

Weiß, E.

1769 - Application of a Flow Cytometric Core Marker Set in the Diagnostic Workup of Patients with Suspected Myelodysplastic Syndromes

Weiss, J.

1536 - Noninvasive, Dynamic Risk Profiling of Primary Central Nervous System Lymphoma By Peripheral Blood Ctdna-Sequencing

Weiss, J.

4022 - Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)

Weiss, L.

1115 - Analysis of the Platelet Proteome Reveals Insights into the Pro-Inflammatory and Pro-Thrombotic State Associated with the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms

Weiß, L. J.

1108 - Gradually Increased Gpiib/Iiia Responsiveness from Preterm and Term Neonatal Infants to Adults Reveals a Complex Phenotypic Switch during Platelet Ontogenesis - Data from the Platelets in Neonatal Infants Study (PLINIUS)
1237 - Mixed Bone Marrow Chimerism after Murine Stem Cell Transplantation Results in Distinct Platelet Subpopulations with Opposing Responsiveness

Weiss, M.

2776 - Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia
3995 - Precision Targeting of MYD88 Mutant DLBCL Using the Novel Combination of Irakimids and BCL2 Inhibition

Weiss, M.

1300 - Functional Profiling Identifies Selective Enhancer Dependencies in MYC-Intact and MYC-Rearranged Diffuse Large B-Cell Lymphoma

Weiss, M. J.

1212 - ETV6 Represses TNF during Stress Hematopoiesis and Regulates HSC Self Renewal
3465 - Increased Potency and Uniformity of Fetal Hemoglobin Induction from Base Editing Compared to Cas9 Nuclease
4782 - Base Editing for Therapeutic Induction of Fetal Hemoglobin in β-Thalassemia

Weiss, R.

895 - Intravenous Fluid Replacement Therapy and Hospital Outcomes for Vaso-Occlusive Episodes in Patients with Sickle Cell Disease

Weiss, S. J.

4459 - The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease

Weiss, S. R.

586 - Aggregation of Enveloped Viruses By Platelet Factor 4 (PF4) and Neutrophil Extracellular Traps (NETs): Implications for the Anti-Viral Properties of NETs

Weisser, M.

161 - RG6234, a GPRC5DxCD3 T-Cell Engaging Bispecific Antibody, Is Highly Active in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Updated Intravenous (IV) and First Subcutaneous (SC) Results from a Phase I Dose-Escalation Study
1659 - Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma

Weissler, K.

3310 - T Cells Expressing a Fully-Human Anti-BCMA Chimeric Antigen Receptor with a Heavy-Chain-Only Antigen-Recognition Domain Exhibit Rapid and Durable Activity Against Multiple Myeloma

Weissman, D.

123 - In Vivo Modification of Hematopoietic Stem Cells By Targeted Lipid Nanoparticles Encapsulating mRNA
2147 - Direct Delivery of mRNA-Loaded Lipid Nanoparticles to the Hematopoietic Stem Cell Niche
- mRNA Vaccines for COVID-19 and Emerging Applications of mRNA Technology

Weitz, I. C.

31 - Sutimlimab Provides Sustained Improvements in Patient-Reported Outcomes and Quality of Life in Patients with Cold Agglutinin Disease: Open-Label Extension of the Randomized, Phase 3 Cadenza Study
1201 - Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Weitz, J. I.

- Plenary Introducer

Weivoda, M.

4477 - MGUS and SMM Plasma Cells Exhibit a Senescence-like Phenotype and Accumulation of Transposable Elements That May Contribute to Disease Progression
- Role of Senescence in Multiple Myeloma Tumorigenesis

Weiwei, Z.

4212 - An Open-Label, Multicenter,Single-Arm, Phase I Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of XNW5004 in Patients with Relapsed or Refractory Hematologic Malignancies

Wek, R.

1308 - Asparagine Bioavailability Regulates the Translation of MYC oncogene in Lymphoid Malignancies

Wekesa, W. N.

4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Welborn, J. L.

2764 - A Phase I Study of Uproleselan Combined with Azacitidine and Venetoclax for the Treatment of Older or Unfit Patients with Treatment Naïve Acute Myeloid Leukemia
3205 - Assessing Time to Diagnosis, End-Organ Damage and Treatment Response in Young Newly Diagnosed Multiple Myeloma Patients
3538 - Identifying Multiple Myeloma Patients Using Automated Data Capture from Electronic Medical Records

Welch, D.

2338 - ALK2 Inhibition and a Modified Activin Receptor Type Iia Ligand Trap Cotherapy Maximized Hematologic Improvements in a Mouse Model of Anemia of Inflammation

Welch, E.

1690 - Minimally Invasive Blood Sampling for BCR::ABL1 transcript Monitoring

Welch, V.

2684 - Veno-Occlusive Disease Risk and Other Outcomes in Patients with B-Cell Precursor Acute Lymphoblastic Leukemia Who Received Inotuzumab Ozogamicin and Proceeded to Hematopoietic Stem Cell Transplantation: A Registry-Based, Observational Study

Wellard, C.

4496 - Real World Comparison of Treatment Outcomes for Myeloma in Elderly Transplant-Ineligible Population with RVD, RD and VCD in Frontline Setting: Results from Mrdr Australia and New Zealand
4526 - How Does Treatment Intolerance Affect Survival in Patients with Multiple Myeloma (MM)?

Weller, C.

4819 - A Novel NGS Assay to Detect Any KMT2A fusion Transcript at Low Levels

Weller, E. A.

2110 - Multivariable Analyses of Prognostic Factors for Progression-Free Survival (PFS) and Complete Response (CR) with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) in the Determination Phase 3 Trial

Wellhausen, N.

355 - Epitope Editing in Hematopoietic Cells Enables CD45-Directed Immune Therapy

Wellinger, L. C.

1958 - Function-Preserving Single Amino Acid Substitutions Shield Hematopoietic Stem and Progenitor Cells from CD117 Targeted Immunotherapy In Vivo
2530 - Engineered Single Amino Acid Substitutions Protect Hematopoietic Stem and Progenitor Cells from CD123 Targeted Immunotherapy

Wellington, R.

3849 - Clonal Analysis Reveals Functional and Transcriptional Heterogeneity of Self-Renewing Fetal Liver Hematopoietic Stem Cells

Wellnitz, D.

736 - High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients – a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)

Wells, B.

3372 - Allogeneic Peripheral Blood Stem Cell Transplantation for Bone Marrow Failure Syndromes Using CD34⁺-Selected Progenitor Cells Co-Infused with a Reduced Number of Non-Mobilized T-Cells

Wells, F.

485 - Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice

Wells, K.

3860 - Clonal Hematopoiesis in a Broad Age Spectrum of Systemic Vasculitis

Wells, P. S.

517 - A Prospective Study of Apixaban for Central Venous Catheter Associated Upper Extremity Deep Vein Thrombosis in Cancer Patients: Catheter 3
1184 - Thrombophilia Gene Mutations for the Prediction of Venous Thromboembolism in Ambulatory Cancer Patients Receiving Chemotherapy
2517 - Blood Biomarkers for the Prediction of Venous Thromboembolism in Perioperative or Hospitalized Cancer Patients: A Systematic Review
3823 - Performance of D-Dimers in Patients with Prior History of Venous Thromboembolism Based on Anticoagulation Status

Welner, R.

4105 - Dysregulated Activating and Inhibitory Receptors on Natural Killer Cells Predicts Immune Escape and Poor Outcomes in Acute Myeloid Leukemia

Welner, R. S.

1229 - Epigenetic Dysregulation Leads to Enhanced IL-1β Signaling and Transcriptional Responses in TET2 Deficient HSPCs
1686 - Metabolic Adaptation to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukemia Stem Cells

Welsh, K.

4223 - Next Generation BTK Inhibitor Acalabrutinib with Bendamustine-Rituximab in First Line Waldenstrom’s Macroglobulinemia: The Brawm Study

Welsh, S. J.

3136 - Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined T Cell Engager and Cytotoxic Therapy in a Multiple Myeloma Preclinical Model
3149 - Key Subsets of Immune Cells in Bone Marrow Myeloid Compartment Indicate Degree of Tumor Infiltration and Avenues for Successful Immunotherapy in Multiple Myeloma

Welslau, M.

1130 - Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag – Results of the 5^th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

Welte, K.

413 - Accumulation of Specific Somatic Leukemia-Associated Mutations in Congenital Neutropenia Precedes Malignant Transformation – New Preconditions for Treatment Decisions

Welter, D.

2226 - Standardized Communication Tool Improves Inpatient-Outpatient Care Transitions for Adults with Acute Leukemia

Welters, M. J.

1480 - Induction of a Systemic Immune Response during Use of an Allogenic Leukemia-Derived Dendritic Cell Vaccine in MRD+ AML Patients Correlates with Clinical Response and MRD Conversion

Weltz, J.

4853 - Assessing the Safety of Discharging Patients Receiving High-Dose Methotrexate with Levels Greater Than 0.1 Umol/L

Wemeau, M.

3643 - In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis
4347 - Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Wemeau, M.

3045 - Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim
4056 - Gilteritinib Activity in Refractory or Relapsed FLT3-Mutated Acute Myeloid Leukemia Patients Previously Treated By Intensive Chemotherapy and Midostaurin: A Study from the French AML Intergroup ALFA/Filo

Wempe, F.

1339 - Translatome Proteomics Identifies Autophagy As a Resistance Mechanism to on-Target FLT3 Inhibitors in Acute Myeloid Leukemia

Wen, B.

4788 - Novel Chemical Series of Anti-ST2 Small Molecules Suppress Allogeneic T Cells Proliferation While Increasing Treg Cells and Improve Gvhd and Survival In Vivo

Wen, C.

830 - Prospective Evaluation of Sorafenib Combined with Chemotherapy in Newly Diagnosed Adult Core-Binding Factor Acute Myeloid Leukemia: An Open-Label, Randomized Controlled, Multicenter Phase II Trial

Wen, F.

2363 - Antiviral Response and HIV-1 Inhibition in Sickle Cell Disease

Wen, H.

2713 - Genetic Variation and Survival Analysis of Childhood AML By C-Huanan AML 2015 Protocol in China:Multicenter Clinical Study in 546 Cases
4121 - _{Minimal Residual Disease after the 2^nd Induction Course Predicted Outcomes in Chinese Children with Acute Myeloid Leukaemia Treated According to the C-Huanan-AML 15 Protocol}

Wen, J.

1968 - Valproic Acid Increased CAR T Cell Cytotoxicity Against Acute Myeloid Leukemia

Wen, K.

148 - Genome-Wide CRISPR-Cas9 Screen Identifies KDM6A As a Modulator of Daratumumab Sensitivity in Multiple Myeloma
241 - BRD9 Is Essential for Ribosome Biogenesis and the Survival of Multiple Myeloma Cells
350 - PHF19 Inhibits Multiple Myeloma Cell Response to Immunotherapy Via Promoting Immunosuppressive Microenvironment
859 - Identification a Novel Molecular Mechanism Underlying the Anti-CD38-Based Treatment Resistance in Multiple Myeloma Patients
3165 - Targeting Autophagy to Overcome Resistance to Immunogenic Chemotherapy in High-Risk Multiple Myeloma
4478 - Γ-Secretase Inhibitors Enhance the Potency of BCMA-Targeting T Cell Engagers Against Multiple Myeloma Cells without Adverse Impact on T-Cell Activation and Differentiation

Wen, K. W.

1527 - Next-Generation Sequencing of Newly-Diagnosed Primary CNS Lymphoma Reveals Alterations in BTG1, ETV6, and 6p Are Associated with Chemoresistance and Inferior Progression-Free Survival

Wen, Q.

3317 - Off-the-Shelf CD33 CAR-NK Cell Therapy for Relapse/Refractory AML: First-in-Human, Phase I Trial
3475 - Amplifying Sting Activation By Bio-Inspired Nanomedicine for Targeted Acute Myeloid Leukemia Chemo- and Immunotherapy

Wen, R.

1202 - CD4+ T Cells Are Required for Production of Disease-Causing Antibodies in an Alloantigen-Specific Murine Model of Fetal/Neonatal Alloimmune Thrombocytopenia

Wen, S. X.

3574 - High Prevalence of Iron Deficiency and Socioeconomic Disparities in Laboratory Screening of Non-Pregnant Females of Reproductive Age

Wen, W. X.

453 - Cross-Talk between Hematopoietic Cells and Fibroblast Subsets Drives Inflammation and Remodelling of the Bone Marrow Microenvironment in Myeloproliferative Neoplasms
698 - Human Bone Marrow Organoids Enable the Study of Hematopoietic Cell-Stromal Interactions and Support the Survival of Malignant Cells from Patients

Wen, X.

3425 - Profiles of Germline Predisposition Gene Variants in Hematologic Disorders and Its Impact on Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation

Wen, Y.

4869 - Patient-Versus Physician-Perceptions of Symptoms, Treatment and Management in Chronic Myeloid Leukemia

Wen, Y.

2588 - Mutant NPM1 Is Recruited to MLL Target Genes Via Its Acidic Stretch and Nuclear Export Factor CRM1 and Regulates Oncogenic Transcription in Acute Myeloid Leukemia

Wen, Y.

257 - Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies

Wen, Z.

4461 - Genomic and Transcriptional Profiling Stratifies Vq Myeloma Lines into Two Clusters with Distinct Risk Signatures and Drug Responses

Wende, A. R.

1686 - Metabolic Adaptation to Tyrosine Kinase Inhibition in Chronic Myelogenous Leukemia Stem Cells

Wendel, G.

2854 - Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma

Wendel, P.

1991 - CRISPR/Cas9 Gene Editing of Immune Checkpoint Receptor NKG2A Improves the Efficacy of Primary CD33-CAR-NK Cells Against AML

Wendelin, K.

51 - Results of the Risk-Adapted, MRD-Stratified GMALL Trial 08/2013 in 281 T-ALL / T-Lbl Patients: Excellent Outcome of Standard Risk Thymic T-ALL

Wendland, K.

1350 - Block of Counter-Regulation By Inhibition of Protein Synthesis Sensitizes Cancer Cells to IRE1α-Mediated Apoptosis Following Unfolded Protein Response
2863 - Alterations of Immune Cells By Large B Cell Lymphoma Persist Years after Achieving Complete Remission and Correlate with Impaired Adaptive Immunity

Wendler, J.

736 - High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients – a Multicenter Study By the Cooperative PCNSL Study Group (MARTA study)
LBA-3 - Effects on Survival of Non-Myeloablative Chemoimmunotherapy Compared to High-Dose Chemotherapy Followed By Autologous Stem Cell Transplantation (HDC-ASCT) As Consolidation Therapy in Patients with Primary CNS Lymphoma - Results of an International Randomized Phase III Trial (MATRix/IELSG43)

Wendtner, C. M.

246 - Pathological RANK Signaling in Combination with TCL1 Drives a Multiple Myeloma-like Disease in Mice
345 - Genetic Markers and Front Line FCR/BR Vs. Rve, Gve and Give Treatment – Outcome Results from the CLL13/GAIA Trial
346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
4420 - Negative Feedback Regulation of MAPK Signaling Is an Important Driver of CLL Progression

Weng, A. P.

69 - High-Plex Imaging and Cellular Neighborhood Spatial Analysis Reveals Multiple Immune Escape and Suppression Patterns in DLBCL
71 - Spatial Tumor Microenvironment Characterization and Outcome of Relapsed/Refractory Classic Hodgkin Lymphoma
308 - Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma
2629 - DNMT3A Limits Myeloid Signaling Responses in Committed T Cells during Normal and Leukemic Development
3940 - MYCN Is Required in Immature T-ALL and Bears Epigenetic Marks Associated with Cell Identity

Weng, C.

3979 - Lipophagy As a Mechanism of Resistance in T-ALL Following Energetic Crisis Induced By Oxphos/MCT1 Blockade: Strategies to Eradicate Residual Disease

Weng, C. C.

1449 - Dual BCL-XL/2 Protac 753B Not Only Potently Induces Apoptosis in Venetoclax-Resistant Primary AML Cells but Also Effectively Eliminates Chemotherapy-Induced Senescent AML Cells

Weng, G.

837 - Association of Genetic Characteristics with Response to Venetoclax Plus Hypomethylating Agents in Relapsed and Refractory Acute Myeloid Leukemia

Weng, H.

415 - Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia

Weng, J.

335 - Is the 2^nd Generation Tyrosine Kinase-Inhibitor a Better Initial Therapy Than Imatinib in Persons with Chronic Myeloid Leukemia Presenting in Accelerated Phase: A Multicenter Retrospective Study
1694 - Subjects with Chronic Myeloid Leukemia Identified As Intermediate- or High-Risk Subjects Using the Imatinib Therapy Failure (IMTF) Model Benefit from Initial Therapy with a Second-Generation Tyrosine Kinase Inhibitor
4328 - Validation and Use of Predictive Scoring Systems for Molecular Responses in 5,203 Persons with Chronic Myeloid Leukemia
4335 - A Predictive Scoring System for Therapy Failure in Persons with Chronic Myeloid Leukemia Receiving Initial a Second-Generation Tyrosine Kinase Inhibitor Therapy
4339 - Outcomes in Patients with Chronic Myeloid Leukemia in the Chronic Phase Randomized to Dasatinib or Imatinib after Suboptimal Responses to 3 Months of Imatinib Therapy: Final 5-Year Results from DASCERN

Weng, J.

293 - Results from the First Phase 3 Crovalimab (C5 Inhibitor) Study (COMMODORE 3): Efficacy and Safety in Complement Inhibitor-Naive Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH)
3974 - Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)

Weng, L.

366 - Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Weng, L.

485 - Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice
663 - Efficient and Specific Multi-Locus Editing of Allogeneic CAR T Cells for Hypoimmunity during Large Scale Manufacture Using Cas12b

Weng, W. K.

2090 - Belumosudil Combination Therapy in Refractory Chronic Graft-Versus-Host Disease
2106 - Outcomes for Acute Myeloid Leukemia Relapse after Allogeneic Hematopoietic Cell Transplantation Remain Poor in the Modern Era
3358 - Higher Rates of Severe Infection and Persistent Cytopenias in Long-Term CAR19 Responders Than after Autologous HCT: A Single Institution Study of 139 Subjects
4657 - Analysis of Bendamustine Lymphodepletion, CD19 CART Expansion, Safety and Efficacy in Patients with Rel/Ref Non-Hodgkin Lymphoma

Weng, X.

1417 - The First Report of Third-Generation TKI Olverembatinib in Adult Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia with T315I Mutation and Relapsed Disease
4049 - A Phase II Study of Flumatinib with Chemotherapy for Newly Diagnosed Ph/BCR-ABL1-Positive Acute Lymphoblastic Leukemia in Adults：Preliminary Results from RJ-ALL2020.2A Trial

Weniger, M.

3741 - A Multimodal Single Cell Atlas of Human Tonsils Reveals New Insights into T and B Cell Differentiation

Wenjie, X.

1559 - Zanubrutinib Plus Ixazomib and Dexamethasone for Newly Diagnosed Symptomatic Waldenström Macroglobulinemia: A Prospective, Phase II Study
2898 - R-DA-Edoch/R-DHAP Alteration Could Overcome High Risk Factors in Younger Mantle Cell Lymphoma

Wenjing, G.

338 - Development and Validation of a Multiple Factor-Based Prognostic Score System of Thrombosis in Polycythemia Vera (MFPS-PV)
4309 - Molecular Analysis of JAK2V617F-Positive Myeloproliferative Neoplasms Reveals Wnt/β-Catenin As a Potential Target for Therapy

Wennerberg, K.

46 - Erythroid/Megakaryocytic Differentiation Confers BCL-XL Dependency and Venetoclax Resistance in Acute Myeloid Leukemia
328 - Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Wennerberg, K.

429 - Deep Multi-Omics Profiling in Cytogenetically Poor-Risk AML
835 - Ex Vivo Venetoclax Sensitivity Testing Predicts Response and Overall Survival in De Novo and s/R/R AML Patients Treated with Azacitidine and Venetoclax

Wentworth, P.

1452 - Decreased Embryonic Splicing Repressor Expression Enhances Splicing Modulator Sensitivity in Pediatric Acute Myeloid Leukemia Stem Cells

Wenzl, F. A.

521 - Cardiovascular Biomarkers for the Prediction of Adverse Cardiovascular Events and Mortality in Patients with Cancer

Wenzl, K.

70 - IRF4 Shapes the Tumor Microenvironment of Follicular Lymphoma
724 - Integrative Genomics Identifies a High-Risk Metabolic and TME Depleted Signature That Predicts Early Clinical Failure in DLBCL
842 - Loss of Nr4a1 Causes an Elevated Expression of Co-Inhibitory Receptor:Ligand Axes and Results in a Diminished T Cell-Mediated Lymphoma Cell Killing in Aggressive Lymphoma
1240 - Increased Tumor-Associated CD66b+ Myeloid-Derived Suppressor Cells in Waldenstrom Macroglobulinemia Inhibit T-Cell Immune Function
1541 - Biological Features of a High-Risk Transcriptional Molecular Subtype in Diffuse Large B-Cell Lymphoma
4156 - Molecular Landscape of Primary Refractory DLBCL

Were, P. A.

4161 - Human Leukocyte Antigen Contributes to Childhood Endemic Burkitt Lymphoma in Eastern Africa: A Case-Control Association Study
4164 - Increased Frequency of Mosaic Chromosomal Alterations in Peripheral Blood Samples of Sub-Saharan African Children with Endemic Burkitt Lymphoma
4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Wereski, M.

2992 - The Second Generation Type II JAK2 Inhibitor, AJ1-10502, Demonstrates Enhanced Selectivity, Improved Therapeutic Efficacy and Reduced Mutant Cell Fraction Compared to Type I JAK2 Inhibitors in Models of Myeloproliferative Neoplasms (MPNs)

Werlang, G. D. C.

4940 - Hematology Referral, Stroke Recurrence and Mortality Among Patients with First Ischemic Stroke and Polycythemia or Thrombocytosis

Werle, D.

4913 - A Multidimensional Approach to Measuring Distress in Children Undergoing Hematopoietic Stem Cell Transplantation: Three Raters’ Perspectives and Stress Biomarkers in Saliva and Blood

Wermke, M.

979 - Phase 1 Dose Escalation Study of the Rapidly Switchable Universal CAR-T Therapy Unicar-T-CD123 in Relapsed/Refractory AML
1442 - Venetoclax Plus High-Dose Cytarabine and Mitoxantrone As Feasible and Effective Novel Treatment for Relapsed AML: Results of the Phase-I SAL Relax Trial

Werner, A.

1245 - Novel Disease-Causing Mutations in UBA1 Reveal Disease Mechanisms in Bone Marrow Failure and Inflammation

Werner, B.

3533 - Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
3539 - Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL) – a Retrospective Health Claims Data Analysis

Werner, C.

4940 - Hematology Referral, Stroke Recurrence and Mortality Among Patients with First Ischemic Stroke and Polycythemia or Thrombocytosis

Werner, G.

3429 - Distinct Patterns in the Reconstitutions of Treg and T-Helper Subsets after Autologous Hematopoietic Stem Cell Transplantation in Juvenile-Onset Systemic Sclerosis Patients

Werner, M.

277 - Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US

Werner, R.

4502 - Pseudoprogression and Sarcoidosis-like Phenomena after CART-Cells and Bispecific Antibodies in Multiple Myeloma

Werner, S.

2481 - The Nupower Study: Nuwiq for Perioperative Management of Patients with Haemophilia a on Emicizumab Regular Prophylaxis
3782 - Efficacy and Safety of Prophylaxis with a Plasma-Derived Von Willebrand Factor/ Factor VIII Concentrate in Previously Treated Patients with Von Willebrand Disease

Wernig, G.

110 - Multi-Omics Profiling of Skin Biopsies of Patients with Sclerodermatous Graft-Vs-Host Disease Suggests Therapeutic Potential of Targeting Don't Eat Me Signals

Wert, T.

4872 - Understanding What Matters to Myelodysplastic Syndrome Patients – a Study of Preferences for Treatments with Hypomethylating Agents

Wert, Y.

1664 - Outcomes with Immunochemotherapy Plus Radiation Versus Immunochemotherapy Alone in Stage I Diffuse Large B-Cell Lymphoma: A Retrospective Study
4836 - Choosing Wisely Ten Years on: Inpatient Thrombophilia Testing

Wert-Lamas, L.

642 - Bioprocessing of MIR17HG Results in Long and Short Noncoding RNAs with Targetable Tumor-Promoting Activity in Multiple Myeloma

Wertheim, B.

3178 - Plasma Cell Leukemia: A Multicenter Retrospective Study of 130 Patients

Wertheim, G.

983 - CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells
1514 - Pharmacologic Inhibition of DYRK1A Results in Hyperactivation and Hyperphosphorylation of MYC and ERK Rendering KMT2A-R ALL Cells Sensitive to BCL2 Inhibition
1547 - A Novel Cryopreservation and Biobanking Strategy to Study Lymphoid Tissue Stromal Cells in Lymphoproliferative Disorders
3959 - Targeting the Mevalonate Pathway in the Mitochondria-Dependent Chemotherapy Resistance of TP53 Mutant Acute Myeloid Leukemia
4621 - Targeting CD38 in T-ALL Upregulates the Targetable Polyamine Metabolism Pathway

Wertheimer, T.

3342 - CAR T Cells and Their Immune Environment Synergize to Shape Distinct Immune Profiles in Response Versus Toxicity in B Cell Lymphoma Patients

Wesemann, D. R.

35 - Blood Group A Enhances SARS-CoV-2 Infection

Wesinger, L. J.

2042 - Utility of Targeted Neurocognitive Testing in Detecting Early Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CAR T-Cell Therapy

West, C.

2199 - Classical Hematology Referrals at an NCI-Designated Cancer Center: Lessons Learned

West, J.

1088 - Haemphagocytic Lymphohistiocytosis in an English Nationwide Cohort Confirms Increasing Incidence and Variation in Trigger Factors
2404 - Factors Influencing 1-Year Survival in Haemphagocytic Lymphohistiocytosis: A National Cohort Study in England

West, J.

3312 - Abrogation of Immune Effector Cell Neurotoxicity Syndrome (ICANS) By Rimiducid (RIM) in Patients Treated with CD19-Specific Chimeric Antigen Receptor Modified T-Cells (CAR-T) Engineered with an Inducible Caspase 9 (iC9 CAR.19)—Clinical and Pharmacodynamic Correlates

West, K.

2705 - Prospective Study of Immune Phenotype and Associated Outcomes in Patients with Leukemia and Acute Respiratory Distress Syndrome

West, R. M.

316 - Updated Results from an Open-Label Phase 1/2 Study of Favezelimab (anti–LAG-3) Plus Pembrolizumab in Relapsed or Refractory Classical Hodgkin Lymphoma after Anti–PD-1 Treatment

West Wade, S.

2274 - Real-World Patient-Reported Outcomes Among Recipients of Axicabtagene Ciloleucel for Relapsed/Refractory Large B Cell Lymphoma

West, W.

349 - Potent Pre-Clinical and Early Phase Clinical Activity of EP300/CBP Bromodomain Inhibitor CCS1477 in Multiple Myeloma
3951 - Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia

West-Mitchell, K.

2408 - Extended Detection in Peripheral Blood Following Infusion of Chronic Granulomatous Disease Patient Autologous Granulocytes Corrected By mRNA Transfection in Patients with Chronic Granulomatous Disease
3840 - Granulocyte Transfusions As an Adjunctive Therapy in Severe Aplastic Anemia

Westbrook, A. L.

3407 - Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis

Westera, L.

1503 - Mutational Mechanisms in Pediatric Acute Lymphoblastic Leukemia with Multiple Relapses

Westerman, D. A.

75 - Time-Limited Ibrutinib and Tisagenlecleucel Is Highly Effective in the Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma, Including Those with TP53 Mutated and Btki-Refractory Disease: First Report of the Tarmac Study
1447 - ALLG AMLM26 Phase 1B/2 Study Investigating Novel Therapies to Target Early Relapse and Clonal Evolution As Pre-Emptive Therapy in AML (INTERCEPT): A Multi-Arm, Precision-Based, Recursive, Platform Trial
4816 - Utility of High-Throughput Sequencing of Immunoglobulin Genes for MRD in Lymphoid Malignancy in the Context of Current Immunotherapeutics

Westermann, J.

539 - Therapy-Related AML: Clinical/Biological Features and Long-Term Outcome in a Cohort of 1133 Adult AML Patients
2704 - Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients

Westermann-Clark, E.

1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency

Westermann-Clark, E.

3739 - Investigating Biomarkers for Primary Immunodeficiency Disorders in Patients with Autoimmune Cytopenia

Westervelt, P.

874 - Mgta-117, an Anti-CD117 Antibody-Drug Conjugated with Amanitin, in Participants with Relapsed/Refractory Adult Acute Myeloid Leukemia (AML) and Myelodysplasia with Excess Blasts (MDS-EB): Safety, Pharmacokinetics and Pharmacodynamics Initial Findings from a Phase 1/2 Study

Westervelt, P.

773 - Phase I Study of Baricitinib Gvhd Prophylaxis in HLA-Matched, Peripheral Blood Allogeneic Hematopoietic Cell Transplant

Westerweel, P. E.

1692 - Kinase Domain Mutation Testing and Clinical Outcome in a Nationwide Chronic Myeloid Leukemia Patient Population
1693 - Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors
4425 - High-Throughput Proteomics Identifies THEMIS2 As Biomarker of Inferior Treatment-Free Survival in Chronic Lymphocytic Leukemia

Westhead, D. R.

735 - Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy

Westhoff, C. M.

3841 - Endothelial Expression of Duffy Antigens in Patients with Fyb-GATA Homozygosity and Suspected Anti-Fy3 Antibody Formation: A Case Series

Westin, J.

322 - MRD-Negativity As a Potential Surrogate Endpoint after Frontline DLBCL Therapy: Pooled Analysis of Trials & Implications for Clinical Trial Design
489 - High Efficacy of the PARP Inhibitor Olaparib Combined with High-Dose Chemotherapy and Autologous Stem-Cell Transplant for Refractory Lymphomas
543 - Determinants of Resistance to Engineered T-Cell Therapies Targeting CD19 in Large B-Cell Lymphomas
659 - Outcomes of Subsequent Anti-Lymphoma Therapies in Patients (Pts) with Large B-Cell Lymphoma (LBCL) Treated with Axicabtagene Ciloleucel (Axi-Cel) or Standard of Care (SOC) in the Second-Line (2L) ZUMA-7 Study
765 - Outcomes of Axicabtagene Ciloleucel in Comparison with Chemoimmunotherapy (CIT) in an Elderly Population for Treatment of Relapsed or Refractory (r/r) Large B-Cell Lymphoma (LBCL) after Two or More Lines of Prior Therapy
848 - Association of the CLL Comorbidity Index (CLL-CI) and International Prognostic Index (IPI) with Overall Survival (OS) and 1-Year Mortality in Patients (pts) with Relapsed or Refractory (r/r) Large B Cell Lymphoma (LBCL) Treated with CD19 Directed Autologous Chimeric Antigen Receptor T (CART) Cell Therapies
960 - Updated Results of an Investigator-Initiated Phase II Study of Pembrolizumab and Romidepsin for Patients with Relapsed or Refractory T-Cell Lymphoma (TCL) with Survival Analysis
1519 - Ultrasensitive MRD Profiling Predicts Outcomes in DLBCL after Frontline Therapy with Tafasitamab in Combination with Lenalidomide and R-CHOP
1623 - Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma
1637 - SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma
1651 - CD19 CAR-T Outcomes in Patients with EBV-Positive DLBCL
1963 - Targetable Cellular Etiology of Prolonged Cytopenia Following CD19 CAR T-Cell Therapy
2041 - Comorbidities Associated with Early Mortality after CD19 CAR-T Cell Therapy
2955 - A Phase 2, Open-Label Study of Loncastuximab Tesirine in Combination with Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Patients with Diffuse Large B-Cell Lymphoma (DLBCL) (LOTIS-9)
3337 - Primary Analysis of a Pilot Study of Prophylactic Anakinra to Mitigate CAR T Cell-Associated Toxicity in Patients with Relapsed or Refractory Large B-Cell Lymphoma
3341 - Predictors for Survival and Relapse in Patients (pts) with Diffuse Large b-Cell Lymphoma (DLBCL) Treated with Anti-CD19 CAR T-Cell Therapy: A Case for Early Intervention in High-Risks Pts Assessed By Day 30
3544 - Impact of Patient Demographics and Neighborhood Socioeconomic Variables on Clinical Trial Participation Patterns for Non-Hodgkin Lymphoma at a Major Academic Institution
3866 - Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy
4264 - Phase 1b Trial of Cereblon-Modulating Agents Iberdomide and CC-99282 Plus R-CHOP in Previously Untreated Aggressive B-Cell Lymphoma
4676 - Effect of Delayed Cell Infusion in Patients with Large B-Cell Lymphoma Treated with CAR T-Cell Therapy

Weston, H.

454 - Germline Missense Variants in SH2B3 Underpin Platelet Count Variation and Inherited MPN

Weston-Bell, N.

3938 - Genomic Panorama and Clonal Evolutionary Trajectory of Classical Hairy Cell Leukemia

Westover, T.

2587 - Human Models of NUP98-Rearranged Leukemia Reveal Fusion-Specific Molecular Mechanisms
2589 - Comprehensive Genomic Landscape and Clonal Architecture in Pediatric Patients with Monosomy 7
3906 - Tracking Clonal Evolution in Pediatric AML
3930 - UBTF-TD Expression Is Necessary and Sufficient for Myeloid Cell Expansion

Westrick, R. J.

2438 - Pregnancy Induces a Thrombogenic Platelet Transcriptome in Mice

Wetering, G. V.

4912 - Indirect Comparisons of the Efficacy of Subcutaneous Epcoritamab Vs Chemoimmunotherapy in Patients with Relapsed or Refractory Large B-Cell Lymphoma

Wetherall, N.

732 - Replacing Procarbazine with Dacarbazine in Escalated Beacopp Dramatically Reduces the Post Treatment Haematopoietic Stem and Progenitor Cell Mutational Burden in Hodgkin Lymphoma Patients with No Apparent Loss of Clinical Efficacy

Wethmar, K.

212 - Inotuzumab Ozogamicin Induction Followed By Standard Chemotherapy Yields High Remission Rates and Promising Survival in Older (>55 Years) Patients with De Novo B-Lymphoblastic Leukemia (GMALL-Initial1 Trial)

Wevers, M. J.

4452 - MAF Translocations Are Enriched in NDMM Patients with Elevated Levels of Circulating Tumor Cells Suggesting a Genetic Basis for Aggressive Disease Course

Wey, M. C.

1353 - Safety, Tolerability, Pharmacokinetics (PK) and Preliminary Antitumor Activity of the Cyclin-Dependent Kinase-9 (CDK9) Inhibitor AZD4573 in Relapsed/Refractory Hematological Malignancies: A Phase 1 First-in-Human Study

Weyand, A. C.

27 - Characteristics and Bleeding Behavior of Females with Mild Hemophilia A: Longitudinal Study from Picnichealth Hemophilia A Database
1170 - Characteristics and Healthcare Utilization of Patients with Mild or Moderate Hemophilia A in the US - an Analysis from the Picnichealth Cohort
2468 - Efficacy of Efanesoctocog Alfa on Physical Functioning: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A
2470 - Quality of Life in Patients with Clinically Severe Von Willebrand Disease: Interim Analysis of Athn 9: A Natural History Study for People with Severe Von Willebrand Disease (VWD)
- Learning in a Virtual Space: How Trainees Can Capitalize Social Media and Virtual Tools
- Gender Disparities in Bleeding Disorders

Weycker, D.

807 - Real-World Effectiveness of Voxelotor for the Treatment of Sickle Cell Disease: Group and Pediatric Subgroup Analyses of Effects on Transfusions, Vaso-Occlusive Crises, and Hospitalizations
2321 - Real-World Study of Patients with Triple-Class Exposed Relapsed or Refractory Multiple Myeloma: Analysis across a Spectrum of Advanced Disease Stage Patients in the United States
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Weyne, J.

2310 - Prevalence of Ocular Comorbidities in Elderly Patients with Multiple Myeloma in the US: An Analysis of 100% Medicare Sample Data during 2007-2020
2326 - Long-Term Efficacy and Safety of Pozelimab Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
3651 - A Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

Whalen, V.

3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Wharton, J.

1170 - Characteristics and Healthcare Utilization of Patients with Mild or Moderate Hemophilia A in the US - an Analysis from the Picnichealth Cohort

Whayman, M.

1659 - Phase 1 Study of CD19 Targeted CD28 Costimulatory Agonist in Combination with Glofitamab to Enhance T Cell Effector Function in Relapsed/Refractory B Cell Lymphoma
4259 - CD19 4-1BBL (RO7227166) a Novel Costimulatory Bispecific Antibody Can be Safely Combined with the T-Cell-Engaging Bispecific Antibody Glofitamab in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Wheat, J.

1292 - Mechanisms of Cistromic Repositioning of the Transcription Factor PU.1

Wheeler, A. P.

590 - Multicenter, Randomized Crossover Trial Comparing Recombinant Von Willebrand Factor and Tranexamic Acid for Heavy Menstrual Bleeding in Von Willebrand Disease

Wheeler, E. C.

3063 - Splicing Modulators Impair DNA Damage Response and Induce Killing of Cohesin-Mutant MDS/AML

Wheeler, M. M.

4809 - Long-Read Sequencing Resolves Complex Structural Variants and Identifies Missing Disease-Causing Variants in Unsolved Cases of Hemophilia

Wheeler, M. L.

3136 - Synergistic Immunostimulatory Effects and Therapeutic Benefit of Combined T Cell Engager and Cytotoxic Therapy in a Multiple Myeloma Preclinical Model

Wheeler, S.

3552 - Strategies for Implementing an Oral Medication Adherence Intervention in Academic and Community Cancer Settings

Whelan, C.

972 - Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Whetton, A.

295 - HOXA9 Nucleates a Repressive Chromatin Complex with Nuclear Matrix-Associated Protein- Safb to Maintain Acute Myeloid Leukemia

Wheway, K.

925 - Single-Cell Analysis of Human Clonal Hematopoiesis Identifies Distinct Impact of DNMT3A and TET2 mutations on Hematopoietic Differentiation
2545 - Dynamics of Clonal Hematopoiesis Inferred By Modelling Deep Bulk Whole-Genome Sequencing Data at a Single Time Point

Whipp, E.

3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma

Whisenant, T.

1452 - Decreased Embryonic Splicing Repressor Expression Enhances Splicing Modulator Sensitivity in Pediatric Acute Myeloid Leukemia Stem Cells

Whitacre, C.

4877 - Optimizing Shared Decision Making about Hydroxyurea in Young Children with Sickle Cell Anemia

White, C.

557 - Initial Treatment Response Is Prognostic and Predictive of Relapse Patterns: Outcomes of >500 Patients Treated for Primary CNS Lymphoma

White, D.

1918 - Iberdomide (IBER) in Combination with Dexamethasone (DEX) in Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Anti-B-Cell Maturation Antigen (BCMA)-Exposed Cohort of the CC-220-MM-001 Trial

White, D.

117 - Real-World Results of Autologous Stem Cell Transplantation in Newly Diagnosed Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
1867 - Real World Data on Outcomes of Anti-CD38 Antibody Refractory, Including Triple Class Refractory, Patients with Multiple Myeloma: A Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database
1921 - Elranatamab in Combination with Daratumumab for Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from the Phase 3 Magnetismm-5 Study Safety Lead-in Cohort

White, D. J.

3200 - Impact of Daratumumab-Containing Regimens in Outcomes of Subsequent Treatments of Relapsed Multiple Myeloma in Real-World Practice from the Canadian Myeloma Research Group Database
3248 - Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone Demonstrates Durable Responses in Triple Class Exposed/Refractory Multiple Myeloma
4494 - Impact of Maintenance Therapy after Salvage Autologous Stem Cell Transplantation in Relapsed Multiple Myeloma
4516 - Once Weekly Selinexor, Carfilzomib and Dexamethasone (XKd) in Triple Class Refractory Multiple Myeloma

White, D. L.

1354 - PTPN11 Mutations Drive Tyrosine Kinase Inhibitor As Well As Venetoclax Resistance in Ph+ ALL Cells, but Are Sensitive to the Combination

White, H. E.

4332 - Digital Droplet (dd) Polymerase Chain Reaction (PCR) Assays Offer Limited Advantages over Conventional Reverse-Transcriptase Quantitative PCR (RT-qPCR) for the Prediction of Molecular Recurrence after Treatment Discontinuation in Chronic Myeloid Leukemia (CML): Results from the Destiny Study

White, J. L.

4509 - A Systematic Meta-Analysis of Cytokine Release Syndrome Incidence in B-Cell Maturation Antigen-Targeting Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies for Patients with Relapsed and/or Refractory Multiple Myeloma

White, J. K.

3362 - Clinical Outcomes in Fresh Versus Cryopreserved Hematopoietic Stem Cell Products in British Columbia: A Retrospective Study
3411 - Real-World Experience with Ruxolitinib Therapy for Steroid Refractory Acute Graft Versus Host Disease
3437 - Autologous Stem Cell Transplantation for Treatment with Curative Intent in Adult Patients with Acute Lymphoblastic Lymphoma

White, K.

485 - Engineered Hypoimmune CAR T Cells Provide Lasting Tumor Control in Fully Immunocompetent Allogeneic Humanized Mice

White, L. S.

1214 - BCLAF1 Regulates Expression of AP-1 Genes and Fetal Hematopoietic Stem Cell Repopulation Activity
2419 - DNA Damage Signals Repress SYK in Early B Cells to Limit Leukemic Transformation

White, M.

1955 - Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies

White, R.

2954 - Magrolimab, Rituximab and Acalabrutinib for Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Results from the Phase 1 PRISM Trial
4423 - Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression

White, S. L.

3458 - Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion

White, S. L.

4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial

White, T. P.

231 - Ibrutinib and Venetoclax in Previously Untreated Waldenström Macroglobulinemia
1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia

Whitechurch, A.

4449 - Shielding the Vulnerable: A Multicentre Australian Rollout of Evusheld to Patients with Chronic Lymphocytic Leukaemia (CLL-SHIELD)

Whitehead, A. K.

527 - Role of Heparan Sulfate 6-O-Endosulfatases in Hematopoiesis

Whitehead, C.

133 - Anticoagulation and Antiplatelet Strategies in Non-Critically Ill Patients with Covid-19

Whitehead, J.

852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

Whiteheart, S. W.

812 - Role of Glycogen Mobilization and Mitochondrial Bioenergetics in Platelet Function, Hemostasis, and Thrombosis
1145 - Unfolded Von Willebrand Factor Interacts with Protein S and Limits Its Anticoagulant Activity
3750 - Theme and Variation: Structuring Thrombus Formation from Jugular/Arterial Puncture Wounds to Occlusive Clots in a Mouse Model

Whiteley, A. R.

84 - Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Whiteson, K.

1728 - Mediterranean Diet Intervention in Patients with Myeloproliferative Neoplasm

Whitlock, J. A.

1510 - Prognostic Importance of Cytogenetic Subgroups in Relapse Risk Stratification in Children and Young Adults with First Relapsed B-ALL: A Children’s Oncology Group Study AALL1331

Whitmill, R.

2739 - CREST-UK: CPX-351 Real-World Effectiveness and Safety Study for the Treatment of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes in the UK

Whitney, D.

2348 - Long Term Outcomes of 63 Patients with Transfusion-Dependent β-Thalassemia (TDT) Followed up to 7 Years Post-Treatment with betibeglogene autotemcel (beti-cel) Gene Therapy and Exploratory Analysis of Predictors of Successful Treatment Outcomes in Phase 3 Trials

Whitworth, H.

1189 - Clinical Characteristics and Acute Management of Pediatric Pulmonary Embolism

Wiatrowski, K. R.

128 - Impact of Therapy on the Anamnestic Response to Seasonal Influenza Vaccination in Patients with Myeloid Malignancies

Wicaksono, G.

357 - Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target
3291 - Humanized Nanobody Anti-CD72 CAR-T Cells Efficiently Eliminate B-Cell Malignancies Via Improved Affinity for CD72 but Induce Persistent Antigen Downregulation In Vivo

Wichlan, D.

1062 - Evaluating Equations for Estimated Glomerular Filtration Rate (eGFR) in Patients with Sickle Cell Disease (SCD)

Wichman, C.

2220 - Understanding the Treatment Preferences of Adults with Cancer
4054 - Older Adults with Acute Myeloid Leukemia (AML) Treated in a Pragmatic Trial: How Do Patients' Function and Health-Related Quality of Life Change with Treatment?

Wichmann, M.

1437 - Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia
2704 - Rapid and Reproducible Karyotyping with Nanopore Sequencing in AML Patients

Wickenhauser, S.

222 - Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia
460 - Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial

Wicker, C.

3723 - Oral SGLT2 Inhibitors in Glycogen Storage Disease Type Ib and G6PC3-Deficiency. Preliminary Results from an Off-Label Study of 21 Patients

Wideman, S.

2 - An Ancient Transcriptional Hub Couples Developmentally Regulated Gene Expression with Metabolism during Erythropoiesis

Widera, M.

755 - Portraying Immunity to Sars-Cov-2 after mRNA-Vaccination in Patients with Multiple Myeloma

Widhopf II, G. F.

1453 - Cirmtuzumab (Zilovertamab) Eliminates ROR1 Positive Leukemia Stem Cells By Blocking Niche Dependent ROR1/WNT5a Signaling
3107 - Wnt5a Induces ROR1-Dependent NFkB Activation to Upregulate MMP9 and Enhance Invasiveness in Chronic Lymphocytic Leukemia

Widmann, K.

2169 - Utilizing TCR-Seq to Detect Tabelecleucel, an Allogeneic Epstein–Barr Virus (EBV)-Specific T-Cell Immunotherapy, Post-Infusion

Widmer, A.

346 - High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations

Widmer, C. C.

3342 - CAR T Cells and Their Immune Environment Synergize to Shape Distinct Immune Profiles in Response Versus Toxicity in B Cell Lymphoma Patients

Wiebking, V.

1628 - Subcutaneous Mosunetuzumab Is Active with a Manageable Safety Profile in Patients (pts) with Relapsed/Refractory (R/R) B-Cell Non-Hodgkin Lymphomas (B-NHLs): Updated Results from a Phase I/II Study

Wiedemann, S.

519 - Early Dynamics of C-Reactive Protein Predict Risk of Venous Thromboembolism in Patients with Cancer Treated with Immune Checkpoint Inhibitors

Wiederkehr, A.

1958 - Function-Preserving Single Amino Acid Substitutions Shield Hematopoietic Stem and Progenitor Cells from CD117 Targeted Immunotherapy In Vivo
2530 - Engineered Single Amino Acid Substitutions Protect Hematopoietic Stem and Progenitor Cells from CD123 Targeted Immunotherapy

Wiedmeier, J. E.

3186 - Pathogenic Germline Variants in a Prospective Multi-Center Cohort of Patients with Multiple Myeloma
3214 - Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) +/- Daratumumab Treatment Results in Sustained Hematologic Response in Patients with AL Amyloidosis: A Retrospective Analysis of Patients at Mayo Clinic

Wieduwilt, M.

1543 - Disparities in Somatic Mutations and Outcomes in Primary Central Nervous System Lymphoma Comparing Patients of Hispanic and Non-Hispanic Ethnicity
LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Wieduwilt, M. J.

- Ph+ ALL in 2022: Is There an Optimal Approach?

Wiegers, S. E.

319 - External Validation Shows That Baseline PET Radiomics Outperform the IPI Risk Score for Prediction of Outcome in DLBCL

Wielgos-Bonvallet, M.

2859 - Transcriptomic Comparison of Non-Hodgkin Lymphomas in Relapsed/Refractory Versus Newly Diagnosed Patients Using Single FFPE Slides
2874 - Deep Peripheral T Cell Immune-Profiling in Relapsed/Refractory Non-Hodgkin Lymphoma: Evaluation of Baseline Samples from the Epcoritamab Epcore NHL-1 Trial
4182 - Evaluation of Epcoritamab and Rituximab Combination in Preclinical Models of B-Cell Non-Hodgkin's Lymphoma (NHL)

Wielockx, B.

515 - Erythropoietin Administration Delays B Cell Maturation and Promotes B Cell to Erythroid Transdifferentiation in Mice

Wiemels, J. L.

4003 - Racial and Ethnic Disparities in Childhood Acute Lymphoblastic Leukemia Risk Due to an IKZF1 Noncoding Regulatory Variant

Wienecke, C.

1437 - Fla-IDA Chemotherapy with or without Venetoclax in Patients with Relapsed/Refractory Acute Myeloid Leukemia

Wienecke, T.

1717 - Prevalence of the JAK2V617F Mutation in Patients with Ischemic Stroke
3043 - Neutrophil-to-Lymphocyte Ratio As a Predictor of All-Cause Mortality in the General Population and Patients with Myeloproliferative Neoplasms

Wienke, A.

1446 - Double-Blind, Placebo Controlled, Randomized, Multicenter, Phase II Study to Assess the Efficacy of the High Affinity CXCR4 Inhibitor BL-8040 As Addition to Consolidation Therapy in AML By the SAL and OSHO Leukemia Study Groups

Wierda, W. G.

Wierenga, A. T.

4117 - Full Spectrum 40-Parameter Single-Tube Flow Cytometry Analysis for Longitudinal Immunophenotyping and Tracing of Clonal Heterogeneity in AML

Wierz, M.

747 - Single-Cell Omics Analyses Identify the TIM-3 Ligand Galectin-9 As Novel Immunotherapy Target for Chronic Lymphocytic Leukemia

Wierzbowska, A.

1388 - A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL – a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)
2744 - A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
2781 - The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients
3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Wiesen, L.

1850 - Validation of a Novel Rac1 Inhibitor As Potent Secdrug Against Activating Ras Mutant and Drug-Resistant Multiple Myeloma

Wiesholzer, M.

3201 - Safety and Survival Outcomes in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma Treated with Lenalidomide-Based or Non–Lenalidomide-Based Treatments in the Real-World MM-034 Study

Wiest, D.

2615 - Fatty Acid Desaturation Is a Metabolic Vulnerability of Acute Myeloid Leukemia Cells
2997 - ERK2 Substrate Binding Domains Play Distinct Roles in Megakaryocytic-Erythroid Lineage Progression and Mediates Clonal Fitness in Myeloproliferative Neoplasms

Wiestner, A.

965 - NX-2127-001, a First-in-Human Trial of NX-2127, a Bruton’s Tyrosine Kinase-Targeted Protein Degrader, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia and B-Cell Malignancies
1788 - Establishment and Characterization of Mouse Models with Primary and Acquired BTK Inhibitor Resistance
1798 - Ibrutinib-Associated Sudden Death in Patients with CLL
1813 - Comprehensive Cardiac Testing in Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients on Ibrutinib
2675 - CD49d Expression Identifies a Biologically Distinct Subtype of Chronic Lymphocytic Leukemia with Inferior Progression Free Survival on BTK Inhibitor Therapy
4423 - Longitudinal Mutation Profiling in CLL Patients during Acalabrutinib Therapy and at Progression
4442 - Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
4488 - Targeting C3d in Combination with Daratumumab: a Strategy to Enhance Therapeutic Potential in Multiple Myeloma
4606 - Co-Stimulatory Signaling Boosts CAR T Cell Efficacy Against CLL

Wiggers, C. R.

4143 - Single-Cell Multi-Omics Reveals Immune Microenvironment Alterations in T-Cell Acute Lymphoblastic Leukemia

Wight, J.

3656 - Effects of Ker-050 on Iron Metabolism: Exploratory Analyses from an Ongoing Phase 2 Study in Patients with Myelodysplastic Syndromes

Wigler, M.

4131 - Whole Genome Sequencing Comparison of Acute Myeloid Leukemia at Presentation and Remission Predicts Patient Outcome

Wignall, C.

4265 - Durable Responses from Acalabrutinib in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisolone (R-CHOP) As First Line Therapy for Patients with Diffuse Large B-Cell Lymphoma (DLBCL): The Accept Phase Ib/II Single Arm Study

Wiita, A. P.

357 - Structural Surfaceomics Reveals an AML-Specific Conformation of Integrin-β2 As an Immunotherapeutic Target
2998 - Profiling the Cell Surface of MPN Blast Phase Suggests Unique Biology and Therapeutic Targets
3155 - Integrating Transcriptomics and Proteomics for the Discovery of Novel Antigen Targets on Surface of Malignant Plasma Cells Amenable for Chimeric Antigen Receptor-T (CAR-T) Cell Approach in the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
3291 - Humanized Nanobody Anti-CD72 CAR-T Cells Efficiently Eliminate B-Cell Malignancies Via Improved Affinity for CD72 but Induce Persistent Antigen Downregulation In Vivo

Wijermans, P. W.

535 - 10-Day Decitabine Versus Intensive Chemotherapy Followed By Transplantation in Fit AML Patients Aged ≥60 Years: Health-Related Quality of Life Outcomes of the Randomized Phase III Trial AML21 of the EORTC Leukemia Group, Gimema, Celg, and Gmds-SG

Wijetunga, N. A.

1573 - “Big Boom” (4 Gy x 1) Radiation Treatment (RT) Versus “Big Boom” (2 Gy x 2) for Non-Hodgkin Lymphoma (NHL)
2854 - Genetic Alterations of Crebbp Are Associated with Radiosensitivity in Follicular Lymphoma
4292 - Safety and Efficacy of Splenic Irradiation for Non-Hodgkin Lymphoma

Wijk, R. V.

9 - Untargeted Metabolomics on Dried Blood Spots of Patients with Sickle Cell Disease Treated with the Pyruvate Kinase Activator Mitapivat
3643 - In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis
3680 - An Endogenous Metabolic Modulator Composition Improves Hydration Status and Decreases Adhesion Properties of Red Blood Cells from Patients with Sickle Cell Disease

Wijnands, C.

971 - Minimal Residual Disease Monitoring By Targeted Mass Spectrometry Allows Early Relapse Detection in Multiple Myeloma

Wik, H. S.

4006 - Pharmacokinetics and Immunogenicity of the First Doses of Peg-Asparaginase -an Alltogether Pilot Study

Wilcox, R.

2033 - Peripheral Blast Count at Apheresis Acts Independent of Disease Burden As a Risk Factor for Survival Following Tisagenlecleucel in Children and Young Adults
4674 - Obesity Associates with Inferior Outcomes and Toxicity in Pediatric and Young Adult Patient with Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia Treated with Commercially Manufactured Tisagenlecleucel

Wilcox, R. A.

3993 - ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas
4279 - A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss

Wilcox, S.

1026 - Iron Supplementation May Selectively Reprofile the Gut Microbiome in Iron-Deficient Bangladeshi Infants

Wilde, L.

1439 - Outpatient Vyxeos Induction without Planned Admission for Select Patients with Secondary Acute Myeloid Leukemia (sAML): A Multicenter Analysis of Safety and Healthcare Resource Utilization

Wilder, J.

3372 - Allogeneic Peripheral Blood Stem Cell Transplantation for Bone Marrow Failure Syndromes Using CD34⁺-Selected Progenitor Cells Co-Infused with a Reduced Number of Non-Mobilized T-Cells

Wildes, T.

171 - Need for Dynamic Frailty Risk Assessment Among Older Adults with Multiple Myeloma: A Population-Based Cohort Study
991 - Variable Frailty Categorization Among Real-World Patient with Multiple Myeloma: A Prospective Cohort Study (MFRAIL)
2302 - Novel Data Analytics Identify Predictors of Quality-of-Life Trajectories in Patients with AML or High-Risk Myeloid Neoplasms

Wildes, T. M.

172 - "...Paying to be a Patient in the Hospital and the Parking Lot": Dyadic Perspectives on Multiple Myeloma-Related Healthcare Access Barriers
3238 - Daratumumab Plus Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) in Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM) Patients (Pts): Final Analysis of Griffin Among Clinically Relevant Subgroups
4557 - Analysis of Transplant-Eligible Patients (Pts) Who Received Frontline Daratumumab (DARA)-Based Quadruplet Therapy for the Treatment of Newly Diagnosed Multiple Myeloma (NDMM) with High-Risk Cytogenetic Abnormalities (HRCA) in the Griffin and Master Studies
4560 - An End-of-Study Subgroup Analysis of Black Patients from the Phase 2 Griffin Study of Daratumumab (DARA) Plus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Patients with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

Wilding, S.

735 - Five-Year Survival Results from the Remodl-B Trial (ISRCTN 51837425) Show Improved Outcomes in Diffuse Large B-Cell Lymphoma Molecular Subgroups from the Addition of Bortezomib to R-CHOP Chemoimmunotherapy
2959 - Quality of Life Trajectories in Patients Treated with R-CHOP for Diffuse Large B-Cell Lymphoma As Part of the Remodl-B Trial (ISRCTN 51837425)

Wiley, B.

2550 - Arcch: Improving the Performance of Clonal Hematopoiesis Variant Calling and Interpretation Using a Consensus Based Approach

Wilhelm, A. R.

398 - Inhibiting Activated Protein C Cleavage of Factor VIII for Hemophilia a Gene Therapy

Wilhelm, B. T.

48 - High Fatality CBFA2T3-GLIS2 Pediatric Acute Megakaryoblastic Leukemia Is Sensitive to BCL-X_L Inhibition

Wilhelm-Benartzi, C.

218 - FLAG-Ida Combined with Gemtuzumab Ozogamicin (GO) Improves Event Free Survival in Younger Patients with Newly Diagnosed Acute Myeloid Leukaemia (AML) and Shows an Overall Survival Benefit in NPM1 and FLT3 mutated Subgroups. Results from the UK NCRI AML19 Trial
431 - Genomic Correlates of Outcome in a Randomised Comparison of CPX-351 and FLAG-Ida in High-Risk Acute Myeloid Leukaemia and Myelodysplastic Syndrome: Results from the UK NCRI AML19 Trial

Wilhite, A.

3646 - Requirement for N⁶-Methyladenosine mRNA Methylation during Human Erythropoiesis

Wilk, C. M.

651 - Clonal Dynamics after Haematopoietic Stem Cell Transplantation Using Genome-Wide Somatic Mutations

Wilk, C. M.

1685 - Bone Marrow-Derived BRAFV600E-Mutated Cells Drive Neurodegeneration in a Mouse Model of Langerhans Cell Histiocytosis

Wilk, C. M.

4318 - Myeloid Progenitors Define Extent of Disease in Mouse Models of Histiocytic Disorders: BRAFV600E Expression in Monocyte Lineage Recapitulates Erdheim-Chester Phenotype

Wilke, A. C.

1500 - Proteomic Characterization of Acute Myeloid Leukemia

Wilkerson, K.

986 - Outcomes of Non-Myeloablative HLA-Haploidentical Bone Marrow Transplant with Thiotepa and Post-Transplant Cyclophosphamide in Children and Adults with Sickle Cell Disease, a Phase II Trial: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC²)
3390 - Effective Desensitization Strategy for Patients with Sickle Cell Disease with High Donor Specific Antibodies Undergoing Haploidentical Bone Marrow Transplant with Posttransplant Cyclophosphamide
4693 - Early Donor T-Cell Engraftment Is Critical for Immune Tolerance in Reduced Intensity Haploidentical Bone Marrow Transplant with Post-Transplant Cyclophosphamide for Sickle Cell Disease: Vanderbilt Global Haploidentical Transplant Learning Collaborative (VGC²)

Wilkerson, R.

2624 - Uncovering Distinct Metabolic Properties of Relapse and Relapse-Fated Clones in B-Cell Acute Lymphoblastic Leukemia

Wilkes, J. J.

3584 - COVID-19 Infection in Children with Down Syndrome and Hematologic Malignancies
4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia

Wilkins, B.

739 - Ruxolitinib Versus Best Available Therapy for PV Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial

Wilkins, S. J.

908 - Disruption of Hephaestin in the Placenta and Fetus Leads to Fetal Anemia

Wilkinson, T.

2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Will, B.

3934 - Deletion of Micro RNA-15/16 Clusters Promotes Leukemic Initiation in AML Via the Deregulation of Hematopoietic Progenitors

Will, M.

940 - DR-01, a Non-Fucosylated Anti-CD94 Antibody, Depletes Leukemic Cells in Ex Vivo and In Vivo Models of Large Granular Lymphocyte Leukemia

Willaime, M.

1910 - What Is the Benefit of Autologous Stem Cell Transplantation in Multiple Myeloma Beyond the Age of 65? Inputs from Real-World Data in the Emmy Cohort
3174 - Retreatment of Patients with Anti CD38-Based Combinations in Multiple Myeloma in Real-Life: Results from the Emmy Cohort Study

Willaume, A.

1667 - Prognostic Value of Lymphopenia and Total Metabolic Tumor Volume in Diffuse Large Cell Lymphoma of B Phenotype

Willcox, A.

687 - Endothelial-Targeted CD39 Ameliorates Pulmonary Hypertension in a Murine Model of Endothelial Toxin Administration

Wille, M.

2336 - Do Andean Aymaras’ Evolutionary Selected Genes to High Altitude Hypoxia Also Influence Hemoglobin Concentration of Europeans and Their Acute Hypoxia Responses?

Willekens, C.

222 - Reduced Venetoclax Exposition to Seven Days of Azacitidine Is Efficient in Treatment-Naïve Patients with Acute Myeloid Leukemia

Willemin, M. E.

3228 - Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Willems, L.

88 - DNA Replication Stress Due to Loss of R-Loops in Myelodysplastic Syndromes with SF3B1 Mutation
616 - Characteristics and Outcomes of Adult Patients with T Prolymphocytic Leukemia: A Real World Study of the French Innovative Leukemia Group (FILO)
1575 - Long-Term Follow-up of Bendamustine Plus Rituximab Regimen in 69 Treatment Naïve (TN) Patients with Waldenström Macroglobulinemia, a Study on Behalf of the French Innovative Leukemia Organization (FILO)
3356 - Efficacy of CAR-T Cells in Primary Central Nervous System Lymphomas: The French Experience of the National LOC Network
4347 - Thrombosis with Non-Proliferative Complete Blood Count Indicative of Underlying Myeloproliferative Neoplasm, Sythrom, a Study on Behalf of the FIM Group

Willemze, A.

2468 - Efficacy of Efanesoctocog Alfa on Physical Functioning: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A
2474 - Efficacy of Efanesoctocog Alfa on Pain in Patients with Hemophilia A: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A
3788 - A Population Pharmacokinetic (PopPK) Model to Characterize Efanesoctocog Alfa (BIVV001) Factor VIII (FVIII) Activity Levels in Patients with Severe Hemophilia A

Willen, S. M.

673 - Incidence of Ischemic Stroke Has Increased in Californians with Sickle Cell Disease in the Post-STOP Era
3709 - No Specific Factors Associated with Risk of Readmission for Rebound Pain in Children with Sickle Cell Disease and Asthma Treated with Systemic Corticosteroids

Willenbacher, W.

4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

William, B. M.

4252 - A Phase I California Cancer Consortium Study of Blinatumomab/Lenalidomide in Relapsed/Refractory Non-Hodgkin Lymphoma: Updated Results and Immune Correlative Analyses

William, B.

2930 - Recurrent KMT2C Mutations As Clonal Hematopoiesis Is Common after Chemotherapy Exposure in Hodgkin's Lymphoma Patients

Williams, A. M.

481 - Combined Genetic Ablation of CD54 and CD58 in CAR Engineered Cytotoxic Lymphocytes Effectively Averts Allogeneic Immune Cell Rejection
1986 - Alloimmune Defense Receptor Harnesses Host Immune Cell Activation to Potentiate Functional Persistence and Anti-Tumor Activity of Off-the-Shelf, Cell-Based Cancer Therapy
3288 - iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma

Williams, A.

2387 - Ketamine Use for Management of Vaso-Occlusive Pain in Children with Sickle Cell Disease

Williams, A. K.

4111 - Uncovering Ethnic Genomic Disparities Associated with Inferior Outcome in African Americans Diagnosed with Acute Myelogenous Leukemia

Williams, A. R.

1794 - Rapid Tumor Debulking of Relapsed/Refractory CLL Patients By PI3Kδ Inhibition and Anti-CD20 Monoclonal Antibody Treatment

Williams, A. M.

902 - Epigenetic Age Acceleration and Neurocognitive Function Among Long-Term Survivors of Pediatric Hodgkin Lymphoma: A Report from the St. Jude Lifetime Cohort

Williams, B.

899 - Identification and Successful Targeting of a Larger Than Expected Health Literacy Gap in Young People with Sickle Cell Disease Transitioning from Pediatric to Adult Care

Williams, C.

4419 - Proteogenomic Analysis of SF3B1^mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways

Williams, D.

3715 - Expansion of Content in the Phenx Toolkit for Sickle Cell Disease Pain

Williams, D. A.

289 - Eltrombopag in Pediatric Patients with Previously Untreated or Refractory/Relapsed Severe Aplastic Anemia: The Phase II Escalate Trial
409 - Regulated Expression of GATA1 As a Gene Therapy Cure for Diamond-Blackfan Anemia
2525 - Altered Cellular Sedimentation during Apheresis Impacts Outcomes of Peripheral Blood Stem Cell Collection Efficiency in Patients with Sickle Cell Disease
3458 - Lentiviral Gene Therapy with Low Dose Conditioning for X-Linked SCID Results in Complete Immune Reconstitution and No Evidence of Clonal Expansion
3466 - Combining the Anti-Sickling βAS3-Globin Gene with BCL11A and ZNF410 Double Shmirs for the Treatment of Sickle Cell Disease
3856 - Septin-6 Regulates Murine and Human Hematopoiesis, and Its Dysregulation Is Associated with Pediatric Myelodysplasia
4774 - Long-Term Outcome of Gene Therapy for X-Linked Severe Combined Immunodeficiency (SCID-X1) Using an Enhancer-Deleted Self-Inactivating Gammaretroviral Vector
4784 - Induction of Fetal Hemoglobin and Reduction of Clinical Manifestations in Patients with Severe Sickle Cell Disease Treated with Shmir-Based Lentiviral Gene Therapy for Post-Transcriptional Gene Editing of BCL11A: Updated Results from Pilot and Feasibility Trial

Williams, D. A.

3695 - A Phase 2, Open-Label Study to Evaluate the Efficacy and Safety of Mgta-145 in Combination with Plerixafor for the Mobilization of Hematopoietic Stem Cells in Patients with Sickle Cell Anemia

Williams, D. C.

800 - ETO2 Recruitment of NuRD to the γ-Globin Locus Involves Multivalent Interaction with GATAD2A
801 - MBD2a-NuRD Binds to the γ-Globin Gene Promoter and Uniquely Forms a Complex Required for Bcl11a Mediated Silencing of Hb F Expression

Williams, E. E.

2717 - Impact of Early Hospitalization, Medical Comorbidities and Allogeneic Stem Cell Transplantation on Survival in Acute Myeloid Leukemia Patients Treated with Venetoclax Based Therapy – a Single Institution Experience from an Academic Center

Williams, E. K.

3498 - High-Efficiency Multi-Drug Functional Profiling in a Microfluidic Device Towards Personalized Predictions in Pediatric Leukemia

Williams, G.

1641 - Myosteatosis As a Predictor of Toxicity Among Older Adults with DLBCL Receiving CHOP-Based Regimens
2299 - Prevalence and Impact of Potentially Inappropriate Medication Use on Post-Transplant Outcomes Among Older Adults with Plasma Cell Dyscrasias Receiving an Autologous Stem Cell Transplant
4528 - Evaluating Concordance between International Myeloma Working Group (IMWG) and Simplified Frailty Index (SFI) Among Older Adults with Multiple Myeloma (MM)

Williams, H.

719 - Pharmacotypes across the Genomic Landscape of Pediatric Acute Lymphoblastic Leukemia and Impact on Treatment Response

Williams, J.

2329 - Comorbidities and Complications in Pediatric Patients with Pyruvate Kinase Deficiency Enrolled in the Peak Registry
2332 - Age of Onset of Complications in Patients with Pyruvate Kinase Deficiency: Analysis from the Peak Registry

Williams, J. C.

40 - CD84 Is a Therapeutically Targetable Driver of Leukemogenesis Via Disruption of Energy Supply in Acute Myeloid Leukemia

Williams, J.

2776 - Development of KT-253, a Highly Potent and Selective Heterobifunctional MDM2 Degrader for the Treatment of Acute Myeloid Leukemia

Williams, J.

3134 - High Prevalence of Beta-Human Papilloma Virus in Patients with Concurrent Chronic Lymphocytic Leukemia and Non-Melanoma Skin Cancer

Williams, K.

276 - Genome-Wide CRISPR/Cas9 Knockout Screen Reveals Novel Gilteritinib Combinations Targeting Oxidative Phosphorylation and De-Novo Purine Biosynthesis Pathways for FLT3-ITD⁺ Acute Myeloid Leukemia
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma
4084 - LP-118, a Selective Bcl-2 Inhibitor with Tuned Bcl-Xl Activity, Causes Myeloid Differentiation and Cell Death in Acute Myeloid Leukemia (AML)

Williams, K. M.

3407 - Abatacept for the Prevention of Gvhd in Pediatric and Adult Patients Receiving 7/8 HLA-Mismatched Unrelated Transplant for Hematologic Malignancies: A Real-World Analysis

Williams, L. S.

4304 - Improved Survival Outcomes for Intensive Versus Standard Chemoimmunotherapy in Primary Mediastinal B-Cell Lymphoma: A Meta-Analysis of 4068 Patients

Williams, L.

4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Williams, L. A.

1698 - Long-Term Molecular Testing and Clinical Response of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase: 5-Year Follow-up from SIMPLICITY, a Prospective, Observational Study
4329 - Five-Year Overall Survival Analysis Using First- and Second-Generation Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in the Chronic Phase in a Prospective Observational Study (SIMPLICITY)

Williams, L. S.

174 - Variability in Pattern of Mutational Signatures in Multiple Myeloma As a Function of Racial Origin
1868 - Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma
2037 - Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
3211 - Validation of the CIBMTR Scoring System in Predicting Early Relapse of Multiple Myeloma Post Autologous Hematopoietic Cell Transplant
3227 - Intravenous Immunoglobulin Prophylaxis Is Associated with Decreased Rate of Infection-Related Hospitalizations in Multiple Myeloma Patients
4748 - Validation of the Gatmo Score in Predicting Mortality Following Autologous Hematopoietic Cell Transplant in Multiple Myeloma Patients
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant

Williams, M. H.

852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

Williams, M.

1404 - Prognostication of the 2016-Who AML with Myelodysplasia-Related Changes Subclass and Mutations in MDS-Related Genes Using the 2022 European Leukemianet Risk Classification: A Retrospective Study
4067 - Outcomes of Newly Diagnosed Therapy-Related AML and AML with Myelodysplasia-Related Changes Treated with 7+3, Hypomethylating Agents with or without Venetoclax and CPX-351: A Retrospective Cohort Study

Williams, M. E.

4242 - Pembrolizumab in Combination with Epigenetic Therapy Is Safe and Active in Heavily Treated Patients with Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL): Preliminary Results from the Embolden Trial

Williams, M. E.

3481 - Nanoliposomal C6-Ceramide Exhibits Synergistic Anti-Cancer Activity with a Small Molecule Agonist of PP2A in Chronic Lymphocytic Leukemia

Williams, N.

651 - Clonal Dynamics after Haematopoietic Stem Cell Transplantation Using Genome-Wide Somatic Mutations
2539 - Clonal Hematopoiesis in Mice Is Common with Age and Accelerated By Microbial Exposure

Williams, P. M.

4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Williams, Jr., R. L.

1328 - Pharmacodynamic Effects of Nirogacestat, a Gamma Secretase Inhibitor, on B-Cell Maturation Antigen in Healthy Participants

Williams, R.

66 - Anti-Leukemic Activity of STRO-002 a Novel Folate Receptor-α (FR-α)-Targeting ADC in Relapsed/Refractory CBF2AT3-GLIS2 AML

Williams, R. A.

852 - The Impact of Time from Diagnosis to Initiation of Chemotherapy on Survival of Patients with Diffuse Large B-Cell Lymphoma in the Veteran`s Health Administration
2276 - Treatment Patterns and Survival Outcomes in Elderly Veterans Diagnosed with Diffuse Large B-Cell Lymphoma
4302 - Survival Outcomes for High Risk Primary Refractory and Relapsed Large B-Cell Lymphoma (LBCL) within the Veterans Health Administration (VHA)

Williams, T. N.

678 - Decreased Red Blood Cell Deformability Contributes to Loss of Splenic Filtration Function and Variations in Spleen Size in Children with Sickle Cell Anaemia

Williams, V. L.

2318 - Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Williams-Blangero, S.

1188 - The Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) 353 R>q in the Coagulation Factor VII (FVII) Gene, F7, is Associated with Decreased Plasma FVII Levels and a Decreased Risk of Coronary Heart Disease (CHD) in Mexican Americans of South Texas
3829 - A Nonsynonymous-Single-Nucleotide Polymorphism (ns-SNP) in TFPI, the Gene Encoding Tissue Factor Pathway Inhibitor (TFPI), is Pleiotropically Associated with Increased Plasma TFPI Levels and a Decreased Risk of Type 2 Diabetes (T2D) in Mexican Americans of South Texas

Willie, E.

3907 - Loss of FBXO11 Function Establishes a Stem Cell Program in Acute Myeloid Leukemia through Dysregulation of the Mitochondrial Protease LONP1

Williford, D.

3523 - A New Phen X Collection: Sickle Cell Disease Psychosocial and Social Determinants of Health Protocols

Willim, R.

937 - KLRG1 Depletion Is a Novel Therapeutic Strategy for Patients with Mature T and NK/T-Cell Lymphomas

Willis, C.

2003 - Safety and Anti-Leukemic Activity of CD123-CAR T Cells in Pediatric Patients with AML: Preliminary Results from a Phase 1 Trial

Willis, C.

2318 - Treatments and Outcomes for Patients at Academic Cancer Centers with Myelodysplastic Syndrome (MDS) By Revised International Prognostic Scoring System (IPSS-R) Scores

Willis, E.

2145 - Vector Analysis of Multicentric Lymphoma in a Severe Hemophilia Α Dog after AAV Gene Therapy

Willis, M.

4769 - Poor Outcomes Among Pediatric Non-Down Syndrome Acute Megakaryocytic Leukemia Patients Irrespective of Receipt of Hematopoietic Stem Cell Transplant

Willman, C. L.

LBA-1 - Consolidation Therapy with Blinatumomab Improves Overall Survival in Newly Diagnosed Adult Patients with B-Lineage Acute Lymphoblastic Leukemia in Measurable Residual Disease Negative Remission: Results from the ECOG-ACRIN E1910 Randomized Phase III National Cooperative Clinical Trials Network Trial

Willner, H.

3459 - Hematopoietic and Immunological Assessment in Fanconi Anemia after Ex Vivo Lentiviral FANCA Gene Therapy with RP-L102

Wills, B.

4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Willy, C.

1130 - Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag – Results of the 5^th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

Wilson, A.

3881 - Establishing an Easy-to-Use 3D BM Niche Model for the Co-Culture of Primary Bone Marrow Mesenchymal Stromal Cells (BM-MSC) with Hematopoietic Stem and Progenitor Cells (HSPC)

Wilson, A.

2468 - Efficacy of Efanesoctocog Alfa on Physical Functioning: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A
2474 - Efficacy of Efanesoctocog Alfa on Pain in Patients with Hemophilia A: Results from the XTEND-1 Phase 3 Clinical Trial in Previously Treated Patients with Hemophilia A

Wilson, A. K.

4876 - Characteristics and Prevalence of Posttraumatic Stress Disorder and Posttraumatic Stress Symptoms Among Adults with Hemophilia a and B

Wilson, A.

3339 - Phase I Study Evaluating Outcomes of Autologous HIV-Specific T Cells Targeting Non-Escaped Epitopes (HST-NEET) Therapy in HIV+ Individuals on ART (NCT03485963)

Wilson, A. J.

740 - A Phase 2 Study of the LSD1 Inhibitor Bomedemstat (IMG-7289) for the Treatment of Essential Thrombocythemia (ET)
1730 - The Use of Avapritinib in Advanced Systemic Mastocytosis: Report of an Open-Label Compassionate Use Program in the United Kingdom

Wilson, A.

2175 - Systematic Evaluation of Synthetic Panel Data Quality with an Application to Chronic Lymphocytic Leukemia
3567 - Anemia Management in Pregnant and Lactating Women in Rural Haiti: Assessing Impact of Interventions Using Data-Adaptive Longitudinal Targeted Learning

Wilson, B.

3324 - Alberta Cellular and Immunotherapy (ACIT) 001, Results of Decentralized Production of Second Generation, Anti-CD19/41BB/CD3z Chimeric Antigen Receptor (CAR) T-Cells in Relapsed/Refractory (R/R) Acute Lymphoblastic Leukemia (ALL) and Aggressive Non-Hodgkin Lymphoma (NHL)

Wilson, B. S.

4147 - A Novel Antibody-Drug Conjugate Directed Towards the Surrogate Light Chain of Malignantly-Transformed B-Cell Precursors Reverses Leukemic Progression in NSG Mice

Wilson, C.

1871 - Despite Use of Upfront Plerixafor and G-CSF, Daratumumab Exposure Reduces Stem Cell Mobilization in Patients with Multiple Myeloma
3836 - Venous Thromboembolism Risk in Patients with Newly Diagnosed Multiple Myeloma Treated with Carfilzomib or Bortezomib in Combination with Lenalidomide and Dexamethasone

Wilson, D.

2637 - Pharmacological Characterization of JNJ-75276617, a Menin-KMT2A Inhibitor, As Targeted Treatment for KMT2A-Altered and NPM1-Mutant Acute Leukemia

Wilson, D.

4248 - Long-Term Outcomes of High-Risk Stage 1/2 Classic Hodgkin Lymphoma Managed with an Advanced Stage Treatment Approach

Wilson, H. P.

143 - Anticoagulation Use for Secondary Prophylaxis Against Recurrent Venous Thromboembolism in Hospitalized Children: A Report from the Children’s Hospital-Acquired Thrombosis (CHAT) Consortium
504 - Diagnosis and Management of Isolated Neutropenia: A Survey of Pediatric Hematologists Oncologists

Wilson, I.

4817 - CD8 Presence and Dynamics in Glofitamab-Treated Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma Using the CD8-Specific PET Tracer ⁸⁹Zr-Crefmirlimab Berdoxam

Wilson, K.

1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials

Wilson, K.

871 - Comparison of Fludarabine/Melphalan (FluMel) with Fludarabine/Melphalan/BCNU or Thiotepa (FBM/FTM) in Patients with AML in First Complete Remission Undergoing Allogeneic Hematopoietic Stem Cell Transplantation – a Registry Study on Behalf of the EBMT Acute Leukemia Working Party
988 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation

Wilson, K.

2114 - Autologous Hematopoietic Cell Transplantation for T-Cell Prolymphocytic Leukemia – a Retrospective Study on Behalf of the Chronic Malignancies Working Party of the EBMT
4732 - Allogeneic Hematopoietic Cell Transplantation in Patients with Therapy-Related Myeloid Neoplasm Following Treatment for Lymphoma: A Study of the Chronic Malignancies Working Party of the EBMT

Wilson, L.

3598 - Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy

Wilson, L.

4707 - Impact of Cytomegalovirus (CMV) Sero-Conversion Pre Allogeneic Stem Cell Transplant on Post-Transplant Outcomes

Wilson, L.

1182 - Thrombotic Manifestations in Patients with Vexas Syndrome
2541 - Clonal Hematopoiesis in Vexas Syndrome

Wilson, M.

3361 - Multi-Centre UK Study of Allogeneic Haematopoietic Stem Cell Graft Cryopreservation Effects on Patient Outcomes

Wilson, M.

3347 - Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom

Wilson, N. W.

4878 - Causes of Death in Patients with Sickle Cell Disease from a Large Population-Based Cohort
- Causes of Death in Patients with Sickle Cell Disease from a Large Population-Based Cohort

Wilson, R. L.

2087 - Impact of Exercise on the Complications of Corticosteroids in Patients with Graft-Versus-Host Disease Following Allogeneic Cell Transplantation: The Restart Trial

Wilson, S. R.

3701 - The Prevalence and Impact of Low Oxygen in People with Sickle Cell Anemia: A Pilot Study

Wilson, T.

2192 - Assessment of Emergency Department Care for Patients with Acute Pain Crisis after the Formation of a Multidisciplinary Team

Wilson, W.

607 - Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma Shows Rituximab Is Highly Effective at Delaying Time to New Treatment without Detrimental Impact Following Next Line of Therapy
1574 - Pembrowm: Results of a Multi-Centre Phase II Trial Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström’s Macroglobulinaemia
3318 - Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies
3347 - Brexucabtagene Autoleucel for Relapsed/Refractory Mantle Cell Lymphoma: Real-World Outcomes in the United Kingdom
4540 - Developing a Flow Cytometric Signature of Carfilzomib Responsiveness in Myeloma
4574 - Impact of Autologous Stem Cell Transplant (ASCT) Versus Consolidation on Health-Related Quality of Life (HRQoL) for Patients with Multiple Myeloma Receiving Carfilzomib Maintenance: Results from the Cardamon Trial

Wilson, W. C.

3942 - DNMT3A Mutations Enhance T-ALL Survival, Which Is Reversed By JAK/STAT Inhibition

Wilson, W. H.

721 - DNA Methylation-Based Burkitt Lymphoma Epitypes Have Distinct Molecular and Clinical Features
952 - Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide (ViPOR) in Relapsed and Refractory Follicular Lymphoma: Analysis of Safety, Efficacy, and Minimal Residual Disease
2939 - Phase 1 Study of Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide in Combination with Polatuzumab (ViPOR-P) in Relapsed/Refractory B-Cell Lymphoma: Preliminary Analysis of Safety and Efficacy
4001 - Effect of Isavuconazole on Plasma and CSF Levels of Ibrutinib and Plasma Levels of Liposomal Doxorubicin Among Patients Receiving Teddi-R for CNS Lymphoma

Wilton, A. S.

4843 - Isolated Thrombocytopenia in Older Adults Is Associated with the Diagnosis of Hematologic Malignancy: A Population-Based Study

Win, M. A.

3569 - Updated Meta-Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Advanced Pancreatic Cancer (APC) Receiving Chemotherapy
4891 - Systematic Review and Meta- Analysis of Randomized Controlled Trials on Primary Outpatient Thromboprophylaxis (POTP) in Patients with Gastric and Gastro-Esophageal Junction (GEJ) Cancers Receiving Chemotherapy

Winburn, I.

2471 - A Retrospective Cohort Study of Switching Patterns Among Hemophilia a and B Patients Using Optum Electronic Health Records (EHR) Database in the United States (US)
4785 - Global Seroprevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Serotypes of Relevance to Gene Therapy

Wind Jensen, A.

2864 - Characterization and Clinical Impact of the Tumor Microenvironment of Post-Transplant Large B-Cell Lymphoma

Wind-Rotolo, M.

391 - AG-946 Normalizes Glycolysis and Improves Red Cell Indices in a Humanized Sickle Cell Mouse Model
1773 - A Phase 2a/2b Multicenter Study of AG-946 in Patients with Anemia Due to Lower-Risk Myelodysplastic Syndromes

Windyga, J.

2469 - Eptacog Beta Efficacy in Treating Mild or Moderate Bleeds in Target Joints of Individuals with Hemophilia A or B and Inhibitors in PERSEPT 1

Windyga, J.

1158 - A Multiple Ascending Dose Study of Mim8 in Patients with Severe Hemophilia a with or without Factor VIII Inhibitors
2486 - Active Lifestyle in Patients with Hemophilia A or B with Inhibitors on Once-Daily Subcutaneous Concizumab Prophylaxis: Results from the Phase 3 explorer7 Study

Windyga, J.

2479 - Emicizumab in Management of Hemophilia_A Patients with High Titer FVIII Inhibitor – Real-World Evidence from Poland
3789 - Personalization of Clotting Factor VIII Replacement Therapy Based on Population Pharmacokinetics in Adult Patients with Severe Hemophilia a Who Frequently Switch Factor VIII Concentrates

Winegarden, III, J. D.

- Amicus Brief: a Michigan Study

Winer, E. S.

377 - Maintenance Therapy with Venetoclax/Azacitidine Can be Safely Given after Venetoclax/FluBu2 RIC Allogeneic Transplantation for the Treatment of High Risk MDS/AML: Results of a Phase 1 Study
1423 - Lower-Intensity CPX-351 + Venetoclax for Patients with Newly Diagnosed Acute Myeloid Leukemia Who Are Unfit for Intensive Chemotherapy: Post Hoc Analysis By Disease Risk Subgroups
2702 - Genetic Predictors of Anthracycline Mediated Cardiomyopathy with Induction Chemotherapy in Acute Myeloid Leukemia (AML)
2795 - Intensive Therapy for NPM1 Mutant AML Patients: Negative Impact of FLT3-ITD^highbut Not FLT3-ITD^low and FLT3-TKD and Role of Transplant in Patients over 60 Years of Age
4004 - Intensity of Induction Regimen and Outcomes Among Adults with Ph+ ALL Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
4022 - Feasibility and Safety of Outpatient Hypomethylating Agent (HMA) + Venetoclax (Ven) Initiation +/- Ramp-up for Patients (pts) with Newly-Diagnosed Acute Myeloid Leukemia (AML)
4030 - FLT3-ITD Does Not Predict Inferior Prognosis Compared with FLT3-wild Type in Acute Myeloid Leukemia (AML) Patients Age ≥ 60 Years: A Retrospective Cohort Study
4077 - Molecular Characterization of Clinical Response in Relapsed/Refractory Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome Patients Treated with Single Agent Emavusertib

Winer, H.

1304 - Cooperation between Mutant IL7R and TLX3 Generates Mixed Myeloid/Lymphoid Leukemia from Thymocyte Progenitors

Winer, S.

4771 - Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

Winestone, L. E.

1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
2217 - Financial Coping Strategies and Financial Assistance Following a Pediatric Hematologic Malignancy
3590 - High Incidence and Mortality of Invasive Fungal Disease in Children and Young Adults with Hematologic Malignancies in Hawaii and Pacific Islands
4955 - Septic Shock and Septic Shock Mortality in Relation to Social Disorganization Index Among Children Being Treated for De Novo Acute Myeloid Leukemia on COG Clinical Trials

Wing, S.

2701 - Clinical and Molecular Profiling of AML Patients with Chromosome 7 or 7q Deletions Incontext of TP53 Alterations and Venetoclax Treatment

Wingard, J. R.

2237 - Racial, Ethnic and Socioeconomic Disparity in Outcomes of Patients with Chronic Graft-Versus-Host Disease: A CIBMTR Analysis
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions

Wingelhofer, B.

3951 - Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia

Wingham, B.

4597 - Tuned IL3-Zetakine Coupled to a CD33 Costimulatory Receptor As a Dual CAR for Safer and Selective Targeting of Acute Myeloid Leukemia

Wingrove, J.

2171 - Differentiation Scoring (DS) Derived from Cellworks Computational Omics Biology Model (CBM) Predicts Response to Hypomethylating Agents (HMA) and Patient Survival in Myelodysplastic Syndrome (MDS)

Winiarska, M.

4615 - CD180 As a Putative Target for Immunotherapy in Aggressive Mature B Cell Lymphomas

Winick, N. J.

901 - The Impact of Cumulative Anesthesia Exposure on Neurocognitive Outcomes in Children with High-Risk Precursor B Acute Lymphoblastic Leukemia: A Multicenter Children’s Oncology Group Study
4942 - Influence of Household Income on Health-Related Quality of Life in Children with Acute Myeloid Leukemia

Winkelmann, M.

1888 - Density of the Spleen in Low-Dose CT Scans Is Associated with High-Risk Disease Features and Shorter Survival in Newly Diagnosed Multiple Myeloma Patients
3348 - Early Real Time Quantification of CD19. CAR T Cells By Flow Cytometry As a Predictive Biomarker for Response in Patients with R/R LBCL
4669 - Body Composition and Immunonutritional Status Impact Survival Outcomes after CD19 CAR T-Cell Therapy

Winkler, J.

2084 - Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd

Winkler, R.

964 - Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study

Winkler, T.

1958 - Function-Preserving Single Amino Acid Substitutions Shield Hematopoietic Stem and Progenitor Cells from CD117 Targeted Immunotherapy In Vivo

Winkler, T. H.

1993 - CD19-Targeted CAR-T Cells in Refractory Systemic Lupus Erythematosus: Safety, Efficacy, and Mechanistic Insights from the First Five Patients
2084 - Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd

Winkowska, L.

4136 - BCR::ABL1-Positive Acute Lymphoblastic Leukemia: Different Clinical Behavior and Relevance of Prognostic Features in Typical ALL and in CML-like Disease

Winograd, B.

2014 - Lava-051, a Novel Bispecific Gamma-Delta T-Cell Engager (Gammabody), in Relapsed/Refractory MM and CLL: Pharmacodynamic and Early Clinical Data

Winter, A.

554 - Poor Survival Outcomes of Checkpoint Inhibitors for B-Cell Lymphomas Relapsing after or Refractory to CAR T-Cell Therapy: A Real-World Cohort from 15 U.S. Academic Institutions
964 - Lisaftoclax (APG-2575) Safety and Activity As Monotherapy or Combined with Acalabrutinib or Rituximab in Patients (pts) with Treatment-Naïve, Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (R/R CLL/SLL): Initial Data from a Phase 2 Global Study
2037 - Assessment of Major Adverse Cardiac Events (MACE) and Arrhythmias in Patients with Large B-Cell Lymphoma Undergoing Anti-CD19 Chimeric Antigen Receptor T-Cell (CAR-T) Therapy: Impact of Baseline Cardiac Biomarkers
2221 - Siltuximab for First-Line Treatment of Cytokine Release Syndrome: A Response to the National Shortage of Tocilizumab
3596 - Real-World Patient Characteristics, Treatment Patterns, and Outcomes in Patients with Stage III/IV Classic Hodgkin Lymphoma Treated with Frontline ABVD: A Retrospective Analysis Using a Real-World Database
4752 - The Role of Corrected Dlco in Predicting Relapse and Mortality Post Autologous Hematopoietic Cell Transplantation in Multiple Myeloma
4754 - Risk of Venous Thromboembolism in Multiple Myeloma Patients Undergoing Autologous Hematopoietic Cell Transplant
4850 - Economic Burden of Hematopoietic Cell Transplantation (HCT) Among Commercially Insured Patients with Hematological Malignancies in the United States (US)
4908 - Feasibility of Patient-Reported Outcome Assessment in the Acute Phase after CAR T-Cell Therapy in Lymphoid Malignancies: A Pilot Study

Winter, J. N.

154 - Double Hit/Double Expressor Lymphomas: A Multicenter Analysis of Survival Outcomes with CD19-Directed CAR T-Cell Therapy
731 - Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study
1000 - Consensus Cachexia Criteria Are Independently Linked to Progression Free and Overall Survival in Multi-Site Analysis of Patients with Aggressive B-Cell Lymphomas Treated with CAR T-Cell Therapy
1666 - Posttransplant Lymphoproliferative Disorder (PTLD) Following Transplantation at Northwestern University: Choice of Immunosuppressive Agents Does Not Impact Outcomes in PTLD
2050 - Delayed Neutrophil Engraftment in Autologous Transplant Patients with Very High CD34+ Cell Collections in a Single Apheresis
2885 - FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort
2970 - Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder
4922 - Impact of Race and Social Determinants of Health on Outcomes in Patients with Aggressive B-Cell Lymphomas Treated with Chimeric Antigen Receptor T-Cell (CART) Therapy

Winter, S. S.

718 - Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
4147 - A Novel Antibody-Drug Conjugate Directed Towards the Surrogate Light Chain of Malignantly-Transformed B-Cell Precursors Reverses Leukemic Progression in NSG Mice

Winter, S. S.

716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL

Winter, S.

1745 - Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Winterberg, D.

435 - The IL7R-Antagonist OSE-127 Blocks Acute Lymphoblastic Leukemia Development Via a Dual Mode of Action

Wintering, A.

3052 - LNK/SH2B3 As a Novel Driver in Juvenile Myelomonocytic Leukemia

Winterman, E.

1387 - Whole Genome Sequencing for Detection of Prognostically Relevant Genetic Abnormalities in Paediatric Acute Myeloid Leukaemia

Winters, A. C.

1421 - Higher-Dose Venetoclax with Measurable Residual Disease-Guided Azacitidine Discontinuation in Newly Diagnosed Patients with Acute Myeloid Leukemia: Phase 2 Hiddav Study
2182 - Utilization of the Tapestri Platform for Quantification of Single Cell Vector Copy Number in CAR T Cell Products
2666 - Venetoclax in Combination with Tyrosine Kinase Inhibitors Demonstrates Efficacy in Preclinical Models of Ph+ Acute Lymphoblastic Leukemia
2791 - Molecular MRD By Digital PCR Is Prognostic of Outcomes in AML Patients on Intensive and Non-Intensive Treatment Regimens
4909 - Identifying Patterns of Neurocognitive Dysfunction through Direct Comparison of Patients with Leukemia, CNS Tumors, and Sickle Cell Disease

Winters, J. P.

880 - Non-Relapse Mortality and Quality of Life with Shared Care after Allogeneic Hematopoietic Cell Transplantation: A Randomized Control Trial

Winton, E.

236 - Efficacy and Safety of Add-on Parsaclisib to Ruxolitinib Therapy in Myelofibrosis Patients With Suboptimal Response to Ruxolitinib: Final Results From a Phase 2 Study
1710 - An Updated Analysis on Safety and Efficacy of Avapritinib in Patients with Advanced Systemic Mastocytosis from the Explorer Clinical Study: Long-Term Efficacy and Safety

Wintrich, S.

2316 - Pan-Stakeholder Core Outcome Set (COS) Definition for Hematological Malignancies within the Framework of Harmony and Harmony PLUS Projects

Wirk, B.

3378 - Viridans Group Streptococcal Bacteremia after Allogeneic Stem Cell Transplant with Post-Transplant Cyclophosphamide

Wischlen, S.

3204 - Patient Characteristics and Survival Outcomes of Lenalidomide Exposed non- Refractory vs. Lenalidomide Refractory Multiple Myeloma Patients in the HONEUR Federated Data Network

Wise, J. F.

2853 - Multi-Omics Profiling of Longitudinal Samples Reveals Early Genomic Changes in Follicular Lymphoma

Wiseman, D. H.

87 - Integrative Analysis of Blast Phase Chronic Myelomonocytic Leukemia Reveals Distinct Transformation Phenotypes Predictive of Drug Response
458 - A Three Gene Leukemic Stem Cell Signature Score Is Robustly Prognostic in Chronic Myelomonocytic Leukemia
2561 - The Functional and Molecular Alterations in Human Bone Marrow Mesenchymal Stem Cells in Chronic Myelomonocytic Leukemia
3951 - Therapeutic Targeting of EP300/CBP By Bromodomain Inhibition in Acute Myeloid Leukemia

Wishart, H. A.

2042 - Utility of Targeted Neurocognitive Testing in Detecting Early Immune Effector Cell-Associated Neurotoxicity Syndrome (ICANS) after CAR T-Cell Therapy

Wisnik, A.

2781 - The Expression of mi-RNAs Involved in the Hematopoietic Niche Microenvironment in Newly Diagnosed AML Patients

Wisniowski, B.

972 - Use of Matrix-Assisted Laser Desorption/Ionisation Time-of-Flight Mass Spectrometry (MALDI-TOF MS) Free Light Chain Assessment for the Diagnosis and Monitoring of Systemic Immunoglobulin Light Chain (AL) Amyloidosis

Wist, M.

1359 - Novel BTK Mutations Conferring Resistance to Non-Covalent BTK Inhibitors and Alternative Treatment Strategy

Wistuba, I. I.

1562 - EOMES⁺ Tr1-like Cells Are Enriched in Areas of NLPHL Group II (Patterns D to F) Supporting the Role of Tregs in Disease Recurrence/Progression

Withers, S. G.

1205 - Immunological Compatibility of Novel Enzyme-Converted Universal Blood Donor Cells

Witkin, A.

592 - A Multicenter Study of Safety, Tolerability, and Effectiveness of Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia

Witkop, M.

2197 - National Hemophilia Foundation Champions a National Research Blueprint Defining a Community-Coordinated Research Ecosystem to Accelerate Progress in Inherited Bleeding Disorders

Witkowski, M.

456 - RAF-Independent MEK Mutations Drive Histiocytic Neoplasms In Vivo and Are Sensitive to Single-Agent ERK Inhibition in Patients

Witt, D. M.

2257 - Development of a Novel Bleeding Quality of Life Patient-Reported Outcome Measure for Older Adults

Witt, D. H.

3151 - Genomic Sequencing of Paired Bone Marrow and Focal Lesion Biopsies of Newly Diagnosed Multiple Myeloma Patients before and after Induction Therapy
3249 - Enhanced Global Disease Assessment with Advanced Imaging and Targeted Myeloma Lesion Biopsy Highlights Spatial Heterogeneity and Detects Residual Disease in Multiple Myeloma

Witten, E.

636 - Immuno-Genetic Changes Underlie Response to Immune Checkpoint Blockade Therapy in Richter’s Syndrome Mouse Models

Wittenberg, M.

622 - Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia – an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Witter, T. L.

18 - Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
3720 - An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)

Wittink, M.

132 - A Patient-Centered Communication Tool for Older Patients with Acute Myeloid Leukemia, Their Caregivers, and Oncologists: A Single Arm Pilot Study

Wittke, C.

4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Wittwer, S.

4685 - Cellular Therapy Product Viability during Long Term Cryopreserved Storage

Witty, A.

1218 - Characterization of Engineered Macrophages and Other Myeloid Cells Differentiated from CD34+ Hematopoietic Progenitor Cells Derived from Pluripotent Stem Cells
2532 - CD82 Is Sufficient to Uniquely Identify Pluripotent Stem Cell-Derived Hemogenic Endothelium with the Hematopoietic Lineage Potency to Give Rise to Bona Fide Lymphocytes
3308 - A CD3 Fusion Receptor (CD3-FR) Uniquely Enables Compatibility of Allogeneic CAR-T and -NK Cells with T Cell Engagers to Enhance Antitumor Function and Limit Antigen Escape

Witzig, T. E.

18 - Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
850 - Evaluating the Impact of Lab-Based Eligibility Criteria By Race/Ethnicity in Frontline Clinical Trials for Diffuse Large B-Cell Lymphoma (DLBCL): A LEO Cohort Analysis
1233 - Phase II Study Assessing Safety and Preliminary Efficacy of High Dose Intravenous Ascorbic Acid in Patients with TET2 Mutant Clonal Cytopenias of Undetermined Significance
2885 - FLIPI-3: A New PET-Based Prognostic Index for Follicular Lymphoma Based on Results from a Validation Study with the ECOG-ACRIN E2408 Cohort
2889 - Treatment Patterns and Outcomes in Relapsed/Refractory Mantle Cell Lymphoma
2900 - Clinical Outcomes in Patients with Mantle Cell Lymphoma Who Received Autologous Stem Cell Transplant in the Second Line Setting
2966 - Dose Intensity and Reasons for Dose Alterations in Patients Excluded from Frontline Diffuse Large B-Cell Lymphoma Clinical Trials Based on Eligibility Criteria: A Mayo Clinic Cohort Study
3720 - An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)
4216 - Waldenstrom Macroglobulinemia and the Clinical Implications of Acquired Von Willebrand Syndrome
4437 - Comparison of Treatment-Emergent Adverse Events of Covalent BTK Inhibitors in Clinical Trials in B-Cell Malignancies: A Systematic Review and Meta-Analysis

Wladyka, C.

3646 - Requirement for N⁶-Methyladenosine mRNA Methylation during Human Erythropoiesis

Wlodarski, M. W.

494 - Germline SAMD9/9L MDS Predisposition Syndromes Are Characterized By Complex Clonal Architecture and Lineage-Specific Escape Mechanisms Including Somatic Genetic Rescue in T and B Lymphocytes
564 - UBTF tandem Duplications Account for a Third of Advanced Pediatric MDS without Genetic Predisposition to Myeloid Neoplasia
919 - Mutational Permutations of a Single Amino Acid Exert Divergent Phenotypic Effects in Human, Mice, and Cellular Models of SAMD9L Bone Marrow Failure Disorder
1265 - Germline Loss-of-Function Mutations in MDM4 Cause p53-Dependent Hematopoietic Cell Death in Patients with Variable Bone Marrow Failure Phenotypes
2577 - Online Platform for SAMD9 and SAMD9L Variant Annotation and Phenotype Correlation
3895 - Multiplex CRISPR/Cas9 Gene Editing in Human Stem Cells to Model Clonal Competition in GATA2 Deficiency
3902 - Transient Monosomy 7 Is a Rare Event in Young Children with SAMD9L Syndrome

Wo, S.

3396 - Post-Transplant Cyclophosphamide, Abatacept and Short Course of Tacrolimus (CAST) for Graft-Versus-Host Disease Prevention Following Haploidentical Peripheral Blood Stem Cell Transplantation

Woan, K.

2105 - Impact of FLT3 Inhibitor-Based Therapies on Outcomes of Acute Myeloid Leukemia (AML) Patients Receiving Allogenic Stem Cell Transplantation: A Retrospective Study
4068 - Survival and Outcomes after Relapse in Newly Diagnosed Acute Myeloid Leukemia (AML) Patients Treated with Venetoclax-Based Chemotherapy

Wobus, M.

1753 - Targeting S100A9 in the Inflammatory Myelodysplastic Hematopoietic Niche Reprograms the Functional Properties of CD271⁺ Mesenchymal Stromal Cells

Woda, B.

2547 - Natural History of Patients with Clonal Hematopoiesis Seen in Hematology Clinics
4122 - Impaired Clearance of DNMT3A/TET2/ASXL1-Mutant Clones with Hypomethylating Agent or Intensive Induction Chemotherapy for Myelodysplastic Syndrome and Acute Myeloid Leukemia

Wodarz, D.

1801 - High Cell Death Rates at Start of Ibrutinib Therapy Predict for Deeper Remissions in Patients with Chronic Lymphocytic Leukemia (CLL)

Woei-a-Jin, F. J. S. H.

152 - Consolidation Improves Survival in Primary Central Nervous System Lymphoma without Preference for Type of High-Dose Methotrexate-Based Induction Treatment Regimen
1535 - Polyostotic DLBCL Is Characterized By a NF-Κb Pathway Affecting Molecular Profile and Superior Survival

Woermann, B. J.

386 - Sex-Associated Differences in Frequencies and Outcome Prognostication of Recurrent Molecular Features in Adults with Acute Myeloid Leukemia (AML) (AMLCG, CALGB [Alliance])
1479 - Validation of the 2022 European Leukemianet Genetic Risk Stratification of Acute Myeloid Leukemia

Woestmann, C.

1544 - Analysis of Immune Pharmacodynamic and Baseline Biomarkers in Patients with Relapsed or Refractory Follicular Lymphoma Treated with Mosunetuzumab in Combination with Lenalidomide

Wohlan, K.

932 - Relocalization of PU.1 Underlies the On- and Off-Tumor Effects of SWI/SNF Blockade in AML
2649 - Combination of the Kdm-Family Inhibitor, Jib-04, Improves Response to Acute Myeloid Leukemia Cells to Venetoclax
3857 - Clonal Competition: Cisplatin Treatment Drives Dominance of TP53- over Tet2-Mutant Stem Cell Clones

Wohlfarth, P.

2964 - Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL – First Data from the Austrian CAR-T Network

Wojcik, K.

2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study

Wojczyk, B. S.

2518 - RBC Transfusion to Severe Anemic Murine Neonates Leads to Systemic Inflammation

Wojdalska, M.

1159 - Real Pandemic World Results of Personalized Prophylaxis of Bleeds in Polish Children and Adolescents with Severe Hemophilia a

Wojtowicz, E.

3852 - Mitochondrial Membrane Potential Defines the HSC Population with Serial Repopulating Potential in Young but Not Aged Animals

Wolach, O.

219 - Long-Term Follow-up of the Phase 3 Viale-a Clinical Trial of Venetoclax Plus Azacitidine for Patients with Untreated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
520 - Thrombin Generation Is Differentially Affected By Anticoagulants in Patients with Acute Lymphoblastic Leukemia – an Ex-Vivo Study
2743 - Utilization of Antifungal Prophylaxis and Treatment for Newly Diagnosed AML Patients Treated with Venetoclax Based Regimens in Routine Clinical Practice – a Prospective Analysis from the Revive Study
4058 - Clinical Predictors for Relapse Among Patients with AML Who Responded to Venetoclax-Based Treatment – a Real-World Prospective Analysis from the Revive Study Group
4771 - Sequential Therapy Vs. Salvage Chemotherapy for Patients with AML Refractory to First Induction Regimen- a Bi-Institutional Retrospective Cohort Analysis

Wolach, O.

4954 - Comparison of Patients with Newly Diagnosed (ND) Acute Myeloid Leukemia (AML) Treated with Venetoclax and Hypomethylating Agents Vs Other Therapies By TP53 and IDH1/2 Mutation: Results from the AML Real World Evidence (ARC) Initiative

Wolanskyj, A. P.

2334 - Bortezomib and/or Daratumumab for Treatment of Refractory Autoimmune Hemolytic Anemia

Wolberg, A. S.

3754 - Thrombocytopenia in a Mouse Model of Pancreatic Cancer
3755 - Identification of Receptors and Signaling Pathways Mediating the Platelet Contribution to Clotting Parameters in Thromboelastography (TEG)
- Laboratory and Translational Hematology

Wold, B.

734 - Biomarker-Driven Treatment Strategy in High-Risk Large B-Cell Lymphoma: Final Results of a Nordic Phase 2 Study

Woldie, I. L.

2256 - National Burden of Encapsulated Bacterial Infections in Sickle Cell Disease

Wolf, D.

561 - Cox Proportional Hazards Deep Neural Network Identifies Peripheral Blood Complete Remission (PB-CR) to be at Least Equivalent to Morphologic CR in Predicting Outcomes of Patients Treated with Azacitidine – a Prospective Cohort Study By the AGMT
2964 - Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL – First Data from the Austrian CAR-T Network

Wolf, E.

2301 - Chronic Opioid Use Is Highly Prevalent and Associated with Inferior Survival in Myeloma Patients in Remission after Autologous Transplant

Wolf, J. L.

250 - Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy
1866 - Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease
2236 - Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
2286 - Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
3218 - A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis
3529 - Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation

Wolf, J.

1316 - Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms

Wolf, J.

1538 - Identification of Robust Predictors for Ibrutinib Response By Multi-Omic Genomics in MYD88 Mutated Waldenstrom’s Macroglobulinemia

Wolf, M.

328 - Integrated High-Throughput Drug Profiling and CRISPR Screening Identify Novel Pathway Vulnerabilities of Leukemic Stem Cells in Chronic Myeloid Leukemia

Wolf, M.

1025 - Differential Effects of Ferric Derisomaltose and Ferric Carboxymaltose on Fatigue in Patients with Iron Deficiency Anemia and Inflammatory Bowel Disease

Wolf, N.

29 - Mortality Trends Among Persons with Hemophilia in the United States, 2000-2021

Wolf, S.

755 - Portraying Immunity to Sars-Cov-2 after mRNA-Vaccination in Patients with Multiple Myeloma
1500 - Proteomic Characterization of Acute Myeloid Leukemia

Wolf, S. N.

4157 - HTLV-1 Carriers with Circulating Dominant Clones Harbor ATL-like Mutational and Transcriptomic Profiles Which Identify an Ultra-High Risk Group for Disease Transformation

Wolf-Garraway, R.

2464 - The Use of a Pegylated Liposome in a Phase II Trial to Enhance the Potency and Extend the Dosing Interval of Prophylactic Standard Half-Life FVIII, without Increasing the Dose
2477 - Prophylactic Treatment of Severe Haemophilia a Patients with Inhibitors to FVIII with Peglip-FVIII

Wolfe, B. D.

870 - Prospective Trial Using Multimodal Measurable Residual Disease Negativity to Guide Discontinuation of Maintenance Therapy in Multiple Myeloma (MRD2STOP)

Wolfe, E.

3859 - Chronic IL1β Exposure Enhances Self-Renewal Ability and Myeloid Priming in TET2 Deficient Stem and Progenitor Cells

Wolfe, R.

930 - The Effect of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Aspirin on Clinical Outcomes in the Healthy Elderly: A Sub-Study of the Aspirin in Reducing Events in the Elderly (ASPREE) Randomized Controlled Trial
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression

Wolfe, S. A.

1259 - Targeting a Putative Intronic Splicing Silencer Salvages Expression from the Recurrent SBDS C.258+2T>C Mutant Allele in Shwachman-Diamond Syndrome Patient Cells and Mouse Model
4786 - Therapeutic Gene Editing of HSCs Ex Vivo without in Vitro Culture Avoids Genotoxicity, Simplifies Procedures, and Preserves Efficiency and Stemness

Wolff, D.

771 - Itacitinib and Corticosteroids As Initial Treatment for Chronic Graft-Versus-Host Disease: Phase 1/2 Results from Gravitas-309
2084 - Expansion of Plasmablasts at Day 90 after Allogeneic Stem Cell Transplantation Predict Chronic Gvhd
3392 - Identification of Bacterial and Viral Consortia for the Production of Intestinal Microbiota-Derived Metabolites Associated with Protection in Allogeneic Stem Cell Transplantation Patients
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Wolff, E.

3233 - Initial Results of Dose Escalation of ISB 1342, a Novel CD3xCD38 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Wolff, E. V.

3871 - LepR⁺ Niche Cell-Derived AREG Compromises Hematopoietic Stem Cell Maintenance Under Conditions of DNA Repair Deficiency and Aging

Wolff, J.

4577 - Mechanisms of Response and Resistance to Combination Decitabine and Ipilimumab for Transplant Naïve and Post-Transplant AML/MDS

Wolfgang, K. J.

696 - Hypoalbuminemia Increases Clot Fibrin Network Density and Impairs Fibrinolysis during Glomerular Proteinuria

Wolfson, J. A.

906 - Comparison of Overall Survival Among Adolescents and Young Adults (AYA) with Newly-Diagnosed Acute Lymphoblastic Leukemia (ALL) Treated with Pediatric-Inspired or Non-Pediatric Inspired Regimens: A Real-World Analysis Using Claims Data
3584 - COVID-19 Infection in Children with Down Syndrome and Hematologic Malignancies

Wolin, A.

1955 - Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies

Wołkow, P.

2867 - MEN1703-Mediated PIM Kinases Inhibition Impairs Protumoral and Immunosuppressive Phenotype and Functions of Macrophages in Classical Hodgkin Lymphoma

Wöll, E.

4572 - Randomized Comparison between Krd and Ktd Induction, Followed By K Maintenance or Control in Transplant Non-Eligible Patients with NDMM: Efficacy and Qol Data (AGMT-MM02 Trial)

Woll, P. S.

1211 - Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor Fractions
3068 - Long-Term Clonal Inversion in an MDS-RS Case with Dual SF3B1 Mutations

Wolleschak, D.

742 - Ruxolitinib Versus Best Available Therapy in Patients with Essential Thrombocythemia: Pre-Specified Interim Analysis of the Randomized Phase 2b Ruxobeat Clinical Trial of the German Study Group for Myeloproliferative Neoplasms (GSG-MPN)

Wolschke, C.

340 - TP53 and Complex Karyotype Represent a Very High-Risk Group in Myelofibrosis Undergoing Hematopoietic Stem Cell Transplantation: An International Collaborative Analysis
3352 - Viral Reactivation and Immune Reconstitution after CAR-T Cell Treatment in Patients with Hematologic Malignancies
3415 - Targeting Molecular Remission with Donor Lymphocyte Infusions Shows Excellent Outcomes for Persistent or Relapsed Myelofibrosis after Stem Cell Transplantation

Wolska-Kusnierz, B.

1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency

Wolter, C.

1142 - Blood-Induced Inflammation in Hemophilia

Woltjer, R.

3760 - Effect of Rosuvastatin on Inflammatory Cytokines during Murine DVT Resolution

Wölwer, C. B.

1004 - The Birth of the Red Blood Cell: Dynamics of Erythroid Enucleation in the Bone Marrow Niche

Won, J. H.

424 - Prognostic Predictability of 2022 European Leukemianet (ELN) Risk Stratification in the Real World
2344 - The Effects of Iron Deficiency on the Gut Microbiota in Young Women
2935 - Role of Autologous or Allogeneic Stem Cell Transplantation in Patients with Peripheral T Cell Lymphomas (PTCLs)
3054 - Neutrophil-to-Lymphocyte Ratio Is More Accurate Than Erythropoietin Level for the Polycythemia Vera Diagnosis

Wondergem, M.

239 - Siremadlin, a Human Double Minute-2 (HDM2) Inhibitor, Added to Ruxolitinib after Suboptimal Response to Ruxolitinib Alone in Patients with Myelofibrosis: Results from Part 1 of the Phase 1/2 Adore Study
1426 - Comparison of Hidac Versus FLAG-IDA in the Treatment of Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndrome: A Retrospective Study

Wong, A.

592 - A Multicenter Study of Safety, Tolerability, and Effectiveness of Antithrombotic Therapy in Hereditary Hemorrhagic Telangiectasia

Wong, A.

1040 - Histone Deacetylase 6 Inhibition Prevents Vaso-Occlusion and Pain in Sickle Cell Mice

Wong, A.

663 - Efficient and Specific Multi-Locus Editing of Allogeneic CAR T Cells for Hypoimmunity during Large Scale Manufacture Using Cas12b

Wong, C. C. L.

1338 - Inhibition of Polo-like Kinase 4 Induced Both Cell Intrinsic and Non-Cell Intrinsic Anti-Leukemia Effects on TP53-Mutated Acute Myeloid Leukemia

Wong, C.

2362 - Accurate Identification of Hemoglobin Variants By Top-Down Protein Analysis Using Capillary Electrophoresis-High-Resolution Mass Spectrometry

Wong, C.

567 - Pretreatment with Tocilizumab Prior to the CD3 Bispecific Cevostamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Showed a Marked Reduction in Cytokine Release Syndrome Incidence and Severity
1924 - Enduring Responses after 1-Year, Fixed-Duration Cevostamab Therapy in Patients with Relapsed/Refractory Multiple Myeloma: Early Experience from a Phase I Study

Wong Doo, N.

2938 - First-in-Human (FIH) Study of the Fully-Human Kappa-Lambda CD19/CD47 Bispecific Antibody TG-1801 in Patients (pts) with B-Cell Lymphoma

Wong, E.

1211 - Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor Fractions

Wong, E.

2588 - Mutant NPM1 Is Recruited to MLL Target Genes Via Its Acidic Stretch and Nuclear Export Factor CRM1 and Regulates Oncogenic Transcription in Acute Myeloid Leukemia

Wong, E. B.

3052 - LNK/SH2B3 As a Novel Driver in Juvenile Myelomonocytic Leukemia

Wong, H.

2727 - Safety and Pharmacokinetics of Subcutaneous Blinatumomab (SC blinatumomab) for the Treatment of Adults with Relapsed or Refractory B Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL); Results from a Phase 1b Study
2732 - Blinatumomab Alternating With Low-Intensity Chemotherapy (CT) Treatment for Older Adults With Newly Diagnosed Philadelphia (Ph)-Negative B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) is Well Tolerated and Efficacious: Safety Run-In Results for the Phase 3 Randomized Controlled Golden Gate Study

Wong, H.

4256 - Enitociclib (VIP152/formerly BAY1251152) Is a Selective and Active CDK9 Inhibitor : Preliminary Safety and Early Signs of Efficacy in Patients with Non-Hodgkin Lymphoma (NHL) and Chronic Lymphocytic Leukemia (CLL)

Wong, H. C.

1894 - Efficacy of Frontline Treatments for Newly Diagnosed Transplant-Ineligible Multiple Myeloma, a Network Meta-Analysis

Wong, J. C.

2589 - Comprehensive Genomic Landscape and Clonal Architecture in Pediatric Patients with Monosomy 7

Wong, J. W.

1211 - Comparative Analysis of Genome-Scale Gene Regulatory Networks in Human Hematopoietic Stem and Myeloid Progenitor Fractions

Wong, J.

546 - Relapse Timing Is Associated with Distinct Evolutionary Dynamics and Response to Salvage Therapy in DLBCL
1518 - Towards a Unified Genetic Classification System for Diffuse Large B-Cell Lymphoma (DLBCL)
2836 - Genetic Determinants of Isolated and Systemic Testicular Diffuse Large B-Cell Lymphoma Highlight a Disease Spectrum
4172 - Recurrent Copy Number Alterations Contribute to a Unique Genetic Landscape in Relapsed-Refractory DLBCL

Wong, J.

1955 - Engineered Stem Cell Antibody Paired Evasion 1 (ESCAPE-1): Paired HSC Epitope Engineering and Upregulation of Fetal Hemoglobin for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Hemoglobinopathies
4585 - Engineered Stem Cell Antibody Paired Evasion-2 (ESCAPE-2): Paired HSC Epitope Engineering and Direct Editing of Sickle Allele for Antibody-Mediated Autologous Hematopoietic Stem Cell Therapy Conditioning for the Treatment of Sickle Cell Disease

Wong, J. B.

3532 - Understanding Treatment Decisions for Hodgkin Lymphoma: A Qualitative Study

Wong, J. K.

747 - Single-Cell Omics Analyses Identify the TIM-3 Ligand Galectin-9 As Novel Immunotherapy Target for Chronic Lymphocytic Leukemia

Wong, L.

3722 - Characterization of ELA026, a Clinical-Stage Monoclonal Antibody That Rapidly and Potently Depletes Myeloid Cells and T Lymphocytes

Wong, L.

492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)
903 - Poverty during Maintenance and Relapse Risk in Children with Acute Lymphoblastic Leukemia (ALL): A Report from Children’s Oncology Group Study (COG-AALL03N1)
2253 - Individual Prediction of Cardiovascular Events in Blood or Marrow Transplant Survivors - a BMT Survivor Study Report

Wong, L.

2000 - Interim Phase I Clinical Data of FT819-101, a Study of the First-Ever, Off-the-Shelf, iPSC‑Derived TCR‑Less CD19 CAR T‑Cell Therapy for Patients with Relapsed/Refractory B‑Cell Malignancies
2004 - Interim Phase I Clinical Data of FT576 As Monotherapy and in Combination with Daratumumab in Subjects with Relapsed/Refractory Multiple Myeloma
3288 - iPSC-Derived CD38-Null NK Cells in Combination with CD38-Targeted Antibody: A Dual Therapeutic Strategy to Enable ADCC and Eliminate Host Immune Cells in Multiple Myeloma
4639 - A Phase I Study of FT538, an Off-the-Shelf, Multiplexed-Engineered, iPSC‑Derived NK Cell Therapy in Combination with Daratumumab in Relapsed/Refractory Multiple Myeloma

Wong, L. L.

2571 - Dose–Exposure–Response Relationships of Biomarkers and Efficacy Measures with Iptacopan, a Complement Factor B Inhibitor, in Patients (pts) with Paroxysmal Nocturnal Hemoglobinuria (PNH) with or without Concomitant Anti-C5 Therapy
3162 - Mezigdomide (CC-92480), a Novel Cereblon E3 Ligase Modulator, Induces Vulnerability of Multiple Myeloma Cells to T-Cell-Mediated Killing
3892 - Sensitivity Analysis on the Primary Efficacy Results of SB12 (Eculizumab Biosimilar) Phase III Study in Paroxysmal Nocturnal Hemoglobinuria Patients

Wong, M.

1894 - Efficacy of Frontline Treatments for Newly Diagnosed Transplant-Ineligible Multiple Myeloma, a Network Meta-Analysis

Wong, M.

3775 - Novel Snake Venom Derived Hemocoagulase Reverses Anticoagulant Effect of Factor Xa Inhibitors, Restores Hemostatic Clot Formation, and Limits Bleeding in Vitro and In Vivo

Wong, N.

1201 - Sustained Complement C1s Inhibition with Sutimlimab in Patients with Cold Agglutinin Disease Results in Continued Efficacy during Part B of the Randomized Placebo-Controlled Phase 3 Cadenza Study (NCT03347422)

Wong, N. C.

930 - The Effect of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Aspirin on Clinical Outcomes in the Healthy Elderly: A Sub-Study of the Aspirin in Reducing Events in the Elderly (ASPREE) Randomized Controlled Trial
2621 - Non-Linear Trajectories of the Epigenome during T-Cell Leukemogenesis Revealed By Analysis of a Mouse Model of Human ETP-ALL
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression

Wong, P.

2908 - Mucosal Associated Lymphoid Tissue Lymphoma in Thailand, a Nationwide Multicenter Registry and Prognostic Index; Results from the Thai Lymphoma Study Group (TLSG) Registry

Wong, P.

4183 - Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

Wong Quiles, C.

3525 - Improving Rates of Annual Transcranial Doppler Screening in Children with Sickle Cell Disease: A Quality Improvement Project

Wong, R.

2629 - DNMT3A Limits Myeloid Signaling Responses in Committed T Cells during Normal and Leukemic Development
3940 - MYCN Is Required in Immature T-ALL and Bears Epigenetic Marks Associated with Cell Identity

Wong, R.

1255 - Intensive Pegcetacoplan Dosing in the Management of Acute Hemolysis As Part of the 307 Open-Label Extension Study
1857 - Carfilzomib Use Among Patients with Relapsed/Refractory Multiple Myeloma in the Asia Pacific Region: Characteristics and Outcomes By Regimen from a Prospective, Real-World Study
2326 - Long-Term Efficacy and Safety of Pozelimab Monotherapy in Patients with Paroxysmal Nocturnal Hemoglobinuria
3651 - A Phase 2, Randomized Trial Evaluating the Safety and Efficacy of Pozelimab and Cemdisiran in Patients with Paroxysmal Nocturnal Hemoglobinuria

Wong, S. W.

160 - Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study
162 - Alnuctamab (ALNUC; BMS-986349; CC-93269), a B-Cell Maturation Antigen (BCMA) x CD3 T-Cell Engager (TCE), in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM): Results from a Phase 1 First-in-Human Clinical Study
250 - Clinical Outcomes and Salvage Therapies in Patients with Relapsed/Refractory Multiple Myeloma Following Progression on BCMA-Targeted CAR-T Therapy
1866 - Outcomes in Patients with Renal Monoclonal Immunoglobulin Deposition Disease
2236 - Safety and Efficacy of BCMA-Targeted CAR-T Therapy in Geriatric Patients with Multiple Myeloma
2286 - Intensity of Cyclophosphamide-Based Bridging Regimens before BCMA-Directed CAR-T Therapy
3166 - Soluble Factors Correlated with High-Grade Cytokine Release Syndrome (CRS): A Comparison of Subcutaneous (SC) Versus Intravenous (IV) Delivery of Alnuctamab (ALNUC; BMS-986349; CC-93269) in Patients (pts) with Relapsed/Refractory Multiple Myeloma (RRMM)
3218 - A Real-World Study on the Feasibility of Minimal Residual Disease Testing By Next-Generation Sequencing in Systemic Light-Chain Amyloidosis
3529 - Significance of the Pee-Value: Relevance of Urine Studies for Patients with Myeloma Undergoing Transplantation
4515 - Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM)
4547 - The Clusterin/Von Willebrand Factor Ratio Is Significantly Lower in Marrow Plasma from AL λ-Type Than from λ-Isotype Monoclonal Gammopathy Patients

Wong, T. N.

3864 - Frequent Whole Blood Donations Select for DNMT3A variants Mediating Enhanced Response to Erythropoietin

Wong, T. E.

1207 - Outcomes of Cold-Stored, Low Titer Group O Whole Blood Transfusions in Non-Trauma Massive Transfusion Protocol Activations in Patients with Cirrhosis

Wong, W. J.

926 - Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis

Wong, W.

1319 - ORM-6151: A First-in-Class, Anti-CD33 Antibody-Enabled GSPT1 Degrader for AML

Wong, W.

1978 - Senti-202, a Selective, Off-the-Shelf, Preclinical CAR-NK Cell Therapy with CD33 and/or FLT3 Activating CAR, Healthy Cell Protection from Endomucin (EMCN) Inhibitory CAR and Calibrated Release IL-15 for Hematologic Malignancies Including AML

Wong, X. F. A.

975 - Development of an Off-the-Shelf Chimeric Antigen Receptor (CAR)-T Cell Therapy for T-Cell Acute Lymphoblastic Leukemia (T-ALL) without Gene Editing

Wong-Rolle, A.

1487 - Spatial-Temporal Multiomic Analysis of Tumor-Immune Interactions in Patients with AML Receiving Pembrolizumab and Decitabine

Wongchai, V.

1654 - Phase Ib/II Trial of the Bruton’s Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination with Rituximab and Lenalidomide in Refractory/Recurrent Primary (PCNSL) and Secondary Central Nervous System Lymphoma (SCNSL)

Wongkhantee, S.

2908 - Mucosal Associated Lymphoid Tissue Lymphoma in Thailand, a Nationwide Multicenter Registry and Prognostic Index; Results from the Thai Lymphoma Study Group (TLSG) Registry

Woo, C. M.

273 - Dual IKZF2 and CK1α Degrader Targets Acute Myeloid Leukemia Cells

Woo, J.

2653 - Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents

Woo, J.

929 - Canakinumab Effects on Erythropoiesis, Cardiovascular Risk, and Clonal Hematopoiesis: Proteogenomic Analysis of the Cantos Randomized Clinical Trial
1745 - Activation of Distinct Inflammatory Pathways in LR-MDS Is Determined By Genetics

Woo, J. G.

4196 - HBB rs334, ABO Rs8176703 and Plasmodium Falciparum Positivity at Enrollment Are Independently Associated with Lower Risk for Endemic Burkitt Lymphoma in Uganda, Tanzania, Kenya, and Malawi

Woo, T.

4352 - Stem Cell-Derived Gene Expression Scores Predict Survival and Leukemic Transformation in Myelofibrosis

Wood, B. L.

531 - Single-Cell Pan-Cancer Analysis Reveals Treatment Resistance Stem/Progenitor-like Subpopulation in the High-Risk Pediatric Leukemia
716 - A Transcriptional Classifier Identifies Pediatric T-Cell Acute Lymphoblastic Leukemias at High Risk for End of Induction Minimal Residual Disease
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia
2725 - A Phase 2 Study of Ruxolitinib with Chemotherapy in Children with Philadelphia Chromosome-like Acute Lymphoblastic Leukemia (AALL1521/INCB18424-269): Biologic Characteristics and Minimal Residual Disease Response of Patients with Non-CRLF2-Rearranged JAK Pathway Alterations
2825 - RPPA-Profiling in Pediatric and Adult T-Cell Acute Lymphoblastic Leukemia Identifies Protein Patterns Associated with Outcome
2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231
4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Wood, C.

2842 - Correlation of Minimal Residual Disease (MRD) at the End of Induction (EOI) and Event Free Survival (EFS) in T-Cell Lymphoblastic Lymphoma (T-LL), a Report from the Children’s Oncology Group (COG) Trial AALL1231

Wood, E. M.

930 - The Effect of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Aspirin on Clinical Outcomes in the Healthy Elderly: A Sub-Study of the Aspirin in Reducing Events in the Elderly (ASPREE) Randomized Controlled Trial
1252 - Efficacy and Safety of Avatrombopag in Combination with Immunosuppressive Therapy in Treatment-Naïve and Relapsed/Refractory Severe Aplastic Anaemia – the Diaamond-Ava-First and Diaamond-Ava-Next Bayesian Optimal Phase II Trials
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression
4237 - Characteristics and Outcomes of Elderly Patients with Classical Hodgkin Lymphoma (cHL): An Australian Lymphoma Alliance (ALA), and Lymphoma and Related Disease Registry (LaRDR) Study
4496 - Real World Comparison of Treatment Outcomes for Myeloma in Elderly Transplant-Ineligible Population with RVD, RD and VCD in Frontline Setting: Results from Mrdr Australia and New Zealand

Wood, H.

4063 - Venetoclax-Based Non-Intensive Combinations Successfully Salvage Molecular Relapse of Acute Myeloid Leukemia and Are an Important Bridge to Cellular Therapy in Relapsed/Refractory Disease – Real-World Data from a UK-Wide Programme

Wood, J. P.

1145 - Unfolded Von Willebrand Factor Interacts with Protein S and Limits Its Anticoagulant Activity

Wood, K. C.

186 - Loss of Cyb5R3 Function Silences Fetal Hemoglobin and Hematocrit Responses to Hydroxyurea in Patients with Sickle Cell Anemia
394 - Preclinical Development and Screening of a Quinone-Nitroalkene Molecule for Sickle Cell Anemia
2365 - Inhibition of Hypoxia Inducible Factor Prolyl Hydroxylase By FG-4592 (Roxadustat) Increases Erythropoietic Stimulation in a Mouse Model of Sickle Cell Disease

Wood, L.

3318 - Safety, Efficiency and Long-Term Follow-up of AUTO1, a Fast-Off Rate CD19 CAR in Relapsed/Refractory B-Cell Acute Lymphoblastic Leukaemia and Other B-Cell Malignancies
4634 - First in Human Study of AUTO4, a TRBC1-Targeting CAR T-Cell Therapy in Relapsed/Refractory TRBC1-Positive Peripheral T-Cell Lymphoma

Wood, N.

2494 - The Clinicalpathological Features of Vaccine-Induced Immune Thrombocytopenia and Thrombosis (VITT) Following ChAdOx1 (AstraZeneca AZD1222) Vaccination and Case Outcomes in Australia

Wood, R.

353 - ISB 2001, a First-in-Class Trispecific BCMA and CD38 T Cell Engager Designed to Overcome Mechanisms of Escape from Treatments for Multiple Myeloma By Targeting Two Antigens

Wood, R.

2380 - Optimizing Dose and Limiting Laboratory Monitoring of Hydroxyurea in Africa: Design of the Promoting Utilization and Safety of Hydroxyurea Using Precision in Africa (PUSH-UP) Trial

Wood, S.

3994 - Elucidating the Molecular Mechanisms of Action of CC-99282, a Novel Cereblon (CRBN) E3 Ligase Modulator (CELMoD) Agent, Via Genome-Wide CRISPR Screen in a Preclinical Model of Non-Hodgkin Lymphoma (NHL)

Wood, T.

2250 - The Safety and Efficacy of Fostamatinib in Patients with Chronic Immune Thrombocytopenic Purpura Treated in a Real-World Community Hematology Setting

Wood, W. A.

278 - Does Race/Ethnicity Impact Umbilical Cord Blood Transplant Outcomes in a Contemporary Era?
1458 - Is Disease Response a Patient-Centered Clinical Trial Endpoint in Acute Myeloid Leukemia: Differences in Symptom Burden and Physical Function By Response Status in the Beat-AML Master Trial
2054 - International Collaborative Study to Compare the Prognosis for Acute Leukemia Patients Transplanted with Intensified Myeloablative Regimens
3552 - Strategies for Implementing an Oral Medication Adherence Intervention in Academic and Community Cancer Settings
3579 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions
3638 - An Analysis of the Worldwide Utilization of Hematopoietic Stem Cell Transplantation for Acute Myeloid Leukemia
4871 - Impact of Public Reporting of Center-Specific Analysis Scores on Hematopoietic Cell Transplant Center Volumes
- Session Introduction
- Moderated Q&A
- Pandemic Preparedness: Highlighting the Role of Real-World Data Hub Programs

Woodley, K.

1318 - Inhibition of Stearoyl-CoA Desaturase Has Anti-Leukemic Properties in Acute Myeloid Leukemia

Woodman, S. E.

4900 - Prediction of Mortality Following Cytokine Storm in Patients with Hematological Malignancies and COVID-19 Infections

Woods, A.

- Precision Medicine for Leukemias - Ivosedinib and Azacitidine for Newly Diagnosed Acute Myeloid Leukemia
- Panel Discussion

Woods, C. M.

1238 - Therapeutic Anti-Jagged1 Antibody Targeting Osteoblast-Related Myeloid Dysplasia to Overcome Standard of Care Resistance

Woods, E. J.

3267 - Transplantation of Hematopoietic Stem and Progenitor Cells from Cadaveric Organ Donors Leads to Long-Term Multilineage Engraftment in NSG Mice

Woods, R. L.

930 - The Effect of Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Aspirin on Clinical Outcomes in the Healthy Elderly: A Sub-Study of the Aspirin in Reducing Events in the Elderly (ASPREE) Randomized Controlled Trial
3865 - The Growth Kinetics of Clonal Hematopoiesis Inform Risk of Blood Cancer Progression

Woodward, J. G.

1145 - Unfolded Von Willebrand Factor Interacts with Protein S and Limits Its Anticoagulant Activity

Wool, J.

3576 - Longitudinal Outcomes of Chronically Transfused Adults with Sickle Cell Anemia and a History of Childhood Stroke

Woolcock, B. W.

844 - TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma

Woolfrey, A.

1956 - GPC-100 Is a Novel CXCR4 Inhibitor That Leads to Improved in Vitro Potency and In Vivo Efficacy in Stem Cell Mobilization When Combined with a Beta-Blocker

Woolley, K.

1931 - The Mydrug Platform Trial: Efficacy and Safety of Daratumumab, Ixazomib, Pomalidomide, and Dexamethasone in Patients with Functionally High-Risk Multiple Myeloma

Worel, N.

2964 - Stringent Nationwide Selection Criteria for CAR-T Cell Therapy Ensure Favourable Outcome of Patients with LBCL – First Data from the Austrian CAR-T Network
4682 - Handling of Allogeneic HPC Grafts in European Transplant Centers during the COVID-19 Pandemic – a Survey from the Infectious Diseases and Cellular Therapy & Immunobiology Working Parties of the EBMT

Wörmann, B. J.

280 - Secondary Neoplasms in AML Long-Term Survivors: Even More Cancer to Come?
388 - German AMLCG-Survivorship Study: Anxiety and Depression Symptoms in AML Long-Term Survivors
2319 - Life Satisfaction and Quality of Life in AML Long-Term Survivors: Primary Results of the AMLCG-Survivorship Study

Worme, S.

2590 - The Role of Histone H3-K27M Mutation in Preleukemic HSC Expansion

Wormser, D.

1693 - Effectiveness of Tyrosine Kinase Inhibitors in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) after Two or More Prior Tyrosine Kinase Inhibitors

Worth, S.

277 - Real-World Treatment Experience of Venetoclax in Combination with Hypomethylating Agents in Patients with Newly Diagnosed Acute Myeloid Leukemia: Updated Experience from a Predominately Community Setting in the US

Worthington, K. H.

4080 - Umbrella Trial in Myeloid Malignancies: The Myelomatch National Clinical Trials Network Precision Medicine Initiative

Wortmann, F.

4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Wossenseged, F.

809 - Examining Sickle Cell Trait Associated Clinical Outcomes in the All of Us research Program

Woszczyk, D.

738 - Mosunetuzumab Monotherapy Continues to Demonstrate Promising Efficacy and Durable Complete Responses in Elderly/Unfit Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

Wouters, A. K.

1104 - Sars-Cov-2-Specific CD4⁺ and CD8⁺ T Cell Responses Can Originate from Cross-Reactive CMV-Specific T Cells
1961 - Broadly Applicable TCR Based Therapy for Multiple Myeloma Targeting the Jchain
4625 - T Cell Receptor-Based Targeting of Immunoglobulin Constant Domains for Treatment of Multiple Myeloma

Wouters, B.

37 - Oncogene EVI1 Drives Acute Myeloid Leukemia Via a Targetable EVI1-CtBP1/2 Interaction and By Repressing Myeloid Regulator CEBPA

Wouters, D.

808 - Sickle Cell Disease Patients Mount Adequate Humoral but Reduced Cellular Responses to COVID-19 Vaccination
3736 - Discordant Cellular and Humoral Responses to a 3-Dose COVID-19 mRNA Vaccination Schedule in Patients with Hematologic Malignancies

Woyach, J. A.

206 - Targeting Venetoclax Resistant CLL Using a Protac-Based BCL-2/BCL-XL Degrader
961 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory CLL/SLL: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
963 - Initial Results from a Phase 1/2 Dose Escalation and Expansion Study Evaluating MS-553, a Novel and Selective PKCβ Inhibitor, in Patients with CLL/SLL
1348 - PRMT5 Inhibition Alters Mitochondrial Dynamics in Mantle Cell Lymphoma Creating Vulnerability to BH3 Mimetic Compounds
1771 - Characterizing the Development of Secondary Myelodysplastic Syndrome (MDS) with Antecedent or Concurrent Chronic Lymphocytic Leukemia (CLL) in the Era of Small Molecule Inhibitors for the Treatment of CLL
1797 - Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study
1812 - Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study
1815 - Contribution of Obinutuzumab to Acalabrutinib Therapy in Patients with Treatment-Naive Chronic Lymphocytic Leukemia: Analysis of Survival Outcomes By Genomic Features
3114 - Efficacy and Safety of Nemtabrutinib, a Wild-Type and C481S-Mutated Bruton Tyrosine Kinase Inhibitor for B-Cell Malignancies: Updated Analysis of the Open-Label Phase 1/2 Dose-Expansion Bellwave-001 Study
3118 - FISH Analysis of CDKN2A/B Deletion in Chronic Lymphocytic Leukemia
3133 - Assessing the Burden of Adverse Events in a Head-to-Head Trial of Acalabrutinib Versus Ibrutinib in Previously Treated Chronic Lymphocytic Leukemia (CLL)
3937 - Dysregulation of PRMT5 in Chronic Lymphocytic Leukemia Supports Transformation to Diffuse Large B-Cell Lymphoma
4218 - Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study
4428 - MS-553, a Selective PKC-ß Inhibitor Inhibits BCR Signaling and Synergizes with Venetoclax for the Treatment of High Risk CLL
4431 - Final Results of the Phase 1/2 Study of Acalabrutinib Monotherapy in Treatment-Naive Chronic Lymphocytic Leukemia with >6 Years of Follow-up
4434 - Phase 1/2 Study of Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: Final Results with >4 Years of Follow-up

Wozniak, J.

2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation

Woznica-Karczmarz, I.

1159 - Real Pandemic World Results of Personalized Prophylaxis of Bleeds in Polish Children and Adolescents with Severe Hemophilia a

Wozniczka, K.

2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Wray, L.

983 - CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Wright, C.

900 - Self-Efficacy and Stigma in Adults with Sickle Cell Disease: An Import Study Analysis
4884 - Pain Attitudes in Adults with Sickle Cell Disease: A Mixed Methods Study

Wright, C. M.

4897 - Multi-Institutional Review of Bridging Radiotherapy Prior to Chimeric Antigen Receptor T-Cell Therapy for B-Cell Lymphomas

Wright, G. W.

2860 - Prediction of Early Disease Progression at 24 Months (POD24) Using Pre-Treatment Biopsies from Patients with Follicular Lymphoma (FL) Treated with Immunochemotherapy (IC)

Wright, H.

1988 - A Dual-Antigen Targeting, Hypoimmune Allogeneic CAR T to Evade Innate and Adaptive Immune Rejection and Overcome Antigen Escape
3457 - CD8-Targeted, Integrating Viral Vectors Transduce Resting T Cells and Enable Extracorporeal Delivery (ECD) for Rapid CAR T Cell Therapies

Wright, H.

2653 - Inhibition of CDC7 with Sgr-2921 in AML Models Results in Enhanced DNA Damage and Anti-Leukemic Activity As Monotherapy and in Combination with Standard of Care Agents

Wright, M.

79 - Early and Deep Molecular Responses Achieved with Frontline Asciminib in Chronic Phase CML – Interim Results from ALLG CML13 Ascend-CML

Wright, S.

529 - Systematically Interrogating Downstream Regulation Mechanisms of HOXA9 in MLL-r Leukemia Via Functional Noncoding CRISPR Screens

Wrighton, P. J.

3847 - Bnip3lb Regulated Mitophagy Maintains the Embryonic Pool of Hematopoietic Stem Cells By Protecting Them from ROS Induced Apoptosis

Wrin, T.

4785 - Global Seroprevalence of Neutralizing Antibodies Against Adeno-Associated Virus (AAV) Serotypes of Relevance to Gene Therapy

Wróbel, T.

1175 - Thrombotic and Bleeding Complications in Patients with Chronic Lymphocytic Leukemia and Severe COVID-19: A Study of Eric, the European Research Initiative on CLL
1388 - A Comparison of Outcomes in Patients with Secondary Acute Promyelocytic Leukemia (APL) and De Novo APL – a Case-Match Retrospective Analysis of Polish Adult Leukemia Group (PALG)
2744 - A Phase 1 Dose-Escalation Study of the Cladribine Added to CPX-351 in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) a Study of the Polish Adult Leukemia Group (AML-1/2018): Preliminary Results of the Dose Escalation Stage
2777 - Prospective Assessment of Measurable Residual Disease Kinetics in Intensively Treated Patients with Acute Myeloid Leukemia - Results of the Polish Adult Leukemia Group PALG-AML1/2016 Study
3448 - Pre-Transplant Multiparameter Flow Cytometric Measurable Residual Disease in Acute Myeloid Leukemia As an Independent Prognostic Factor for Survival after Myeloablative Allogeneic Hematopoietic Cell Transplantation
4062 - A Polish Acute Leukemia Group Prospective Multicenter Clinical Trial to Compare the Efficacy of Two Standard Induction Therapies (DA-90 vs DAC) and Two Standard Salvage Regimens (FLAG-IDA vs CLAG-M) in Acute Myeloid Leukemia (AML) Patients ≤ 60 Years Old (PALG-AML1/2016)

Wrobel, T.

74 - Glofitamab Monotherapy Induces High Complete Response Rates in Patients with Heavily Pretreated Relapsed or Refractory Mantle Cell Lymphoma

Wroblewski, K.

3672 - Area of Residence As a Screening Tool for Sickle Cell Disease Outcomes in Chicago Pediatric Patients

Wroblewski, T.

- Introduction
- A Novel Treatment for Pyruvate Kinase Deficiency - Mitapivat
- A New Therapy for Histiocytic Disorders - Cobimetinib
- Panel Discussion

Wronowski, B.

305 - Identification of PTPN11 mutations As Early Events in the Development of Acute Myeloid Leukemia

Wu, B.

4346 - BMS-986158, a Potent BET Inhibitor, As Monotherapy and in Combination with Ruxolitinib or Fedratinib in Intermediate- or High-Risk Myelofibrosis: First Results from a Phase 1/2 Study

Wu, B.

384 - A US National View of Prevalent and Newly Diagnosed Multiple Myeloma in 2021: A Retrospective Analysis of National All-Payer Claims Database
2284 - Burden of Hospitalization before and after a Disease Progression Following Triple-Class Exposure in Patients with Relapsed and Refractory Multiple Myeloma
2297 - Patients’ and Caregivers’ Perspectives from Social Media Towards Disease Burden and Innovative Treatment Options in Multiple Myeloma

Wu, B.

2989 - A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data

Wu, B.

4470 - MDM2-p53 Inhibitor Alrizomadlin (APG-115) Enhances Antitumor Activity of Pomalidomide in Multiple Myeloma (MM)

Wu, B.

4254 - A Preliminary Analysis of Chidamide Combined with R-GemOx (rituximab, gemcitabine and oxaliplatin) As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Study

Wu, B.

1342 - Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma

Wu, C. J.

633 - Evolutionary History of Transformation from Chronic Lymphocytic Leukemia to Richter Syndrome
636 - Immuno-Genetic Changes Underlie Response to Immune Checkpoint Blockade Therapy in Richter’s Syndrome Mouse Models
748 - ZNF683 (Hobit) Marks a CD8+ T Cell Population Associated with Anti-Tumor Immunity Following Anti-PD-1 Therapy for Richter Syndrome
2078 - Systematic Identification of Autosomal and Y-Encoded Minor Histocompatibility Antigens Reveals Predictors of Chronic Gvhd and Candidate GVL Targets
2097 - Allogeneic Stem Cell Cryopreservation Is Associated with Equivalent Survival and Relapse Rates with Lower Rate of Severe Chronic Gvhd
2098 - Expansion of a CD8+ Temra Population and Activating T-Cell Interactions Characterize the Graft Versus Leukemia Response in Relapsed AML
3103 - Integrating High-Throughput Dynamic BH3 Profiling and Molecular Phenotyping to Identify Therapeutic Vulnerabilities in CLL
3128 - Prevalence of Clonal Hematopoiesis of Indeterminate Potential in Patients with Monoclonal B-Cell Lymphocytosis Compared to Untreated Chronic Lymphocytic Leukemia
4419 - Proteogenomic Analysis of SF3B1^mut CLL Reveals Altered Protein Signaling Cascades and Metabolomic Pathways
4426 - Characteristics of Rare Germline ATM Variants in Chronic Lymphocytic Leukemia (CLL)
4432 - Association of Clonal Hematopoiesis of Indeterminate Potential with Time to First Treatment, Incidence of Richter’s Syndrome, and Overall Survival in Patients with Chronic Lymphocytic Leukemia
4577 - Mechanisms of Response and Resistance to Combination Decitabine and Ipilimumab for Transplant Naïve and Post-Transplant AML/MDS

Wu, C.

2260 - Real-World Treatment Patterns and Outcomes of Patients with Newly Diagnosed Multiple Myeloma: An Analysis Using National Health Insurance Service Database

Wu, C.

1294 - Single-Cell Multi-Omics Analysis Reveals Hematopoiesis of Aberrant Mast Cells in Systemic Mastocytosis

Wu, C.

16 - Ongoing Production of Tissue-Resident Macrophages from Hematopoietic Stem Cells in Healthy Adult Macaques
125 - Clonal Dynamics of HDR-Edited HSPCs Targeting the CD33 Locus in Rhesus Macaques
2149 - Comparing the Impact of NHEJ-CRISPR/Cas9 and Base Gene Editing on Rhesus Macaque Hematopoietic Stem Cell Clonal Behavior and Integrity

Wu, C.

737 - Glofitamab Plus R-CHOP Induces High Response Rates and a Favorable Safety Profile in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma (DLBCL): Results from a Phase Ib Study

Wu, C.

4518 - The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients

Wu, C. O.

34 - Predictors, Risk Factors and Outcomes of Patients with SAA with Anti-HLA Class I Antibodies Treated with Immunosuppressive Therapy
197 - The Role of Heterozygous Variants in SAMD9/9L and Recessive Bone Marrow Failure-Related Genes in Adults with Severe Aplastic Anemia
1182 - Thrombotic Manifestations in Patients with Vexas Syndrome
2541 - Clonal Hematopoiesis in Vexas Syndrome
2582 - Treatment of Refractory Diamond-Blackfan Anemia with Eltrombopag
2583 - Characterizing Immunodeficiency in Patients with Telomere Biology Disorders
3840 - Granulocyte Transfusions As an Adjunctive Therapy in Severe Aplastic Anemia

Wu, C. M.

22 - Arterial Thromboembolism Is Prevalent and Often Suboptimally Managed in Immune Thrombocytopenia
24 - Management and Outcomes of Venous Thromboembolism in Adults with Immune Thrombocytopenia

Wu, D.

3050 - Phase Ⅱ,Open-Label, Multicenter, Single-Arm Study Investigating the Efficacy and Safety of Ropeginterferon Alfa-2b in Chinese Patients with Polycythemia Vera Resistant or Intolerant to Hydroxyurea(HU)

Wu, D. P.

2443 - Switching from Eltrombopag to Hetrombopag in Patients with Primary Immune Thrombocytopenia (ITP): Post-Hoc Analysis of a Multicenter, Randomized Phase III Trial

Wu, D.

3142 - Biological Characterization and Differential Gene Expression Analysis of CYT-338 NK Cell Engager (NKE) Against CD38 Expressing Tumors Including Multiple Myeloma (MM)

Wu, D.

595 - Mutation Spectrum of FLT3 and Significance of Non–Canonical FLT3 Mutations in Hematological Malignancies
601 - Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial
957 - Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
1391 - Venetoclax, Cladribine Plus Low-Dose Cytarabine Achieved High Remission in Patients with Relapse/Refractory Acute Leukemia: Preliminary Results of a Phase II Study
1885 - TP53 Gene Deletion or Mutation in Newly Diagnosed Multiple Myeloma Patients By FISH with Cytoscan Arrays and Targeted Panel Sequencing
2569 - Current Use of Androgens in Bone Marrow Failure Disorders: A Report from the Severe Aplastic Anemia Working Party (SAAWP) of the European Society of Blood and Marrow Transplantation (EBMT)
2971 - The Impact of Chimeric Antigen Receptor T Cell Quality to Clinical Safety and Efficacy in Non-Hodgkin Lymphomas
2989 - A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor Bgb-11417 in Adult Patients with Mature B-Cell Malignancies: Preliminary Data
3226 - Comparison of Next-Generation Flow Cytometry (NGF) and Next-Generation Sequencing (NGS) in the Assessment of Minimal Residual Disease in Multiple Myeloma
3452 - Haplo-Cord HCT Versus Haplo-Identical HCT for Acute Leukemia Patients Not in Remission: A Multicenter Study
4146 - Integrative Genomic and Transcriptomic Profiling Reveals Distinct Molecular Subsets in Adult Mixed Phenotype Acute Leukemia
4518 - The Independent Adverse Prognostic Significance of 1q21 Gain/Amplification in Newly Diagnosed Multiple Myeloma Patients
4643 - Safety and Efficacy of CD22 and CD19 Chimeric Antigen Receptor T Cell Treatment Bridging to Autologous Stem Cell Transplantation As Consolidation Therapy for B-Cell Acute Lymphoblastic Leukemia
4647 - Anti CD19 CART Therapy Following Allogenic Hematopoietic Stem Cell Transplantation Improved the Survival of Patients with BCR::ABL1-like Acute Lymphoblastic Leukemia
4757 - Comparable Outcomes Following Non-First-Degree and First-Degree Related Donor Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia Patients in Complete Remission: A Study from the Global Committee and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation

WU, D.

1759 - A Phase 1b Study to Evaluate Safety and Efficacy of IBI188 in Combination with Azacitidine (AZA) As a First-Line Treatment in Subjects with Newly Diagnosed Higher Risk Myelodysplastic Syndrome

Wu, D.

2007 - Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies

Wu, D.

1008 - Whole-Exome Sequencing Identifies Fanc Heterozygous Germline Mutation As an Adverse Factor for Immunosuppressive Therapy in Chinese Aplastic Anemia Patients Aged 40 or Younger: A Single-Center Retrospective Study
3756 - Synergistic Effect of Low-Dose Cyclosporine a on Eltrombopag (EPAG) in the Management of Prior Epag and Multiline Failed Immune Thrombocytopenia Patients: A Single-Center, Self-Control Study

Wu, D.

4694 - Fludarabine, Busulfan and Melphalan Based Conditioning Reduced Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myeloid Malignancies: A Multicenter Retrospective Analysis

Wu, D.

415 - Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia

Wu, E.

3629 - The Influence of Social Vulnerability on the Prognosis of Chronic Myeloid Leukemia in Adults across the United States
4930 - The Effects of Social Vulnerability on the Prognosis and Outcomes of Hodgkin’s Lymphoma in Adults across the United States

Wu, F.

3425 - Profiles of Germline Predisposition Gene Variants in Hematologic Disorders and Its Impact on Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation

Wu, F.

4630 - Phase I Study of a BCMA-Directed CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma Manufactured in <3 Days Using the High-Performance Platform

Wu, F.

2148 - AAV8 Gene Therapy for Hemophilia A Patients from China

Wu, G.

411 - Rare Deleterious TCF3 Germline Variants and Predisposition to Acute Lymphoblastic Leukemia in Children
717 - Progenitor Sub-Populations in Treatment Resistant T-ALL
718 - Comprehensive Genome Characterization of Childhood T-ALL Links Oncogene Activation Mechanism and Subtypes to Prognosis
1501 - The Influence of Genetic Ancestry on Disease Biology in Pediatric T-Cell Acute Lymphoblastic Leukemia

Wu, G.

706 - TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2

Wu, H.

1630 - Mosunetuzumab with Polatuzumab Vedotin Is Effective and Has a Manageable Safety Profile in Patients Aged <65 and ≥65 Years with Relapsed/Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL) and ≥1 Prior Therapy: Subgroup Analysis of a Phase Ib/II Study
1637 - SUNMO: A Phase III Trial Evaluating the Efficacy and Safety of Mosunetuzumab in Combination with Polatuzumab Vedotin Versus Rituximab in Combination with Gemcitabine Plus Oxaliplatin in Patients with Relapsed or Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

Wu, H.

432 - Personalization of Induction Therapy for Pediatric AML to Ara-C+Dauno+ Etoposide (ADE) or Clofarabine+Ara-C According to a Polygenic Ara-C SNP Score- ACS10
2711 - Proteomic Analysis Identifies Epigenetic Modifiers and Potential Negative Regulators of Leukemogenesis KMD6A and SETDB1 to be Induced Post In Vivo Decitabine Exposure in Pediatric AML
2800 - Genome-Wide Association Study Identifies Variants Associated with Clinical Outcomes in Pediatric Patients with Newly Diagnosed Acute Myeloid Leukemia

Wu, I.

4711 - Haploidentical Transplant Using Selective Ex-Vivo Tcrαβ Depleting and Memory T Cell Add-Back Results in More Favorable Gvhd-Free /Relapse Free Survival (GRFS) As Compared to Post-Transplant Cyclophosphamide for Adults with Hematological Malignancies - a Comparative Analysis of 170 Patients in a Multicenter Study in Singapore

Wu, I. Q.

2052 - Haploidentical Hematopoietic Cell Transplantation of Ex Vivo Tcrαβ-Depleted Grafts with CD45RA-Depleted Memory T Cell Add-Back Reduces Chronic Graft-Versus-Host Disease and Results in Favourable Gvhd-Relapse Free Survival: 5-Year Follow-up of 107 Patients Treated in a Multicenter Study in Singapore

Wu, J. J.

4627 - A Comparison of Overall Survival with Brexucabtagene Autoleucel (Brexu-cel) CAR T-Cell Therapy (ZUMA-2) and Standard of Care (SCHOLAR-2) in Patients with Relapsed/Refractory Mantle Cell Lymphoma (R/R MCL) Previously Treated with a Covalent Bruton Tyrosine Kinase Inhibitor (BTKi)

Wu, J.

492 - Late Morbidity and Mortality after Autologous Blood or Marrow Transplantation (BMT) for Lymphoma in Children, Adolescents and Young Adults – a Report from the BMT Survivor Study (BMTSS)

Wu, J.

3492 - Identification of Nodular Lymphocyte-Predominant Hodgkin Lymphoma Variant Morphology Using Artificial Intelligence

Wu, J. Z.

1660 - Preliminary Results of Penpulimab Combined with RMA (rituximab, methotrexate, and cytarabine) for Newly Diagnosed Primary Central Nervous System Lymphoma

Wu, J.

257 - Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study
2007 - Allogeneic and Autologous Anti-CD7 CAR-T Cell Therapies in Relapsed or Refractory T Cell Malignancies
3286 - Multi-Omics Reveal Plasma Molecular Signatures of B-ALL Patients during CAR-T Cell Therapy
4626 - BTK Inhibitors Improve CART19 Cell Therapy By Modulating Immune System
4636 - Single-Cell Profiling Reveals Contribution of IFITM1 Expression to Severe CRS in CAR-T-Treated B-ALL

Wu, J.

4605 - Multi-Antigen Targeting By Novel Combination of CAR-T Cells and hnCD16 Transgene, Yields in Complete Tumor Clearance Via Antibody Dependent Cellular Cytotoxicity

Wu, J.

2916 - XPO1 Inhibitor (ATG-010) Plus GemOx Regimen for Heavily Pretreated Patients with Relapsed or Refractory (R/R) T and NK-Cell Lymphoma：Updates of the Phase Ib Touch Study
4640 - Efficacy and Safety of Relmacabtagene Autoleucel in Adults with Relapsed/Refractory Follicular Lymphoma in China

Wu, J.

3872 - Sitagliptin Alleviates Excessive Autophagy in Macrophages in Immune Thrombocytopenia Patients to Promote Megakaryopoiesis Via the AMPK/mTOR Pathway

Wu, J.

4293 - Efficacy and Safety of Zanubrutinib Combined with R-CHOP Regimen in the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma with Extranodal Involvement: A Single-Arm, Prospective Phase II Trial

Wu, J.

2951 - Preliminary Result of Phase 1 Trial of Orelabrutinib in Combination with Rituximab, Methotrexate, and Dexamethasone in Patients with Newly Diagnosed Primary CNS Lymphoma Implementing Bayesian Design for Dose-Seeking

Wu, J.

2246 - Clinical Characteristics Impacting Health-Related Quality of Life in Persons with Von Willebrand Disease

WU, J.

LBA-4 - Post-Transplant Cyclophosphamide, Tacrolimus, and Mycophenolate Mofetil As the New Standard for Graft-Versus-Host Disease (GVHD) Prophylaxis in Reduced Intensity Conditioning: Results from Phase III BMT CTN 1703

Wu, J. T.

1872 - Increased COVID-19 Breakthrough Infection Risk after Sars-Cov-2 Vaccine Boosting in Patients with Plasma Cell Disorders: A Large Nationwide Veterans Affairs Study

Wu, J.

443 - Subcutaneous Epcoritamab + R-Dhax/C in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma Eligible for Autologous Stem Cell Transplant: Updated Phase 1/2 Results

Wu, J.

560 - Validation of the 5^th Edition of the World Health Organization Classification of Myelodysplastic Neoplasms on 852 Consecutive De Novo Patients from a Single Institute
1764 - Unique Clinical Features and Mutation Profile in De Novo Myelodysplastic Syndromes with MF-1 and a Proposed Model for Distinguishing MDS with MF-2/3 from TN-PMF Based on Clinical and Genetic Covariates
1780 - IPSS-M Is More Powerful for MDS Patients Older Than 60 Years Old

Wu, K. L.

1922 - Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years
1926 - Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years

Wu, K.

LBA-6 - Zanubrutinib Demonstrates Superior Progression-Free Survival (PFS) Compared with Ibrutinib for Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma (R/R CLL/SLL): Results from Final Analysis of ALPINE Randomized Phase 3 Study

Wu, K.

1016 - Clinical, Immunological Features, Treatments, and Outcomes of Autoimmune Hemolytic Anemia in Patients with RAG Deficiency

Wu, K. W.

4867 - Healthcare Resource Utilization and Costs Associated with AL Amyloidosis: A Retrospective Matched Cohort Study

Wu, L.

3772 - Combination of Thrombopoietin Receptor Agonist and Recombinant Human Thrombopoietin for Treating Cancer Therapy Induced Thrombopenia

Wu, L.

3871 - LepR⁺ Niche Cell-Derived AREG Compromises Hematopoietic Stem Cell Maintenance Under Conditions of DNA Repair Deficiency and Aging

Wu, L.

797 - Real-World Comparison of Time to Next Treatment for Patients with CLL Initiated on First-Line Treatment with Ibrutinib Versus Acalabrutinib
3132 - Real-World Outcomes with First-Line Ibrutinib (Ibr) Versus Chemoimmunotherapy (CIT) in Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): Final Analysis Results from the InformCLL Registry
3578 - Real World Treatment Patterns in Patients with Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Switching from First Line Ibrutinib to Acalabrutinib

Wu, L.

3756 - Synergistic Effect of Low-Dose Cyclosporine a on Eltrombopag (EPAG) in the Management of Prior Epag and Multiline Failed Immune Thrombocytopenia Patients: A Single-Center, Self-Control Study

Wu, L. S.

97 - Teclistamab, a B-Cell Maturation Antigen (BCMA) x CD3 Bispecific Antibody, in Patients with Relapsed/Refractory Multiple Myeloma (RRMM): Correlative Analyses from MajesTEC‑1
1911 - Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple Myeloma
3228 - Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of Teclistamab

Wu, M.

575 - Basiliximab in the Prevention of aGVHD for Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Thalassemia Major: A Prospective, Multicenter, Open-Label, Randomized Controlled Study

Wu, M.

2339 - DISC-0974, an Anti-Hemojuvelin Antibody, Reduces Hepcidin and Mobilizes Iron in Healthy Volunteers
3641 - DISC-0974, an Anti-Hemojuvelin (HJV) Monoclonal Antibody, Reduced Hepcidin and Improved Anemia in a Rat Model of Chronic Kidney Disease
3657 - Preclinical Pharmacokinetics and Pharmacodynamics of DISC-0998, a Humanized Anti-Hemojuvelin (HJV) Monoclonal Antibody to Suppress the Production of Hepcidin
3661 - Bitopertin, a Selective Glycine Transporter 1 Inhibitor, Reduced Protoporphyrin IX (PPIX) Level and Improved Liver Fibrosis in a Mouse Model of Erythropoietic Protoporphyria (EPP)

Wu, N.

2277 - Trial in Progress: Follicular Lymphoma Outcomes in Relapsed/Refractory Patients Treated with Systemic Therapy in a Real-World Assessment (FLORA)
3601 - Trial in Progress: Outcomes in Patients with Relapsed/Refractory Diffuse Large B‑Cell Lymphoma Treated with Systemic Therapy from Real-World Experience (ORCHID)
4896 - Incidence of Second Primary Malignancies (SPMs) in Patients in the US with Triple-Class-Exposed (TCE) Relapsed or Refractory Multiple Myeloma (RRMM)

Wu, Q.

601 - Venetoclax Plus Decitabine for Young Adults with Newly Diagnosed ELN Adverse-Risk Acute Myeloid Leukemia: Updated Results of a Phase 2 Trial

Wu, Q. V.

1690 - Minimally Invasive Blood Sampling for BCR::ABL1 transcript Monitoring
3316 - Timing of PD-L1 Blockade with Durvalumab May Affect Outcomes of CD19 CAR-T Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma

Wu, Q.

3800 - Factor X Activator for Hemophilia Patients with Inhibitors: A Phase 1, First-in-Human, Multi-Center, and Open-Label Trial

Wu, R.

1168 - Shorter Time Interval from Inhibitor Detection to Starting Low-Dose Immune Tolerance Induction Therapy Is Associated with Better Inhibitor Eradication Outcomes in Severe Hemophilia a Children with High-Titer Inhibitors in China
2476 - Protocol and Primary Analysis of Lome: A Randomized Trial of Low- Versus Intermediate-Dose Immune Tolerance Induction with Recombinant Factor VIII (Omfiloctocog alfa, SCT800) in China
3776 - Single-Cell Sequencing of Immune Cells from Hemophilia a Patients with Inhibitors and Acquired Hemophilia a Patients
3797 - Pharmacokinetics, Efficacy and Safety Evaluation of FRSW107 in Previously Treated Hemophilia a Patients: A Multicentre, Open-Label, Non-Randomized Phase III Study

Wu, S. C.

35 - Blood Group A Enhances SARS-CoV-2 Infection

Wu, S. J.

4854 - Cost-Effectiveness Analysis of Frontline Treatment with Polatuzumab Vedotin in Diffuse Large B-Cell Lymphoma

Wu, S.

71 - Spatial Tumor Microenvironment Characterization and Outcome of Relapsed/Refractory Classic Hodgkin Lymphoma
308 - Integrated Single Cell Analysis Reveals Co-Evolution of Malignant B Cells and the Tumor Microenvironment in Transformed Follicular Lymphoma

Wu, S. J.

1342 - Characterization of JNJ-80948543, a Novel CD79bxCD20xCD3 Trispecific T-Cell Redirecting Antibody for the Treatment of B-Cell Non-Hodgkin Lymphoma

Wu, S.

2821 - MLL (KMT2A)-rearranged Acute Lymphoblastic Leukemias Are Addicted to S-Adenosyl Methionine (SAM): Implications for Therapy

Wu, S. W.

2769 - Targeting the WT1^mut-Mir-193a Transcriptional Axis with INT-1B3, a Novel Lipid Nanoparticle-Formulated Mir-193a-3p Mimic in Acute Myeloid Leukemia

Wu, S.

1540 - Novel Non-Coding, Coding and Structural Variants in Hairy Cell Leukemia from Whole Genome Transcriptome Sequencing

Wu, S.

875 - First in Human Study of Anti-Viral Veto Cells Enabling Successful Engraftment without Severe Gvhd in Non-Myeloablative T Cell Depleted Haploidentical Hematopoietic Stem Cell Transplantation (HSCT)
1623 - Phase II Study of Pembrolizumab and Fractionated External Beam Radiotherapy in Patients with Relapsed and Refractory Large B-Cell Lymphoma

Wu, T.

4228 - A Study of Linperlisib in the Treatment of Patients with Relapsed and/or Refractory Peripheral T-Cell Lymphoma

Wu, T.

595 - Mutation Spectrum of FLT3 and Significance of Non–Canonical FLT3 Mutations in Hematological Malignancies

Wu, T.

102 - Single-Cell RNA-Sequencing of 245 Tumor Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveals Novel Insights into Malignant Plasma Cell Biology
108 - Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Progression in Patients with High-Risk Smoldering Multiple Myeloma Treated with Immunotherapy
244 - Single-Cell RNA Sequencing of Rare Circulating Tumor Cells in Precursor Myeloma Patients Reveals Molecular Underpinnings of Tumor Cell Circulation
354 - Single-Cell RNA-Sequencing of 370 Bone Marrow and Peripheral Blood Immune Cell Samples from Patients with MGUS and Smoldering Multiple Myeloma Reveal Significant Immune Dysregulation at the MGUS Stage, and Novel Interactions between Tumor and Immune Cells
3184 - Dysregulated Humoral and Cellular Response to Sars-Cov-2 Vaccination in Patients with MGUS and SMM

Wu, T.

3425 - Profiles of Germline Predisposition Gene Variants in Hematologic Disorders and Its Impact on Prognosis of Allogeneic Hematopoietic Stem Cell Transplantation

Wu, T.

434 - CD58 Could be As a Leukemic Marker in Relapsed/Refractory B-ALL Patients after Multiline Therapies
1657 - Effects of BMI, Albumin and NRS 2002 Changes on Prognosis in Patients with Hematological Malignancies during CAR T Treatment
3359 - Exploring the Efficiency and Survival of CAR T-Cell Therapy in DLBCL Patients with MYC and/or TP53 Abnormalities
3974 - Molecular Biomarker Analyses for Exploring the Therapeutic Mechanism of Lemzoparlimab and Azacitidine (AZA) in Newly Diagnosed Higher Risk Myelodysplastic Syndrome (HR-MDS)
4266 - Daratumumab-Primed Venetoclax Combined with Cage for Refractory/Relapsed T-Lymphoblastic Leukemia/Lymphoma Patients: Single-Arm, Open-Label, Phase I Study
4661 - Subsequent Secondary CAR-T Cell Therapy Was Superior to Chemotherapy in Patients with Refractory/Relapsed B-Cell Lymphoma after Failure of Anti-CD19 CAR-T Cell Therapy
4675 - Interpreting Immune Reconstitution and Clinical Outcome By Single-Cell Transcriptomic Analysis in T-ALL Patients Undergoing Donor-Derived CD7 CAR-T Immunotherapy

Wu, T. K.

629 - Efficacy and Safety of Ropeginterferon Alfa-2b for Pre-Fibrotic Primary Myelofibrosis and DIPSS Low/Intermediate-1 Risk Myelofibrosis

Wu, V.

4131 - Whole Genome Sequencing Comparison of Acute Myeloid Leukemia at Presentation and Remission Predicts Patient Outcome

Wu, W.

1792 - Novel BTK Mutations Conferring Resistance to the Second-Generation, Irreversible BTK Inhibitor Orelabrutinib (ICP-022)
1811 - Ibrutinib Plus Fludarabine, Cyclophosphamide, and Rituximab As Inital Treatment for Chronic Lymphocytic Leukemia/ Small Lymphocytic Leukemia
3104 - Integrating Multi-Omics to Reveal the Clonal Evolutionary Characteristics in CLL Patients with Zanubrutinib Resistance
3108 - Single-Cell RNA Sequencing Reveals the Characteristics of High Proliferating Tumor Cells in Btki-Resistant Progression to Richter Transformation and Accelerated CLL

Wu, W.

2855 - Prompt Assessment of Tumor Load and Treatment Response in Patients with Lymphoma By a Blood-Based Multi-Omics Approach

Wu, W.

3475 - Amplifying Sting Activation By Bio-Inspired Nanomedicine for Targeted Acute Myeloid Leukemia Chemo- and Immunotherapy

Wu, W.

706 - TP63 Fusions Drive Enhancer Rewiring, Lymphomagenesis, and Dependence on EZH2

Wu, W.

3336 - High Safety and Efficacy of CRISPR-Based Non-Viral PD-1 Locus Specific Integrated Anti-CD19 CAR-T Cells (BRL-201) in Treating Relapsed or Refractory Non-Hodgkin's Lymphoma: First-in-Human Phase I Study

Wu, W.

1568 - A National, Multicenter, Retrospective Study of Castleman Disease Implementing Cdcn Criteria: 'severe Imcd' Is Indeed Severe
3202 - Analysis of Clinical Characteristics and High-Risk Factors of Patients with Extramedullary Relapse Multiple Myeloma

WU, W.

3464 - The Experimental Gene Therapy on Type 2A/Iic VWD Mouse Model with AAV Vector Delivering Only VWF Propeptide Expression cassette4

WU, W.

3776 - Single-Cell Sequencing of Immune Cells from Hemophilia a Patients with Inhibitors and Acquired Hemophilia a Patients

Wu, X.

3842 - Magnetic Fractionation of Red Blood Cells Based on Oxygen Saturation in Sickle Cell Disease

Wu, X.

2788 - Somatic Mutations in TP53 Identified in T-Cells of Patients with TP53-mutated AML
2812 - Characterization of Dysregulated Transcription in TP53-Mutated AML Subpopulations

WU, X.

4694 - Fludarabine, Busulfan and Melphalan Based Conditioning Reduced Relapse after Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Myeloid Malignancies: A Multicenter Retrospective Analysis

Wu, X.

3456 - Highly Efficient & Specific Repair of MAGT1 Mutation in Xmen Patient T Cells and Hematopoietic Stem Cells

Wu, X.

2146 - Improved Lentiviral In Vivo Gene Therapy for Chronic Granulomatous Disease

Wu, X.

679 - Base Editing of Hematopoietic Stem Cells Rescues T-Cell Development for CD3d Severe Combined Immunodeficiency

Wu, X.

13 - High Prevalence of Epigenetic Mutations in Histiocytic and Dendritic Cell Disorders: Results from Molecular Analysis of a Large Cohort from Histiocytosis Working Group
18 - Secreted Sars-Cov-2 Encoded ORF8 Protein Stimulates Pro-Inflammatory Cytokines and Predicts Severe Clinical Outcome
3720 - An Ex Vivo Monocyte Stimulation Test Predicts Severity of COVID-19 Infection in Patients with Chronic Lymphocytic Leukemia (CLL)

Wu, X.

4044 - Efficacy, Safety, and Population Pharmacokinetic Modeling of Intravenous Recombinant Erwinia Asparaginase (JZP458) in Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma: Results from Study AALL1931

Wu, X.

1472 - Clinical and Functional Implications of MYC Variants As a New Class of Pathogenic Variants in AML

Wu, X.

415 - Phosphorylation Stabilized TET1 Acts As an Oncoprotein and Therapeutic Target in B-Cell Acute Lymphoblastic Leukemia
2152 - Targeting PRMT9 Elicits Cgas-Mediated Anti-Leukemia Immunity
2153 - Receptor Targeted Delivery of the p38γ Inhibitor PIK-75 By Organic-Core Templated Lipid Nanoparticles in Cutaneous T Cell Lymphoma
2837 - Blockade of the Immune Checkpoint CD47 By TTI-621 Potentiates the Response to Anti-PD-L1 in Cutaneous T Cell Lymphoma
4591 - Targeting Intestinal Epithelial Ceacam1 Expands Peripheral Tregs and Prevents Steroid-Refractory Acute Gut Graft-Versus-Host Disease

Wu, X.

2064 - Fludarabine- and Low-Dose Cyclophosphamide-Based Conditioning Regimens for Unmanipulated Hematopoietic Cell Transplantation from Unrelated Donors and Matched Siblings in Patients with Fanconi Anemia: Results from the Cbmtr

Wu, Y. J.

2454 - Real-World Study of the Use of Iguratimod to Treat Chronic/Refractory ITP
3872 - Sitagliptin Alleviates Excessive Autophagy in Macrophages in Immune Thrombocytopenia Patients to Promote Megakaryopoiesis Via the AMPK/mTOR Pathway

Wu, Y.

3380 - Double Filtration Plasmapheresis for Desensitization during Haploidentical Stem Cell Transplantation in Patients with Positive Donor-Specific Anti-HLA Antibodies
3417 - Muticenter Retrospective Comparable Study of Prophylactic Versus Preemptive Modified Donor Lymphocyte Infusion for Patients with High-Risk Acute Leukemia after Allogeneic Hematopoietic Stem Cell Transplantation

Wu, Y.

1381 - Homoharringtonine-Based Induction Regimens Combined with ATRA-Based Maintenance in Chinese Pediatric AML: A Report from the Cclg-AML 2015 Protocol Study

Wu, Y.

2157 - Discovery and Preclinical Study of Novel BTK Degrader HZ-Q1060
3472 - Discovery of HZ-L105, a Next Generation of Bcl-2 Inhibitor, Overcomes Bcl-2 Mutation and Exhibits Superior Antitumor Activity
3482 - HZ-R061, a Selective STAT3 Degrader with Activity in Preclinical Model of Hematologic Malignances

Wu, Y.

1949 - ER Stress Sensor PERK Regulates T-Cell Allogeneic and Anti-Tumor Responses Distinctly
1957 - S1P/S1PR1 Signaling Differentially Regulates Allogeneic Response of CD4 and CD8 T Cells through Modulating Mitochondrial Content and Metabolism
3269 - Transcription Factor Fli-1 Regulates T Cell Immunity and Tolerance in Gvh and GVL Responses

Wu, Y.

1895 - Improvement of Abdominal Fat Pad Biopsy Technique in Systemic Light Chain Amyloidosis and Establishment of an Outcome Prediction Tool with Machine Learning

Wu, Y.

4033 - Siremadlin Monotherapy and in Combination with Donor Lymphocyte Infusion for Patients with Acute Myeloid Leukemia Post Allogeneic Stem Cell Transplantation Who Are in Complete Remission but at High Risk for Relapse

Wu, Y.

4254 - A Preliminary Analysis of Chidamide Combined with R-GemOx (rituximab, gemcitabine and oxaliplatin) As Salvage Treatment for Transplant-Ineligible Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Prospective, Multicenter, Single-Arm, Phase II Study

Wu, Y.

2914 - Peripheral Neuropathy in Children with High Risk Hodgkin Lymphoma (HL): The Role of Protocol-Stipulated Dose Modification in the Children’s Oncology Group (COG) AHOD1331 Study
2921 - Evaluating CHIPS in Pediatric High Risk Hodgkin Lymphoma Treated on AHOD1331

Wu, Y. Z.

3950 - Methylome Analysis of Epstein-Barr Virus with Nanopore Sequencing Reveals Viral State Dynamics

Wu, Y.

4500 - Clinical Significance and Molecular Characteristics of Circulating Plasma Cells in Multiple Myeloma

Wu, Z.

1424 - Real-World Treatment Patterns and Transfusion Burden Among Newly Diagnosed Older Adults with Acute Myeloid Leukemia

Wu, Z.

2745 - High Efficacy of Azacitidine Plus Hag in Acute Myeloid Leukemia: A Multi-Center, Phase 2 Clinical Trial

Wu, Z.

1361 -

Ferroptosis Patterns Predicting Prognosis and Drug Resistance in Acute Lymphoblastic Leukemia

Wu, Z.

1509 - Prognostic Significance of Epigenetic Modifiers Gene Mutations in Adult Acute Lymphoblastic Leukemia at Diagnosis

Wu, Z.

193 - JAK 1/2 Inhibition Preserves Hematopoietic Progenitor and Stem Cells, Prevents Aplasia, Inhibits Pro-Inflammatory Cytokines, and Prolongs Survival in Murine Immune Bone Marrow Failure

Wu, Z.

2013 - Outcome of Tandem CD19/CD20 CAR Therapy with 3-Year Follow-up in R/R B-NHL

Wu, Z.

257 - Autophagy Facilitates Cancer-Intrinsic Evasion of CAR T Cell-Mediated Cytotoxicity in B-Cell Malignancies
1998 - Bispecific CS1-BCMA CAR-T Cells Are Clinically Active in Relapsed or Refractory Multiple Myeloma: An Updated Clinical Study

Wu-corts, D.

2538 - Transcription Factor Profiling Reveals That CEBPA Promotes Ribosomal RNA Synthesis in Myeloid Progenitors

Wucherpfennig, K. W.

1828 - Inhibition of MICA and MICB Shedding Enhances Cytokine-Induced Memory-like NK Cell-Mediated Activity Against Multiple Myeloma

Wuchter, P.

1316 - Inhibition of Lysyl Oxidases Synergizes with 5-Azacytidine to Restore Erythropoiesis in Myeloid Neoplasms
4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Wudhikam, K.

2025 - Prognostic Impact of Comorbidities on Outcomes of Patients (pts) with Relapsed or Refractory Large B-Cell Lymphoma (r/r LBCL) Treated with Chimeric Antigen Receptor T-Cell Therapy (CART)

Wudhikarn, K.

2908 - Mucosal Associated Lymphoid Tissue Lymphoma in Thailand, a Nationwide Multicenter Registry and Prognostic Index; Results from the Thai Lymphoma Study Group (TLSG) Registry
3900 - Inherited Germline DNA Repair Gene Defects Are Prevalent Among Thai Patients with Myeloid Neoplasms

Wudhikarn, K.

2144 - The Enrichment of T-Cell Proliferation and Memory Gene Signatures of CD79A/CD40 Co-Stimulatory Domain Enhances CD19CAR-T Cell Efficacy
3277 - Co-Stimulation of CD28/CD40 Signaling Molecule Potentiates CD19CAR-T Cell Functions and Stemness

Wudhikarn, K.

615 - CNS Relapse in T-Cell Lymphoma Index: A Risk Score to Predict Central Nervous System Relapse in Patients with T-Cell Lymphomas

Wuerthner, J.

1542 - Identification of Predictive Biomarkers for Response of R/R DLBCL Patients Treated with Loncastuximab Tesirine Using Low Pass Whole-Genome Sequencing (WGS)
1594 - Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)
4192 - CD25, Soluble CD25, and CCL17 As Potential Predictors of Clinical Response to Camidanlumab Tesirine in Patients with Relapsed/Refractory Classical Hodgkin Lymphoma

Wuest, A.

2594 - Ogdh Is a Genetic Vulnerability and Therapeutic Target in Acute Myeloid Leukemia

Wuillème, S.

4404 - Artificial Intelligence Using Multimodal Data for Myelodysplastic Syndrome Screening

Wujcik, D. M.

3548 - Beliefs, Goals, Preferences, and Top Concerns of Patients with Acute Myeloid Leukemia at a Treatment Decision Visit
3551 - Feasibility of Real-World Assessment of Patient-Reported Outcomes in Acute Myeloid Leukemia By Cytogenetic Risk and Treatment Status

Wulf, G.

832 - Gemtuzumab Ozogamicin Plus Intensive Chemotherapy for Patients with NPM1-Mutated Acute Myeloid Leukemia
957 - Allogeneic Hematopoietic Stem Cell Transplantation Achieves Long-Term Survival in Extranodal Natural Killer/T-Cell Lymphoma: A Retrospective Analysis of the EBMT Lymphoma Working Party
3344 - CART Therapy or Allogeneic Stem Cell Transplantation in ≥ Third Line Treatment of Large B Cell Lymphoma (LBCL)
4665 - Real-World Results of CAR-T Cell Therapy for Large B Cell Lymphoma with CNS Involvement: A GLA/DRST Study
4672 - Organ Complications after CD19 CAR T-Cell Therapy for Large B Cell Lymphoma. a Retrospective Study from the EBMT Transplant Complications and Lymphoma Working Partys

Wulf, G.

988 - Validation of the Transplant Conditioning Intensity (TCI) Score for Allogeneic Hematopoietic Cell Transplantation
4739 - Registry Data Indicate a Meaningful Chance for Successful Pregnancies after Allogeneic Stem Cell Transplantation: Results from the German Stem Cell Transplant Registry (DRST)

Wulff, J.

4660 - 3-Year Follow-up Analysis of ZUMA-5: A Phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) in Patients with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

Wulff Risør, B.

893 - Cost-Utility of Venetoclax Plus Obinutuzumab for Treatment-Naïve Patients with Chronic Lymphocytic Leukemia without Del17p/TP53-Mutation Compared to Chlorambucil Plus Obinutuzumab

Wulftange, W.

3675 - Extracellular Vesicles from Sickle Red Blood Cells Activate Endothelial Cells and Trigger Von Willebrand Factor-Mediated Sickle Red Cell Adhesion

Wullschleger, S.

936 - MP0533: A Multispecific Darpin CD3 Engager Targeting CD33, CD123, and CD70 for the Treatment of AML and MDS Designed to Selectively Target Leukemic Stem Cells

Wun, C. C.

2884 - Acalabrutinib Plus Venetoclax and Rituximab in Patients with Treatment-Naïve (TN) Mantle Cell Lymphoma (MCL): 2-Year Safety and Efficacy Analysis

Wun, T.

673 - Incidence of Ischemic Stroke Has Increased in Californians with Sickle Cell Disease in the Post-STOP Era
3414 - Subsequent Solid Neoplasms Following Hematopoietic Cell Transplantation (HCT) for Hematologic Malignancies: Comparing Center for International Blood and Marrow Transplant Research (CIBMTR) and California Cancer Registry (CCR) Data
3421 - Comparison of Vital Status and Cause-Specific Mortality after Hematopoietic Cell Transplantation between the Center for International Blood and Marrow Transplant Research and the California Cancer Registry: A Record-Linkage Analysis from 1991 to 2018
4520 - Utilization of Autologous HCT in Multiple Myeloma: A Novel Linkage of CIBMTR, Cancer Registry and Hospitalization Data in California

Wunderlich, M.

931 - IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML
1274 - TET2-Mediated mRNA and DNA Oxidation in Leukemia Homing and Immune Evasion
1275 - TRIM13 Is a Novel Cell Cycle Hub Regulated By CHAF1B to Promote Acute Myeloid Leukemogenesis
1489 - In Vivo Crispr Screening Identifies Novel Vulnerabilities in ETO2/GLIS2-rearranged Leukemia
3913 - JMJD1C Interacts with the Ncor Corepressor Complex and Is Required for Human MLL-AF9 Leukemogenesis
4380 - ASXL1 Mutations Are Associated with a Response to the Combination of Alvocidib and 5-Azacytidine in Higher-Risk Myelodysplastic Syndromes

Wurtz, M.

2378 - Return Visit Rates after an Emergency Department Treat-and-Release Visit for Children with Sickle Cell Pain Episodes

Wyder, M.

1275 - TRIM13 Is a Novel Cell Cycle Hub Regulated By CHAF1B to Promote Acute Myeloid Leukemogenesis

Wynn, R.

4584 - Development of Anti-CD45 Antibody Drug Conjugates As Targeted Conditioning Agents for Transplantation/Gene Therapy with Potent Anti-Leukemic Properties
4656 - Donor-Derived, In Vivo T-Cell Expansion Using Granulocyte Transfusions after Cord Blood Transplant Induces Remission in Children with Relapsed, Refractory Acute Myeloid Leukemia and Is Associated with a Cytokine Release Syndrome

Wynn, R. F.

776 - Specific Cytogenetic Abnormalities at Diagnosis Predict Survival after Hematopoietic Cell Transplant in Poor-Risk Pediatric Acute Myeloid Leukemia: A PDWP/EBMT Study
4895 - Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study

Wynn, R. F.

266 - Outcome of Haematopoietic Cell Transplantation in 813 Children with Fanconi Anaemia: A Study on Behalf of the EBMT Severe Aplastic Anaemia Working Party and Paediatric Disease Working Party
997 - Systematic Intention to Treat Analysis of Real-World Outcomes in Children and Young Adults Receiving Tisagenlecleucel: From Elegibility through Treatment Failure
2132 - T-Cell Replete Unrelated Cord Blood Transplant Give Superior Outcomes to Other Donor Sources in High Risk and Relapsed/Refractory Paediatric Myeloid Malignancy
4650 - Dual Antigen Targeting with Co-Transduced CD19/22 CAR T Cells May Prevent Antigen-Negative Relapse after CAR T Cell Therapy for Relapsed/Refractory ALL

Wynn, R. F.

782 - Biochemical Engraftment and Clinical Outcomes Following Ex-Vivo Autologous Stem Cell Gene Therapy for Mucopolysaccharidosis Type IIIA

Wynn, T.

783 - Long-Term Durable FVIII Expression with Improvements in Bleeding Rates Following AAV-Mediated FVIII Gene Transfer for Hemophilia A: Multiyear Follow-up on the Phase I/II Trial of SPK-8011

Wynne, J.

2234 - Real-World Treatment Patterns Among Patients with Newly-Diagnosed (ND)-Acute Myeloid Leukemia (AML) in the United States (US)

Wysocki, M.

4083 - A Phase II Clinical Trial of E7820 for Patients with Relapsed/Refractory Myeloid Malignancies with Mutations in Splicing Factor Genes

Wysokinska, E.

593 - Prevalence of Vitamin C Deficiency and Bleeding at a Tertiary Care Center: Mayo Clinic Florida (MCF) Experience
2491 - Accuracy and Prediction of D-Dimers for Pulmonary Embolism in Patients with COVID-19 Infection
3833 - Clinical Characteristics of Cohort of 113 Patients with Cancer-Associated Non Bacterial Thrombotic Endocarditis
3834 - No Difference in Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations

Wysokinski, W. E.

2491 - Accuracy and Prediction of D-Dimers for Pulmonary Embolism in Patients with COVID-19 Infection
3817 - Development of a Machine Learning Model Using Electrocardiogram Signals to Determine Acute Pulmonary Embolism
3833 - Clinical Characteristics of Cohort of 113 Patients with Cancer-Associated Non Bacterial Thrombotic Endocarditis
3834 - No Difference in Venous Thromboembolism Outcomes after COVID-19 and Influenza Vaccinations

Author Index: W